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Abstract 
The submucosal glands (SMGs) of the respiratory system are specialized structures 
essential for maintaining airway homeostasis. The significance of SMGs is 
highlighted by their involvement in respiratory diseases such as cystic fibrosis and 
asthma, where their phenotype and function are severely altered. Uncovering the 
normal development of the airway SMGs is essential to elucidate their role in these 
disorders, however, very little is known about their morphogenesis.  
 
To begin to understand the mechanisms involved in their arborisation, the 
development of the nasal SMGs was investigated, with glands being categorised into 
different subsets based on their locations and methods of development. We also used 
these heterogeneous nasal glands as a model to investigate the process of lumen 
formation within gland ducts.   
 
Due to the imperative role of FGF signalling during the development of other 
branched structures, we investigated the role of Fgf10 during the branching 
morphogenesis of the nasal SMGs. In the Fgf10 null embryo, some nasal SMGs were 
absent while others showed normal duct elongation but defective branching, 
indicating that different glands require Fgf10 for selective stages of development. 
Furthermore, certain SMGs present in the Fgf10 homozygote were missing in the 
Fgfr2b mutant, suggesting compensation by another FGF ligand.  
 
In Fgf10 heterozygous mice the tracheal glands were reduced in size at an early age, 
with an altered A/P distribution of the SMGs postnatally, a deficit in glands that was 
not recovered in adults. The functional consequence of the reduction of SMGs in adult 
heterozygotes was investigated and showed that tracheal SMGs in Fgf10 mutant mice 
produce less mucus. Considering this, we assessed the ability of mutant mice to 
respond to respiratory challenges. We also analysed the defective salivary gland 
phenotype of Fgf10 heterozygotes and showed that gland dysplasia gave rise to a 
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1. Introduction 
1.1 The Mammalian Respiratory System 
1.1.1 Structure of the Mammalian Respiratory System 
The vertebrate evolutionary transition from water to land moulded a highly complex, 
interconnecting closed network of organs designed for successful gas exchange. The 
mammalian respiratory system is made up of a conserved structure consisting of two 
types of airways: the respiratory airways (RAs), where gas exchange takes place and 
the conductive airways (CAs), which function in directing air to the RAs. The CAs of 
the system consist of the nasal and oral cavity, pharynx, larynx, trachea, bronchi, 
bronchioles and terminal bronchioles (Figure 1.1), while the RAs include the 
respiratory bronchioles, alveolar ducts and alveoli. 
Cells of the body require oxygen from the external environment to produce adenosine 
triphosphate, the main currency of energy used in metabolic processes. Cellular 
respiration produces carbon dioxide, which is toxic in large amounts and needs to be 
expelled from our body. On average the resting human will inhale over 20,000 times a 
day, taking in over 12,000 litres of air on a daily basis (Rogers, 2007). Considering 
the composition of the external environment, with every breath, our body takes in a 
torrent of harmful inhalants and airway irritants (Seaton et al., 1995). Considering 
this, the soft tissues of our respiratory system are constantly exposed to the effects of 





Figure 1.1 Structure of the human respiratory system outlining the conductive 
airways and the lungs. 
The anterior respiratory system consists of both the nasal and oral cavities. It 
continues into the posterior region of the throat known as the pharynx, leading into 
the larynx, which additionally plays a role in sound production. The larynx also 
protects the anterior trachea, or windpipe, which is a long tube held open by C-shaped 
cartilage rings. The trachea bifurcates into the three-lobed right lung and the two-
lobed left lung via two tubes known as the bronchi, which are also held open and 
protected by cartilage rings. Bronchi branch into an array of smaller tubes called the 
bronchioles, whose walls are devoid of cartilage. From here the system continues into 
respiratory airways (RAs) consisting of the respiratory bronchioles, alveolar ducts and 







1.1.2 Protection of the Mammalian Respiratory System 
Not only do the CAs function in directing air to the RAs, they are also required to 
warm, humidify and filter the air before it reaches the lungs. To carry out this function 
the walls of the CAs are lined with a specialized respiratory epithelium (RE). The RE 
is a pseudostratified columnar epithelium whose tight junctions between its epithelial 
cells render it ideal as a protective and immunological barrier (Xiao, 2013). All of the 
epithelial cells sit on a basement membrane, or basal lamina, which is a rich matrix 
sheet of proteins that acts as a structural support, as well as a communication medium 
for neighbouring epithelial cells (LeBleu et al., 2007). The apical epithelial cell 
surfaces of the RE are specialized with hair like projections known as cilia. These 
cilia move in synchronized beats in an anterior direction, moving airway mucus away 
from the lungs.  
Airway mucus plays a vital role in maintaining airway homeostasis as it provides the 
first line of defence against airborne irritants in the nasal cavity, and is essential in the 
mucociliary process carried out in all of the CAs, ensuring no foreign particles reach 
the lungs. Not only does its thick consistency trap foreign particles; its protein 
constitution additionally contains bactericidal enzymes, hindering any risk of 
infection. 
In humans, 5% of the respiratory mucus is secreted by goblet cells, which are 
glandular, simple columnar cells that are found scattered within the respiratory 
epithelium (Reid, 1960). The nucleus of these cells is found basally, while the apex of 
the cell is rich in mucin secretory granules (Freeman, 1962). The remaining 95% of 
the mucus secretion is released by the nasal and tracheal submucosal glands (SMGs) 
that lie in the underlying submucosal layer beneath the RE (Reid, 1960). 
 
1.2 The SMGs of the Respiratory System 
1.2.1 Temporal Localisation of the SMGs 
The SMGs are hidden in the submucosal connective tissue running along the 
conductive airways. Nasal SMGs are organised into various named groups that are 
located in the medial and lateral nasal cavity walls (Grüneberg, 1971; Cuschieri and 
Bannister, 1974), while in the trachea, SMGs lie in the submucosal layer between the 
cartilage rings and smooth muscle (Finkbeiner, 1999). In the mouse, SMGS are found 
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in the upper trachea with the highest volume of tracheal glands found at the anterior 
boundary between the cricoid cartilage (CC) of the larynx and the first tracheal 
cartilage ring (C1) and extending no further than the sixth cartilaginous ring (C6) 
(Borthwick et al., 1999; Rawlins and Hogan, 2005). In humans these glands are also 
localised more uniformly in the anterior trachea, but are known to spread entirely 
through the tracheal tube all the way down to the submucosal layer of the bronchi 
(Sturgess and Imrie, 1982; Borthwick et al., 1999). In the mouse, nasal SMGs begin 
to develop on embryonic day (E) 12.5 with the appearance of the first lateral nasal 
gland (or Steno’s gland) in the form of a single tube with all subgroups of nasal 
SMGs being reported to begin their development by E17.5 (Grüneberg, 1971; 
Michael et al., 1994). In mice, it has been reported that the tracheal SMGs first appear 
on postnatal day (P) 2 as initial gland buds that then undergo morphogenesis with all 
tracheal SMGs initiated by postnatal day P21 (Borthwick et al., 1999; Rawlins and 
Hogan, 2005). 
1.2.2 Cellular Composition of the SMGs 
The SMGs boast a typical tree-like structure common to all branched organs such as 
the mammalian lungs, kidney, mammary glands, lacrimal glands and salivary glands. 
Research has shown that tracheobronchial SMGs consist of three distinct domains in 
relation to the overlying RE: (A) the secretory region of the distal gland, (B) the 
medial collecting region and (C) the proximal ciliated duct (Meyrick et al., 1969; 
Wine and Joo, 2004)(Figure 1.2). The secretory region is made up of two main 
secretory cell types: serous cells and mucous cells. Glandular acini, “acinus” meaning 
“berry” in Latin, describes the cluster of serous secretory cells found at the distal 
gland that forms a closed off sac surrounding a central lumen (Meyrick and Reid, 
1970)(Figure 1.2). These distal serous cells make up 61% of the overall secretory cell 
volume making it the primary defensive cell of the airway mucosa (Basbaum et al., 
1990). Serous cells produce a watery solution primarily made up of mucins (MUC2, 
MUC7), proteoglycans and bactericidal proteins such as lactoferrin and lysozyme 
(Masson et al., 1966; Klockars and Reitamo, 1975; Finkbeiner, 1999). Serous tubules 
then lead into more proximal mucous tubules with mucous cells making up 39% of 
the remaining secretory gland volume (Basbaum et al., 1990) (Figure 1.2). Mucous 
cells produce a thick gel containing mucins MUC2 and MUC5 and antimicrobial 
peptide Cathelicidin (Finkbeiner, 1999). The protein consistency of mucus provides 
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ideal lubrication and acts as a chemical barrier to the exposed epithelium. The serum 
and mucus secreted by these specialized cells accumulates in a non-ciliated collecting 
duct and is then passed through a ciliated duct into the airway lumen (Figure 1.2). It is 
generally believed that mucus is expelled into the airway through the movement of 
the cilia within the ducts, however no concrete evidence indicates this is the case and 
it is suggested that the fluid is rather moved through a means of bulk flow (Ballard 
and Spadafora, 2007). Once secreted into the airway, mucus is swept away from the 
lungs to the pharynx by RE cilia movement where it is either swallowed and ingested, 
or is removed from the body by sneezing or coughing. 
1.3 The SMGs and Airway Disease 
The importance of SMG structure and function is increasingly emphasised as more 
and more evidence shows their involvement in an array of respiratory diseases. The 
most common hyper-secretory diseases in which SMGs play a role are cystic fibrosis, 
asthma and chronic bronchitis.  
1.3.1 Cystic Fibrosis 
Cystic Fibrosis (CF) (OMIM #219700) is an autosomal recessive disorder seriously 
affecting the respiratory system as well as the digestive system, due to the 
overproduction of mucus with a thick viscosity (Rowe et al., 2005). The prevalence of 
CF in the UK is approximately 1 in 2500 live births, with the highest international 
rate of 1 in 1461 live births found in the Republic of Ireland (Fitzgerald and Ryan, 
2011). The major repercussion of CF is lung disease as high mucus concentration 
blocks the airways leading to inflammation, atelectasis, and chronic hypoxia 
(Fitzgerald and Ryan, 2011). Defective mucociliary clearance and the accumulation 
of thick mucus also provide an ideal moist environment for the proliferation of 
harmful bacteria, most commonly Pseudomonas aeruginosa and Staphylococcus 





Figure 1.2 Schematic illustration outlining the cellular composition of the 
submucosal glands. 
The distal glands are composed of closed sacs of serous cells, which form acini. 
These serous cells secrete a watery like secretion rich in bactericidal enzymes. Acini 
run into tubules of mucous cells, which secrete a thicker gel like substance rich in 
glycosylated proteins. These two types of secretions are then combined in a collecting 
duct, whose wall is composed of non-ciliated columnar epithelial cells. The collecting 
duct then runs into a ciliated duct made of more respiratory epithelial-like cells that 
possess beating cilia on their apical surfaces. Mucus is secreted through this ciliated 




The aetiology of CF lies in a defect of ion channels involved in mucus secretion. In 
1989, extensive studies elucidated that one gene, cystic fibrosis transmembrane 
conductance regulator (CFTR) was the main culprit for the disease (Riordan et al., 
1989; Kerem et al., 1989; Rommens et al., 1989). The CFTR gene is located on 
chromosome 7 and encodes for a 1480 amino acid CFTR protein (Riordan et al., 
1989). In healthy individuals, the membrane bound CFTR protein acts as an ion 
channel, modulating the hydro-electrolytic flux and controlling osmotic gradients 
between epithelial cells and airway mucus (Vankeerberghen et al., 2002). In normal 
conditions, airway mucus is approximately 98% water (H2O) (Wine and Joo, 2004). 
This is maintained by CFTR channels allowing the passage of negatively charged 
chloride ions (Cl-) out of the epithelial cells into the overlying airway mucus. 
Following this, positively charged sodium ions (Na+) follow and pass into the mucus 
via separate membrane bound sodium channels. This higher ion concentration in the 
overlying mucus causes the movement of H2O through osmosis from the epithelial 
cell and surrounding tissues into the mucus. In sufferers of CF, the CFTR channels 
are permanently closed, blocking off translocation of Cl- ions into the mucus. This 
causes epithelial cells to have a negative charge and leads to the movement of H2O 
from the mucus into the epithelial cell, rendering airway mucus a lot thicker due to a 
severe decrease in water content. This thick mucus then coats the airways, as well as 
the pancreas and lumens of the digestive system, causing serious respiratory and 
digestive difficulties and increased susceptibility to bacterial infection. 
The airway SMGs are the primary mucus-producing machines of the respiratory 
system. Engelhardt et al. (1992) showed that the serous cells, and a small percentage 
of cells of the collecting ducts of human SMGs of the bronchi are predominant sites 
of CFTR expression focusing interest on SMGs as culprits in the pathogenicity of CF. 
One of the earliest steps in CF pathophysiology is the occlusion and dilation of SMG 
ducts, evident in third trimester neonates with CF (Ornoy et al., 1987). Infants with 
CF then show early onset of hyperplasia and hypertrophy of SMGs (Oppenheimer and 
Esterly, 1975; Sturgess and Imrie, 1982). Later studies elucidated that the distribution 
of SMGs in two CFTR-deficient mouse models is abnormal, with glands extending 
more posteriorly in homozygous animals indicating that there is not only an ion 
channel/secretion defect but also suggesting a SMG developmental defect associated 
with CF (Borthwick et al., 1999).  
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1.3.2 Asthma 
Asthma is a common inflammatory disease of the respiratory system that is 
characterized by periodic episodes of shortness of breath, wheezing and a recurrent 
cough. These responses are due to complex processes including airway hyper-
responsiveness to irritants, inflammation and reversible structural changes to the 
airways referred to as “airway remodelling”. Bronchoconstriction, the main cause of 
shortness of breath during an asthma attack, is brought about by airborne stimulants 
referred to as “asthma triggers”. These triggers are irritants such as pollen, house dust 
mites, cigarette smoke and fungal spores. Upon inhalation, these triggers influence 
changes within the lower bronchiole tubes. The bronchioles of the respiratory system 
are not held open by cartilaginous rings unlike the more anterior trachea and bronchi 
and therefore their walls, made of smooth muscle, can freely change in diameter. This 
characteristic renders bronchioles susceptible to constriction, leading to breathing 
difficulties or asthma attacks. 
In sensitized individuals, upon inhalation of asthma triggers, the irritants are detected 
by cell surface receptors of epithelial cells in the bronchioles. This detection 
stimulates both smooth muscle constriction and an immune response to tackle 
invasion of foreign stimuli. To date over 100 inflammatory mediators are known, 
including mast cells, T-cells and eosinophils (Barnes et al., 1998; Barnes, 2004). 
Constriction of bronchiole smooth muscle causes muscle cells to contract, tightening 
and decreasing the diameter of the bronchiole tubes. Additionally, the inflammatory 
response also reduces the size of the bronchiole lumen and thus significantly impairs 
the volume of air received by the lungs. 
While investigation continues into smooth muscle activity and inflammation 
pathways involved in asthma, research has also begun to focus on the additional 
pathophysiological feature of mucus hyper-secretion. Increasing evidence shows that 
airways of asthmatic patients become blocked with mucus plugs, and that the 
consistency of this mucus changes, becoming more gel like and solidified (Sheehan et 
al., 1995; Rogers, 2004). Comparison of the mucus occupying ratio (MOR) of 
airways of asthma sufferers that died of severe asthma attack was significantly greater 
than the MOR of chronic asthma sufferers and control patients (Aikawa et al., 1992; 
Rogers, 2004). Goblet cell hyperplasia and an increase in goblet cell mucin stores 
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contribute to this influx in mucus secretion (Aikawa et al., 1992; Ordoñez et al., 
2001). Furthermore, hyperplasia of the bronchial SMGs is a well defined feature of 
asthma airways with gland:bronchial wall area ratio being significantly increased in 
both chronic asthma sufferers and those that die of sudden attack, compared to control 
patients (Aikawa et al., 1992; Rogers, 2004). 
1.3.3 Chronic Obstructive Pulmonary Disease 
Chronic Obstructive Pulmonary Disease (COPD) is an umbrella term for a collection 
of airflow limitation respiratory diseases including chronic bronchitis, a disease of the 
airways, and emphysema, inflammation of the pulmonary parenchyma. It has been 
estimated to be the fifth-leading cause and the sixth leading cause of death in high-
income and low-middle income countries, respectively (Mannino and Buist, 2007). 
Unlike asthma, COPD progresses slowly and airway obstruction and inflammation is 
usually irreversible (Barnes, 2004). Cigarette smoke is the most common and lethal 
COPD trigger, yet others include air pollutants, industrial toxins and chemicals (Baur 
et al., 2012).  
In chronic bronchitis, inhalation and long-term exposure to COPD triggers lead to the 
inflammation and fibrosis of the bronchiole walls. Similarly to asthma this leads to 
the reduction of bronchiole diameter, dramatically reducing airflow. Additionally, 
within the airway lumens, accumulation of mucus leads to plugging, further reducing 
airflow to the lungs. In sufferers of chronic bronchitis, the bronchial SMGs are 
hypertrophic, displaying mucus hyper-secretion and an increase in mucous cells 
compared to serous cell counterparts (Reid, 1960; Rogers, 2008). This mucous:serous 
cell ratio imbalance leads to an altered protein consistency of the mucus released into 
the airway lumen and a significant increase in the MUC5A:MUC5B ratio (Rogers, 
2004). While mucus plugs are easier to dislodge in patients of COPD compared to 
sufferers of asthma, mucus plugging and blockage can still lead to terminal infection 
and mortality (Prescott et al., 1995; Rogers, 2004). Chronic bronchitis sufferers also 
show an influx of neutrophils and macrophages in their bronchial SMGs (Saetta and 
Turato, 1997). 
Considering the critical involvement of SMGs in the above respiratory conditions, 
little is known about the developmental and homeostatic mechanisms of the 
respiratory glands. In order to elucidate if a developmental defect occurs in sufferers 
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of disease, normal developmental signalling factors, modulators and pathways 
involved in SMG morphogenesis must be delineated. 
1.4 Signalling in SMG Development 
1.4.1 Wnt/β-catenin Signalling 
The Wnt signalling pathway is an evolutionary conserved pathway, critical for 
controlling the development of an organism. Many developmental processes such as 
cell proliferation, migration, polarity and fate determination rely on the regulation of 
Wnt signalling (Komiya and Habas, 2008). A total of 19 Wnt ligands have been 
identified in humans and these can trigger one of two categories of Wnt transduction 
pathways, the canonical Wnt/β-catenin cascade, and the non-canonical Wnt/β-
catenin-independent cascades, which include the Wnt/Planar Cell Polarity pathway 
and the Wnt/Calcium pathway. The former of these, the canonical Wnt signalling 
pathway, is the most studied and involves the binding of extracellular Wnt ligands to 
transmembrane bound Frizzled receptors. In the absence of Wnt ligand binding, 
cytoplasmic β-catenin is constantly broken down by the Axin complex (Figure 1.3, 
A). This protein compound consists of Axin, a scaffolding protein, glycogen synthase 
kinase 3 (GSK3), casein kinase 1 (CK1) and the adenomatous polyposis coli gene 
product (APC). Together, GSK3 and CK1 phosphorylate β-catenin, rendering it 
recognisable to the E3 ubiquitin ligase subunit β-Trcp (Liu et al., 2002; Davidson et 
al., 2005; Zeng et al., 2005). Subsequent ubiquitin of β-catenin occurs, followed by its 
proteosomal degradation (He et al., 2004) (Figure 1.3, A). This constant breakdown of 
β-catenin prevents it from translocating into the nucleus. Following Wnt-ligand 
binding to Frizzled, along with one of its co-receptors, low-density lipoprotein 
receptor related protein 5 (LRP5) or LRP6, Dishevelled (Dsh), another scaffolding 
protein, is recruited to the Frizzled receptor (Wallingford and Habas, 2005)(Figure 
1.3). Dsh activation triggers LRP5/6 phosphorylation, which in turn leads to the 
recruitment of the Axin complex to the LRP receptor (Mao et al., 2001). This receptor 
binding to the Axin complex prevents the β-catenin inhibitory effects of these 
proteins, and thus β-catenin degradation (He et al., 2004). β-catenin now accumulates 
within the cytoplasm and translocates into the nucleus where it can activate Wnt-
responsive genes, by regulating the function of specific transcription factors. The 
most studied nuclear mediators targeted by Wnt signalling belong to the lymphoid 
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enhancer factor 1/T-cell factor (LEF-1/TCF) family (Eastman and Grosschedl, 1999; 
Arce et al., 2006). 
Using the Lef1 -/- mouse to study the biological role of this gene, it was shown that 
knockout mice failed to develop organs such as teeth, hair follicles and mammary 
glands (van Genderen et al., 1994). As these organs require epithelial-mesenchymal 
interactions similar to developing SMGs, it was hypothesised that Wnt/β-catenin 
activity may be involved in the development of the nasal SMGs. Using the β-
catenin/Tcf-βgal reporter (TOPGAL) mouse, it has been shown that the canonical 
Wnt pathway is active during early nasal gland bud formation (Driskell et al., 2007). 
Additionally, the transcription factor Lef1, has been shown to be highly expressed in 
progenitor cells of early SMG buds in the mouse nose and trachea, and the ferret 
trachea, and in Lef1 knockout mice amorphous aggregates of cells develop where 
nasal SMGs are seen in wildtypes (Duan et al., 1998, 1999; Driskell et al., 2004). Lef1 
promoter expression has been shown to be regulated by the Wnt3-a ligand during 
SMG morphogenesis, and in the Wnt3-a knockout mouse, SMG Lef1 expression was 
lost and cell proliferation of epithelial gland cells was reduced in SMG buds (Driskell 
et al., 2007). While these studies have given insight into the necessity of Wnt 
signalling for early SMG bud formation, the involvement of Wnt molecules in later 
stages of respiratory gland development has not been investigated.  
 
1.4.2 Bone Morphogenetic Protein Signalling 
The bone morphogenetic proteins (BMPs) belong to the transforming growth factor β  
(TGFβ) superfamily (Miyazono et al., 2010). The BMPs play a multitude of roles 
during early embryonic patterning and morphogenesis such as the regulation of cell 
proliferation, differentiation, apoptosis and cell-fate determinations (Hogan, 1996; 
Kishigami and Mishina, 2005). Twenty BMPs have been identified, all having 
heterogeneous functions during developmental processes such as neurogenesis, bone 
and cartilage formation, and organogenesis (Hogan, 1996; Zhao, 2003). 
 
In general, the BMP pathway involves the extracellular BMP ligands binding to the 
cell membrane bound BMP receptors (BMPR). These receptors are serine-threonine 
kinase receptors that belong to two groups, Type I and Type II (Massagué et al., 
1994). BMPs bind to the Type I BMPR with higher affinity to that of Type II (Wrana 
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et al., 1994; Kirsch et al., 2000). In order for ligand binding to stimulate an 
intracellular signal, heterodimerization of one Type I and one Type II BMPR is 
required (Figure 1.4). Upon BMP ligand binding to the Type I receptor, the Type II 
receptor is recruited (Kirsch et al., 2000; Carreira et al., 2014). The Type II BMPR 
then catalyses the phosphorylation of the intracellular serine-threonine domain of the 
Type 1 BMPR, recruiting a cytoplasmic receptor-activated Smad protein (either 
Smad1, 5 or 8).  (Wrana et al., 1994). Phosphorylation of one of these Smads triggers 
the recruitment of another cytoplasmic Smad, Smad4 (Whitman, 1998). This dimeric 
Smad complex can now translocate into the nucleus where BMP target genes can be 
activated. A number of extracellular antagonists also function in regulating the 
pathway. These include such soluble proteins as Noggin, Gremlin and Chordin, which 
form complexes with BMP ligands, preventing them from binding to their cell 
receptors (Yanagita, 2005; Walsh et al., 2010).  
It has been previously shown that BMP signalling is critical for the development and 
patterning of the trachea and lungs (Weaver et al., 1999; Eblaghie et al., 2006; Li et 
al., 2008). The only investigation into the roles of BMP signalling in respiratory gland 
development have been shown during that of the tracheal SMGs (Rawlins and Hogan, 
2005). Using the Bmp4lacz reporter mouse, it was reported that at P2 when tracheal 
buds were initiating from the respiratory epithelium, Bmp4 was expressed throughout 
the underlying mesenchyme. During later development at P7, Bmp4 detection was 
reduced and found only in the mesenchyme close to the newly formed gland branches 
(Rawlins and Hogan, 2005). By P28, Bmp4 expression had reduced even further, and 





Figure 1.3 The canonical Wnt/β-catenin pathway. 
(A) In the absence of Wnt ligand binding to the membrane bound Frizzled receptor 
and its co-receptor LRP5/6, the Axin complex binds to cytoplasmic β-catenin. This 
binding leads to the phosphorylation of β-catenin by CK1 and GSK3β, leading to the 
degradation of β-catenin, and preventing its translocation into the nucleus. (B) Upon 
extracellular Wnt ligand binding, a Frizzled-LRP receptor complex is formed, leading 
to the recruitment of Dsh by Frizzled. This phosphorylates LRP5/6, which triggers 
Axin recruitment to the receptor complex. Recruitment of Axin inhibits the 
phosphorylation of β-catenin by the Axin complex, and thus prevents its degradation. 
β-catenin now accumulates within the cell and translocates into the nucleus where it 
regulates activation of LEF/TCP transcription factors and Wnt-responsive genes, 




Figure 1.4 The BMP signalling pathway. 
Extracellular BMP ligand binding to the transmembrane BMP receptors Type I and 
Type II. Phosphorylation of the Type I receptor by the Type II BMPR leads to the 
intracellular activation of Smad1, 5 or 8. This Smad protein will then phosphorylate 






1.4.3 Ectodysplasin A Signalling 
The role of the Ectodysplasin A (EDA) pathway has been investigated in the 
development of a number of ectodermal derived organs. Signalling through this 
pathway involves the binding of EDA A1, a member of the tumor necrosis factor 
(TNF) family, to a death domain transmembrane receptor, EDAR (Srivastava et al., 
1997; Headon and Overbeek, 1999). EDA ligand binding to EDAR leads to the 
recruitment of the intracellular adaptor protein EDAR Associated Death Domain 
(EDARADD). Recruitment of EDARADD to the receptor leads to the formation of a 
complex containing the cytoplasmic proteins TNF Receptor Associated Factor 6 
(TRAF6), TGF-β Activated Kinase 1 (TAK1) and TAK Binding Protein 2 (TAB2) 
(Morlon et al., 2005). This leads to the activation of the IκB kinase complex (IKK), 
which is a compound of two kinase sub-units, IKK1 and IKK2, as well as the 
regulatory component NF-kappaB essential modulator (NEMO) (Döffinger et al., 
2001; Morlon et al., 2005). Activation of the IKK complex triggers recruitment and 
the phosphorylation of inhibitor kappa-B (IκB), a nuclear factor-kappaB (NFκB) 
inhibitor. Phosphorylation of IkB leads to its degradation, and NFκB translocates into 
the nucleus where it acts as a transcription factor, regulating target genes involved in 
cell proliferation, differentiation and survival (Gilmore, 2006; Oeckinghaus and 
Ghosh, 2009). 
Requirement for the EDA signalling pathway in both nasal gland and tracheal SMG 
development has been investigated (Grüneberg, 1971; Rawlins and Hogan, 2005). 
Interestingly, analysis of the Tabby mouse, the knockout model of the gene required 
for Eda, showed that specific groups of the anterior nasal glands were completely 
absent while others developed normally (Grüneberg, 1971). In another study, Edar 
expression was seen within the tracheal epithelium at early stages of tracheal SMG 
development at P4 (Rawlins and Hogan, 2005). Tracheal SMGs were also completely 
absent in the adult Tabby mouse, as well as in the early Edaradd knockout at P7, 
indicating that EDA signalling is required for early SMG initiation and budding 
(Rawlins and Hogan, 2005). Human patients with mutations in EDA, EDAR or 
EDARADD suffer from the disorder hypohidrotic ectodermal dysplasia (HED), 
which gives rise to developmental defects in teeth, hair, salivary glands and, in 
keeping with the mouse data above, develop problems associated with the respiratory 




Figure 1.5 The Ectodysplasin A signalling pathway. 
EDA ligand binding to its transmembrane receptor EDAR recruits EDARADD and a 
TRAF6-TAK1-TAB2 complex is formed. This complex activates the IKK complex 
containing kinases IKK1, IKK2 and NEMO. The IKK complex recruits and 
phosphorylates IκB, leading to its degradation. The inhibitory function of IκB is now 
diminished and NF-κB can translocate in to the nucleus where it functions as a 





1.4.4 Fibroblast Growth Factor (FGF) Signalling 
Rawlins & Hogan (2005) established that in Fgf10 heterozygous (+/-) mice at P20 
fewer tracheal SMGs had developed. Of the glands that did develop, they were only 
located anteriorly by the CC and C1 and had not undergone full branching while no 
glands were seen between the more posterior cartilaginous rings (Rawlins and Hogan, 
2005). The exact role of Fgf10 however, or other Fgfs, during nasal and tracheal SMG 
development has not been elucidated. Considering this, the work of this thesis has 
focused on uncovering the role of FGF signalling in the early patterning of the 
respiratory SMGs.  
1.5 FGF Family of Signalling Factors 
1.5.1 FGF Ligands 
FGFs make up one of the largest family of polypeptide proteins critical for tissue 
patterning and development. As the brain is a rich source of fibroblasts, the first FGFs 
(FGF1 and FGF2) were discovered as bovine pituitary cell mitogens (Gospodarowicz, 
1975). Today, 22 members (FGF1-FGF22) of the FGF family are known within the 
human genome (Ornitz and Itoh, 2001). Despite their sequence similarities to other 
FGF ligands, FGF11-FGF14 however, do not bind to fibroblast growth factor 
receptors, so therefore are not considered as true FGF ligands (Olsen et al., 2003). 
The genomic locations of each FGF gene varies, with the exception of FGF3, FGF4 
and FGF19 which are found linked on chromosome 11 in humans and chromosome 7 
in mice (Ornitz and Itoh, 2001). The length of the coding sequences in all human FGF 
genes also varies from 5kb (in FGF3 and FGF4) to 100 kb (FGF12) (Ornitz and Itoh, 
2001). These diverse structures allow FGFs to play differential roles during both 
embryonic development and adult tissue homeostasis. During embryonic 
organogenesis, FGFs are critical for cell processes such as proliferation, 
differentiation and migration (Tsuboi et al., 1990; Sun et al., 1999; Lanner and 
Rossant, 2010), with FGF signalling being imperative for normal craniofacial 
development (Stanier and Pauws, 2012) as well as limb and lung morphogenesis (Min 
et al., 1998; Sekine et al., 1999). In adults, the roles of FGFs are highlighted in wound 
healing processes, nervous system maintenance and tissue repair (Werner, 1998; 
Barrientos et al., 2008).  
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1.5.2 FGF Receptors 
Four cell membrane-bound FGF receptors (FGFRs) have been identified in 
vertebrates, each having different affinities for different FGF ligands. The four 
receptors, FGFR1-FGFR4, are composed of the common protein structure of most 
tyrosine kinase receptors (Johnson et al., 1990).  This structure can be divided into 
three core areas referred to as (A) the extracellular domain, (B) the transmembrane 
domain and (C) the intracellular domain (Figure 1.6). The extracellular region of the 
receptor acts as the ligand-binding area and is comprised of three immunoglobulin-
like domains (IgI-III) (Lee et al., 1989). The IG superfamily of proteins is one of the 
largest found in the human genome and one of the most important in protein 
interactions. These domains are so called as they share a common 70-100 amino-acid 
complex with immunoglobulins (Barclay, 2003). Furthermore, a region of acidic 
amino acids is located between IgI and IgII, which is known as the “acid box” (Figure 
1.6). This acidic stretch is hypothesised to play a role in auto-inhibition of the FGF 
receptor (Kalinina et al., 2012). The single-span region of the receptor within the 
plasma membrane is known as the Transmembrane Domain (TM) and aids in receptor 
dimerization stability upon ligand binding (Li and Hristova, 2010). The intracellular 
domain of the receptor, found within the cell, is the signal transducing area of the 
receptor. It is composed of tyrosine kinase domains (TKs) with a carboxyl–terminal 
tail, and upon receptor dimerization, this tail is phosphorylated and intracellular 
signalling pathways are triggered.  
Through mRNA alternative splicing processes, splice variants of the FGFRs are 
formed (Figure 1.7). The presence of an alternatively spliced exon within the IgIII 
domain of the receptor gives rise to one of three potential receptor isoforms; IIIa, IIIb 
or IIIc (Yayon et al., 1992; Miki et al., 1992) (Figure 1.7). This only occurs in 
FGFR1-FGFR3, as it has been demonstrated that only the IIIc isoform occurs in 
FGFR4 (Vainikka et al., 1992). This mechanism allows a single gene to give rise to 
alternative isoforms of a receptor, rendering the receptors promiscuous for ligand 
affinities (Ornitz et al., 1996).  For example, in the case of FGFR2 (Figure 1.7), the 
splice variant IIIb binds to FGF3, FGF7 and FGF10 with high affinity, while the IIIc 
receptor binds to FGF2, FGF4, FGF6, FGF8 and FGF9 (Ornitz et al., 1996). Not only 
do these two receptor isoforms display different ligand affinities, they also differ in 
their tissue expression patterns with FGFR2IIIb (FGFR2b) found primarily in 
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epithelium and FGFR2IIIc (FGFR2c) in mesenchymal cells (Peters et al., 1992; Orr-
Urtreger et al., 1993). Therefore alternative sequences of FGFRs and their isoforms, 
along with differential sequences of FGF ligands, create a repertoire of ligand-
receptor binding specificities. 
 
Figure 1.6 The general structure of FGFRs. 
The membrane bound FGFRs have a conserved protein structure similar to that of all 
tyrosine kinase receptors. The extracellular domain consists of three immunoglobulin-
like domains (IgI, IgII and IgIII). Between IgI and IgII lies a stretch of 8-amino acids 
known as the “acid box”. The region of the receptor that is found within the plasma 
membrane is known as the Transmembrane Domain (TM). The intracellular domain 
found within the cytosol consists of two split tyrosine kinase domains (TK) and a 
carboxyl-terminal tail (C-). It is this tail that undergoes phosphorylation upon ligand-
receptor binding and an intracellular cascade is triggered. 
 
 





Figure 1.7 Generation of FGFR2 splice variants by alternative splicing. 
Different FGFR isoforms are generated by alternative splicing mechanisms. 
Alternative usage and interpretation of exon 8 and exon 9 of the Fgfr2 allele into the 




1.5.3 FGF Intracellular Signalling Pathway 
The initiation of an intracellular signalling transduction pathway relies on 
extracellular binding of ligands to the receptor. FGFs are referred to as monomeric 
growth factors, meaning each ligand can only bind to one receptor (Spivak-Kroizman 
et al., 1994). FGF signalling, similar to all TK activated pathways, requires 
dimerization of two receptors, therefore two monomeric FGF ligands are recruited, 
with one ligand binding with high affinity to both the IgII and IgIII domains of the 
extracellular region of each FGFR (Schlessinger, 2000)(Figure 1.8). FGF proteins do 
however contain two binding sites, allowing for binding to their high affinity receptor 
as well as a cell surface Heparan Sulphate Proteoglycan (HSPG) molecule (Pye and 
Gallagher, 1999)(Figure 1.8). This additional binding to HSPG causes a 
conformational change within the FGF protein, allowing it to bind stably to its FGFR 
and facilitates receptor dimerization (Spivak-Kroizman et al., 1994; Faham et al., 
1996; Loo et al., 2001). 
Receptor dimerization then leads to the intracellular phosphorylation of the TK 
domains of each FGFR (Schlessinger, 1988; Jiang and Hunter, 1999). Following TK 
phosphorylation, a number of intracellular signalling cascades are triggered that are 
required for a multitude of developmental processes (Figure 1.8). These include the 
phospholipase C gamma (PLC-ϒ) pathway which initiates calcium release and 
activates protein kinase C to influence cell motility (Burgess et al., 1990; Mohammadi 
et al., 1991), and the phosphatidylinositol-3 kinase (PI3K) which activates Akt/protein 
kinase B needed for the mediation of cell survival (Ong et al., 2001)(Figure 1.8, B). 
The most common route of FGF signalling during developmental processes is through 
the activation of the rat sarcoma homologue (RAS)/mitogen-activated protein kinase 
(MAPK) cascade. This pathway functions in activating target genes involved in 
cellular differentiation and proliferation (Figure 1.8, B). 
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Figure 1.8 FGFR receptor dimerization and activation of intracellular pathways. 
(A) Receptors exist singly within the cell membrane in their inactive form before 
binding with extracellular FGF ligands (orange). (B) Two FGF ligand molecules are 
required to bind to two cell membrane bound FGF receptors for successful FGFR 
dimerization. Binding with cell surface HSPG is also critical for successful dimerization 
and signalling. Upon ligand binding tyrosine kinase domains (TK) are activated within 




1.5.4 The Ras/MAPK Pathway 
Considering the various structures and form of FGF ligands, FGF receptors and the 
diverse pathways triggered by FGF signalling, the story of the FGFs is a complex one. 
For the sake of this study, investigation was focused primarily on the Ras/MAPK 
pathway and the role of this cascade during SMG development. Following FGFR 
dimerization and auto-phosphorylation of its TK domains, the lipid-anchored docking 
protein FGFR Substrate-2 (FRS2) is phosphorylated and its tyrosine phosphorylation 
sites bind to the adapter protein Growth Factor Receptor Bound Protein 2 (Grb2) 
(Kouhara et al., 1997) (Figure 1.9). The binding of Grb2 to the FRS2 and the RTK 
recruits Son of Sevenless (SOS), a guanine nucleotide exchange factor, to the cell 
membrane which then binds to Grb2 forming a complex (Pierre et al., 2011). The 
location of this complex allows it to activate the cell membrane bound G-protein Ras. 
In its inactive state Ras is bound to the nucleotide guanosine diphosphate (GDP). 
When bound to SOS, GDP is exchanged with guanosine triphosphate (GTP), which 
then activates Ras (Figure 1.9). The activated GTP bound Ras then recruits effector 
proteins to the cell membrane, in particular Raf, a protein kinase usually found in the 
cytosol (Leevers et al., 1994) (Figure 1.9). This recruitment phosphorylates and 
activates Raf, which in turn phosphorylates the MAPK kinase MEK (MEK1/MEK2) 
on its serine and threonine residues (Crews et al., 1992; Leevers et al., 1994; Gardner 
et al., 1994). MEK kinase then phosphorylates MAPKs such as extracellular signal-
regulated protein kinases (ERKs)(Figure 1.9). Following activation, ERKs translocate 
into the nucleus and activate target transcription factors such as PEA3 and ERM, 
which belong to the E-twenty-six (ETS) family of transcription factors (Wasylyk et 
al., 1998; Yordy and Muise-Helmericks, 2000) (Figure 1.9). These are required to 
mediate cell differentiation, mitogenesis and proliferation. 
1.5.5 Downstream Targets of the MAPK Pathway 
Members of the ETS domain transcription factor family all contain a conserved 
sequence within their DNA-binding domain. This ETS domain is a winged helix-turn-
helix structure that binds to target DNA motifs with a central 5’-GGA(A/T)-3’ 
sequence (Watson et al., 1988; Sharrocks et al., 1997). Conserved sequences within 
the remaining amino acid domains of each ETS family member also arise and based 
on these similarities, ETS proteins are categorised into subfamilies. For example, the 
PEA3 (polyoma enhancer activator 3) subfamily contains three ETS-domain 
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transcription factors, ETV1, PEA3 (or ETV4) and ERM (or ETV5). The three PEA3 
family transcription factors are almost 50% identical in their overall structure, with 
95% identity in the ETS-domain (reviewed in de Launoit et al. 1997). Extensive 
studies have shown that the PEA3 group of ETS domain transcription factors are 
targets of MAPK signalling and are involved in Ras-induced cell transformation 
processes (Janknecht, 1996; Wasylyk et al., 1998; Yordy and Muise-Helmericks, 
2000). Due to this function, the ETS domain transcription factors are critical for cell 
proliferation and differentiation mechanisms in a multitude of tissue types during 
embryonic development (Chotteau-Lelièvre et al., 1997; Remy and Baltzinger, 2000; 
Paratore et al., 2002; Chotteau-Lelievre et al., 2003). 
1.5.6 Modulators of the MAPK Pathway 
Being a complex pathway, there are also a number of modulators of FGF signalling 
that work through feedback loops to tightly regulate activity. Evolutionary conserved 
Sprouty (Spry) is both induced by and inhibits the Ras/MAPK pathway involved in 
FGF signalling. With four members in mammals (Dikic and Giordano, 2003), it has 
been identified that SPRY can antagonize the pathway in one of two ways. Firstly, 
SPRY1 and SPRY2 can bind to Grb2 preventing its phosphorylation of SOS and 
subsequent activation of Ras (Hanafusa et al., 2002)(Figure 1.9). Secondly, SPRY2 
and SPRY4 can also inactivate the pathway further downstream by binding to Raf and 
preventing MAPK activation (Yusoff et al., 2002; Sasaki et al., 2003)(Figure 1.9). 
Other attenuators of the pathway have also been identified such as Sef in zebrafish 
(Fürthauer et al., 2002) and nuclear map kinase phosphate 1 (MKP1) and cytoplasmic 




Figure 1.9 Schematic drawing of the Ras/MAPK signalling pathway activated by 
FGF-FGFR binding. 
Extracellular ligand binding triggers intracellular phosphorylation of FGFR TK 
domains. This leads to the phosphorylation of FRS2, which allows the formation and 
activation of the Grb2 and SOS complex. The complex permits the guanosine 
nucleotide exchange of membrane bound Ras, from GDP to GTP. The activated GTP-
bound Ras recruits Raf to the membrane and phosphorylates the Raf protein. 
Activated Raf phosphorylates the MAPK kinase (MAPKK) MEK, which in turn 
phosphorylates the MAPK ERK. Activated ERK translocates into the nucleus where 
it targets specific transcription factors essential for cell proliferation and 
differentiation. Sprouty (Spry) molecules act as negative feedback regulators by 
inhibiting SOS activation by binding to Grb2 or by preventing the phosphorylation of 




1.6 Branching Morphogenesis 
Branching morphogenesis is the elegant developmental process where a single tube 
arises from an endothelial or epithelial sheath and undergoes continual budding and 
clefting to create a complex network of branched tubes. The entire process involves a 
multitude of cell behaviours such as proliferation, migration and differentiation, as 
well as epithelial interactions with adjacent tissues and extracellular matrix. Many 
structures have evolved this branched architecture as it allows for a large surface area 
to be contained in a small volume of space, thus making it ideal for organs that 
function in transporting liquid or gas. The sprouting tubes are composed of 
endothelial cells in the branched vasculature and lymphatic systems, while they are 
composed of epithelial cells in most other branched structures of the body. For 
relevance to this study, the branching of epithelial structures will be discussed.  
1.6.1 Branching of the Drosophila melanogaster Tracheal System 
The tracheal system of the fruit fly (Drosophila melanogaster) is a complex branched 
structure that has provided immense insight into the cellular and genetic mechanisms 
involved in the process of branching morphogenesis in vivo. Although comprising of 
only approximately 80 cells, this respiratory structure supplies oxygen to every cell of 
the body and provides an ideal model system for investigating branching (Samakovlis 
et al., 1996; Kerman et al., 2006). The process begins with 10 clusters, or placodes, of 
ectodermal derived epithelial cells forming along the surface of the Drosophila larva 
(Figure 1.10 A). These placodes are formed by cell proliferation, which cause 
epithelial sacs to invaginate into the underlying mesoderm (Samakovlis et al., 1996). 
Once the epithelial sacs are formed cell proliferation arrests. From these sacs, the 
tracheal branches develop, with their development being divided into three main 
stages; (1) Primary (2) Secondary and (3) Terminal branching (Samakovlis et al., 
1996). The primary branches are formed from six buds arising from each epithelial 
sac at stage 12 of fruit fly development (Figure 1.10 A and B). At stage 15 of 
development, two secondary branches arise in a uniform fashion from the primary 
branches (Figure 1.10 C and D) followed by the sprouting of numerous terminal tubes 
at stage 16 (Samakovlis et al., 1996). 
 
Investigation into the signalling mechanisms patterning the fruit fly tracheal system 
elucidated a role for FGFs. Drosophila have one FGF ligand homologue, encoded by 
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the gene branchless (bnl) and two FGFRs, encoded by the genes breathless (btl) and 
heartless (htl). Studies have shown that mutations in both btl and its ligand bnl, led to 
defective tracheal cell migration and abnormal tracheal branching (Lee et al., 1996; 
Sutherland et al., 1996). Although tracheal pit formation is FGF independent, and 
relies on another Drosophila ligand encoded by the gene trachealess (trh) (Isaac and 
Andrew, 1996), bnl expression surrounding the epithelium acts as a chemoattractant 
for the outgrowth of both the air sacs and the primary branch cells, and activates btl 
expression within the epithelial cells (Sutherland et al., 1996; Glazer and Shilo, 1991; 
Sato and Kornberg, 2002)(Figure 1.10 A-B). Once the primary branches elongate and 
reach the bnl expressing cells, elongation of the primary branch ceases (Figure 1.10 
C). The high level of Bnl ligand signal induces the expression of the ETs domain 
transcription factor pointed (pnt) within the tubule epithelial cells which in turn 
activates spry expression (Hacohen et al., 1998). Spry then functions in inhibiting the 
expression of bnl in distal tubule cells, restricting the influence of Bnl to the tracheal 
tip cells, which then form secondary branches (Hacohen et al., 1998) (Figure 1.10 C-
D). The terminal branches do not develop as stereotypically as the primary and 
secondary. Their sprouting and extension is triggered by oxygen level detection 
(Jarecki et al., 1999). Hypoxic conditions do however trigger bnl expression and 
through Btl, terminal branches develop similar to the primary and secondary branches 
(Jarecki et al., 1999). 
1.6.2 Branching of the Mammalian Lung 
A similar invagination mechanism is observed during the development of the 
endodermal mammalian trachea and lung. The trachea and oesophagus arise from the 
primitive anterior foregut through a series of morphological changes involving 
endodermal and mesodermal interactions at E9 in mice and about 4 weeks into 
gestation in humans (reviewed in Warburton et al. 2005). Initially, two folds emerge 
from the ventral side of the foregut tube. One of these, the proximal protruding fold is 
known as the ventral diverticulum, which later becomes the laryngotracheal tube 
(Clark, 1999; Ioannides et al., 2002) while the distal protrusion becomes the ventral 
pancreas, biliary system and liver (El-Gohary et al., 2010). The laryngotracheal tube 
undergoes bifurcation resulting in the outgrowth of two separate lung buds. In mice, 
one bronchiole branch extends from the left, while four branches extend from the 
right bud (Metzger et al., 2008). In humans, two bronchiole branches extend from the 
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left bud while three branches elongate from the right bud. A further two branches 
extend from each bronchiole branch; eventually ending in terminal tubes whose ends 
will form the alveoli of the lungs. The three-step patterning of murine lung branching 




Figure 1.10 Branching morphogenesis of the Drosophila melanogaster tracheal 
system. 
(A) The selection of placodal cells requires trachealess expression. (B) The 
outgrowth of the placode is caused by branchless expressing cells acting as a 
chemoattractant. Localisation of branchless in the mesenchyme attracts the primary 
branches from the original epithelial sac. Epithelial cells express the receptor 
breathless. (C) When the primary branches have elongated, they arrest growth when 
they reach cells of high branchless expression. This high concentration induces 
pointed, followed by sprouty, within the epithelial cells inhibiting branching in the 
more proximal tubes. (D) Through Breathless, branchless expressing cells induce 
secondary branch formation in the most distal epithelial cells. 
 
FGFs are required at all stages throughout mammalian lung development (Bellusci, 
Grindley, et al., 1997; Min et al., 1998; Weinstein et al., 1998). In particular FGF10 
and its receptor FGFR2b are critical for early lung branching morphogenesis (Peters 
et al., 1994; Bellusci, Grindley, et al., 1997).   The Fgf10 gene is located on 
chromosome 13 (13A3-A4) and chromosome 5 (5p12-p13) in mice and humans 
respectively (Crackower et al., 1998; Emoto et al., 1997). The role of Fgf10 and its 
receptor Fgfr2b, is emphasised by the shared defects of both Fgf10 homozygous (-/-) 
and Fgfr2b -/- mice, who die at birth due to agenesis of the lungs (Sekine et al., 1999; 
Min et al., 1998; De Moerlooze et al., 2000). FGF10 plays a similar role to 
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Branchless, as it acts as a chemoattractant for lung budding from the laryngotracheal 
tube and subsequent initial bronchiole elongation (Bellusci, Grindley, et al., 1997). 
Fgf10 is expressed in the splanchnic mesenchyme surrounding the foregut endoderm 
as early as E9.5 in the mouse when the two lung buds are originating, with higher 
levels of Fgf10 RNA detected adjacent to the larger right bud (Bellusci, Grindley, et 
al., 1997). As development continues from E10.5-E11.5, and as bronchiole buds stem 
from the left and right presumptive bronchi branches, Fgf10 is expressed in the 
mesenchyme around emerging buds (Bellusci, Grindley, et al., 1997). Fgf10 
expression is maintained in the surrounding mesenchyme as branching morphogenesis 
continues, while its receptor Fgfr2b is expressed in the epithelial branches of the lung 
(Peters et al., 1992, 1994; Bellusci, Grindley, et al., 1997). Furthermore, Fgf10 can 
induce ectopic bud formation from lung epithelium in culture (Bellusci, Grindley, et 
al., 1997). Similar to the Drosophila tracheal system, it has been shown that FGF 
signalling through FGFR2b induces Spry2 expression, which inhibits the downstream 
activation of Ras pathway molecules (Tefft et al., 1999; Mailleux et al., 2001). Sonic 
hedgehog (Shh) signalling from the branching lung stalks has also been shown to 
negatively regulate Fgf10, as Fgf10 expression increases in the surrounding 
mesenchyme in Shh knockout studies (Bellusci, Grindley, et al., 1997; Pepicelli et al., 
1998; Miller et al., 2004). Additionally, upregulation of Shh expression in transgenic 
lungs leads to a decrease in Fgf10 transcripts in the splanchnic mesenchyme (Bellusci, 
Grindley, et al., 1997). 
1.6.3 Branching of the Mammalian Salivary Gland 
Mice and humans have three pairs of major salivary glands that secrete saliva into the 
oral cavity: the parotid (PG), submandibular (SMDG) and sublingual glands (SLG), 
as well as numerous minor salivary glands which are located in the tongue, palate, 
cheeks and lips (Hand et al., 1999). The murine SMDG has been an exceptional 
model of branching morphogenesis both in vivo and ex vivo as it can be readily 
isolated and grown in in vitro organ culture (Borghese, 1950). Its stages of 
development can be divided into distinct steps (Melnick and Jaskoll, 2000). First 
evidence of the SMDG is seen when it is in its Pre Bud stage at about E11.5 where a 
thickening in the oral ectoderm forms a SMDG placode (Figure 1.11, A). By E12.5, 
continuous cell proliferation causes this placode to elongate and invaginate into the 
underlying mesenchyme as a solid stalk of cells (Figure 1.11, B). At this Initial Bud 
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stage, mesenchymal cells begin to condense around the SMDG bulb, forming the 
salivary gland capsule in which the SMDG and SLG are enclosed (Borghese, 1950; 
Miletich, 2010). At about E13.0, the initial epithelial bud begins to sprout branches. 
This stage is referred to as the Pseudoglandular stage and is brought about by initial 
bud clefting and outgrowth of new epithelial stalks (reviewed in Miletich 2010) 
(Figure 1.11, C). Continual clefting and elongation of solid stalks proceeds to the 
Canalicular stage at E15.5 where lumen formation through a process of cavitation 
begins throughout the main gland ducts and branches (Figure 1.11 D). Spaces form 
within the epithelial stalks, which eventually, at the Terminal Differentiation stage, 
beginning at E17.5, start to fuse to form one continuous lumen, elegantly hollowing 
out branches into epithelial tubes (Melnick and Jaskoll, 2000; Wells and Patel, 2010) 
(Figure 1.11, E). The first signs of cellular differentiation can be identified by the first 
detection of mucin transcripts at E14, however mucin proteins are not evident in the 
end buds until E17 (Figure 1.11 E) (Jaskoll et al., 1998). 
It has been shown that murine SMDG development requires an interaction between 
mesenchymal FGF10 and its epithelial receptor FGFR2b for successful branching 
morphogenesis (Ohuchi et al., 2000). Previous reports indicate that Fgf10 is not 
required for initial salivary gland bud formation, which is more dependent on Fgf7, 
however Fgf10 is crucial for successional epithelial duct elongation and branching 
morphogenesis (Jaskoll et al., 2005; Steinberg et al., 2005). Fgf10 is expressed in the 
mesenchyme underlying the presumptive salivary gland epithelium from E11.5 
(Wells et al., 2013). Ex vivo manipulation of SMDGs in organ culture demonstrates 
that exogenous FGF10 peptide applied at both the Prebud and Pseudglandular stage 
gives rise to a significant increase in number of epithelial branches due to an increase 
in epithelial cell proliferation (Jaskoll et al., 2005). Furthermore application of FGF10 
to isolated SMDG epithelial rudiments induces duct elongation in a dose dependent 
manner by stimulating proliferation at the tips of ducts (Steinberg et al., 2005). Jaskoll 
et al. (2005) showed in Fgf10 null mice that the SMDG initiated to its Initial Bud 
stage at E12.5 however it was unable to develop further, and at E13.5 any epithelial 
evidence of the SMDG was absent. Unlike the Fgf10 knockouts, heterozygous Fgf10 
+/- mice are viable and in mouse pups at postnatal day (P) 0, SMDGs were present 
but had fewer ducts and terminal buds (Jaskoll et al., 2005). Another study by 
Entesarian et al. (2005) investigated Fgf10 +/- adult salivary glands and concluded 
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they were hypoplastic compared to WTs yet the histology of the SMG and SLG were 
similar to WT counterparts.  
Expression of Spry 1 and Spry 2 is apparent throughout the SMDG epithelium during 
both Initial Bud and Pseudoglandular stages while Spry 4 is restricted to the distal 
epithelial cells only (Zhang et al., 2001). This suggests that negative feedback 
regulators are involved in controlling the influence of FGF signalling on more distal 
ductal cells. Furthermore, application of the MEK 1/2 inhibitor UO126 in in vitro 
cultured salivary glands inhibited the effects of FGF10 on epithelial stalk elongation, 
indicating that FGF10 induced cell proliferation is working through ERK 1/2 
(Steinberg et al., 2005). 
In humans, mutations in FGF10 or its receptor FGFR2b, lead to Lacrimo Auriculo 
Dento Digital (LADD) syndrome (OMIM 149730), also known as Levy-Hollister 
syndrome. This rare autosomal dominant disorder was first characterized by Hollister 
et al. (1973) who reported anomalies in a Mexican man and five of his eight children. 
These defects included hypoplasia or aplasia of the lacrimal glands of the eyes, 
obstruction of the nasolacrimal duct, cup shaped ears, hearing loss, tooth 
abnormalities, and digit and limb malformations (Hollister et al., 1973). Although dry 
mouth was a symptom of the original patients identified, it wasn’t until later that 
studies elucidated that in addition to the lacrimal gland defects, hypoplasia, atresia 
and aplasia of the salivary glands were also characteristic of the disease (Shiang and 
Holmes, 1977; Thompson, Pembrey, and J. M. Graham, 1985). A milder form of this 
disease, known as Aplasia of Lacrimal and Salivary Glands (ALSG) (OMIM 180920), 
also occurs and gives rise to the same symptoms as LADD, most often including 
xerothalmia (dryness of the eye) and xerostomia (dry mouth) (Wiedemann, 1997; 
Milunsky et al., 1990).  
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Figure 1.11 Branching morphogenesis of the mammalian salivary gland. 
(A) Prebud stage: Salivary gland morphogenesis is first evident at E11.5 as an 
epithelial placode invaginating from the oral epithelium into the underlying 
mesenchyme. (B) Initial Bud stage: By E12.5, the epithelial cells proliferate and a 
solid bulb like structure forms. (C) Pseudoglandular stage: Sprouting of epithelial 
branches is clear by E13.5. (D) Canalicular stage: By E15.5, continual branching has 
occurred and canalization has begun to create spaces within the solid epithelial stalks. 
(E) Terminal Differentiation stage: By E17.5, branching continues and luminal 
spaces have connected to form a continuous lumen within the gland. Cellular 




1.7 Aims of this Thesis 
It is evident that the respiratory SMGs play a critical role in maintaining airway 
homeostasis and host defence. Disruption in gland cellular composition and function 
can lead to severe diseases and the molecular mechanisms at the basis of these defects 
need to be elucidated. The aim of this thesis is to follow gland development, in both 
the nasal cavity and trachea, and uncover the role of FGF signalling during their 
morphogenesis.  
 
The main goals of this work include: 
1. To uncover the development and temporal localisation of the anterior nasal 
glands in the mouse and investigate the cellular processes involved in their 
morphogenesis. 
2. To analyse the phenotype of anterior nasal and tracheal SMGs in Fgf10 -/- and 
Fgf10 +/- mice and delineate the expression patterns of other Fgfs and their 
downstream targets during SMG development. 
3. Considering the phenotype in Fgf10 +/- adults previously described (Rawlins 
and Hogan, 2005),  I aim to investigate whether a reduction in SMGs has a 
negative effect on the mucociliary clearance and overall respiratory health of 
these animals.  
4. To investigate the salivary gland dysfunction in Fgf10 +/- mice and analyse 
the influence reduced saliva flow has on oral health. 
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2. Materials and Methods 
2.1 Animals 
2.1.1  Animals 
Animals were housed in the Biological Services Unit (BSU), New Hunt’s House, 
Guy’s Campus, King’s College London. For tracing normal gland development, mice 
of CD1 background were used. Staff of the BSU maintained all CD1 mice and carried 
out timed mating and plug checking procedures.  
 
Fgf10-deficient mice were first generated by Min et al. (1998) (Mouse Genome 
Informatics ID 1099809). Homozygous (Fgf10 -/-) and heterozygous (Fgf10 +/-) 
mice were generated by targeted mutation of exon 1 of the Fgf10 allele of 129X1/SvJ 
clones. Positive clones were injected into fertilized C57BL/6 females. Chimeric males 
that were produced were then crossed with 129 SVJ or Swiss black females (Min et 
al., 1998). Heterozygote males and females from each line were crossed to produce 
Fgf10 +/- and Fgf10 -/- mice. Fgf10 +/- were crossed with CD1 mice upon arrival to 
the Craniofacial Development and Stem Cell Laboratory, King’s College London by 
Dr. Albert Basson and kept on this background for this study. 
 
Fgfr2b -/- specimens have been previously described (De Moerlooze et al., 2000) 
(Mouse Genome Informatics ID 2153811). Fgfr2b -/-  mice were generated by Cre-
mediated excision of the floxed IIIb exon (exon 8) of 129X1/SvJ positive clones. 
Chimeras were generated by injecting Fgfr2IIIb-/-cond eggs into fertilized C57Bl mice 
with pCAGGs Cre vector (De Moerlooze et al., 2000). Samples of E18.5 Fgfr2b -/- 
mice investigated in this study were taken from slide stocks in the Craniofacial 
Development laboratory that had kindly been provided previously by Dr. David Rice, 
University of Helsinki, Finland. 
2.1.2  Embryo Collection 
Mice were mated in the late evening and a midnight mating was assumed. Midday of 
the day at which a vaginal plug was discovered was recorded as embryonic day (E) 
0.5. Pregnant female mice were culled by cervical dislocation and carried on ice to the 
Craniofacial Development laboratory, Guy’s Hospital.  
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2.1.3  Postnatal Pup Collection 
The day female mice littered down was recorded as P0. Pups were humanely culled 
using an interperitoneal injection of 20% sodium pentobarbital solution (JML, 
RM190) at a concentration of 100mg/kg body weight. 
2.1.4  Adult Collection 
For the collection of adult specimens, where tracheal tissue was not required, animals 
were culled by cervical dislocation. As this method damages the trachea, adult males 
and females were culled by exposure to rising levels of CO2 gas for studies where the 
tracheal tissue was needed.  
2.2  Dissection and Preparation of Tissue 
2.2.1  Preparation of Embryonic Tissue 
Uteri were dissected from pregnant dams and transferred to ice cold phosphate 
buffered saline (PBS) (Oxoid). Embryos were collected on the required ages based on 
the date of vaginal plug discovery. Embryos were carefully dissected by uterine wall 
and fetal membrane removal. After dissection, embryos were staged accurately by 
weight (Peterka et al., 2002) and by external features (Theiler, 1989).  In the case of 
collection of Fgf10 transgenic embryos, tail clips of embryos were carefully collected 
using a sharp scissors and were gently transferred to 1.5ml eppendorf tubes for 
genotyping. Specimens were decapitated and heads were fixed in 4% 
paraformaldehyde in PBS (PFA) overnight at 4°C. Tracheas were also collected for 
older staged embryos at E18.5 and fixed overnight. For tissue collected for in situ 
hybridisation procedures, all solutions used were made up with PBS treated with 
diethylpyrocarbonate (DEPC) (Sigma). 
2.2.2  Preparation of Postnatal and Adult Tracheal Tissue 
Following sacrifice by rising levels of CO2, animals were transferred to the 
Craniofacial Development laboratory on ice. Under a dissection microscope, an 
incision was made through the sternum and the rib cage was opened. Tracheal tissue 
was identified and the trachea was dissected out using a sharp scissors by a clean 
anterior cut through the thyroid ligament above the thyroid cartilage, and a posterior 
cut between the tracheal cartilage rings by the bronchial bifurcation. Tracheas were 
fixed overnight in PFA at 4°C. 
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2.2.3  Tissue Dehydration, Embedding and Sectioning 
Following overnight fixation, tissue underwent two 30-minute washes in PBS at RT 
followed by dehydration washes in increasing methanol concentrations (Table 2.1). 
After dehydration, tissue was put in Isopropanol (Sigma Alrdrich) overnight at 4°C. 
Following another brief isopropanol wash, tissue was transferred to glass vials, as 
plastic containers are not suitable for subsequent clearing steps. Samples were then 
cleared in 1,2,3,4 Tetrahydronapthalene (Sigma Aldrich) at RT, until tissue appeared 
transparent. Samples then underwent four 60 minute washes in liquid premium 
polyisobutylene histological wax (Ultraplast, Solmedia) at 65°C. If required, 
occasionally samples would be transferred to fresh wax and stored at 4°C overnight. 
The next morning, tissue would be placed at 65°C for an hour, or until wax had 
melted, and wax washes would resume. At a Leica EG1150H, samples were then 
transferred into metal moulds where they would be positioned accurately. Tissue was 
solidified at the base of the metal mould by placing the mould on a 4°C cold plate. A 
labelled plastic embedding cassette (VWR International) was then placed on the top 
of the wax block and more hot wax would be added to keep it in place, ensuring no air 
bubbles formed. The mould was then transferred to a larger cold stage and left to 
solidify for 30 minutes at 4°C. Wax blocks were then stored at RT until required. 
Table 2.1 Solution composition and washing conditions of dehydrating methanol 
series. 






PBS 100% PBS Room temperature 4°C 
30% 30% methanol, 
70% PBS 
Room temperature 4°C 
50% 50% methanol, 
50% PBS 
Room temperature 4°C 
70% 70% methanol, 
30% deionised H2O 
Room temperature 4°C 
80% 80% methanol, 
20% deionised H2O 
4°C -20°C 
90% 90% methanol, 
10% deionised H2O 
4°C -20°C 
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95% 95% methanol,   
5% deionised H2O 
4°C -20°C 
100% 100% methanol 4°C -20°C 




2.2.4  Tissue Sectioning and Mounting 
Excess wax was trimmed from wax blocks using a razor blade, so embedded tissue 
was tightly framed. Using a Leica RM2245 microtome, serial 9µm sections were cut 
through tissue and collected. For anterior nasal gland analysis, sagittal sections were 
collected along the left/right axis through the entire embryonic head. For tracheal 
tissue analysis, frontal sections were collected from the ventral to dorsal plane. Tissue 
sections were collected as long ribbons where they were then cut into individual 
sections using a razor blade and placed on the surface of water in a paraffin section 
mounting bath (Electrothermal) set at approximately 42°C. This warm heat allowed 
wax sections to flatten out smoothly where they could then be mounted on 
Superfrost™ plus microscope slides (Thermoscientific). For those tissue sections 
designated for in situ hybridisation analysis, serial sections were mounted on 
alternative slides to allow the detection of different RNA probes on comparable 
sections. Additionally, DEPC treated H2O was used in the water bath for mounting 
sections required for in situ hybridisation. Slides were then left on a slide drying 
bench (Thermoscientific) overnight at 42°C to allow tissue to adhere to the slide. 
Slides were then stored in a slide box at 4°C. 
2.3  Histological Staining 
2.3.1  Haematoxylin and Eosin with Alcian Blue Staining 
Haematoxylin and Eosin (H&E) stain is one of the most common techniques used to 
stain acidic and basic structures of tissues. Haematoxylin, a basic dye, is used to stain 
acidic structures purple, such as heterochromatin in the nucleus and parts of the 
cytoplasm containing RNA. In contrast, Eosin an acidic dye, will stain basic 
structures a pinkish red, such as the cytoplasm and muscle fibres. In addition to these 
dyes, Alcian Blue can by applied to visualise mucopolysaccharides (Mowry, 1956). 
This characteristic makes Alcian Blue a suitable dye for visualising SMGs as mucous 
cells, and mucus secretion will be stained. 
 
H&E with Alcian Blue staining was carried out by either Dr. Alasdair Edgar 
(Craniofacial Development Department, King’s College London) or myself. Slides 
were dewaxed by immersion in Histoclear II™ (National Diagnostics), twice for 10 
minutes. Tissue was then rehydrated by decreasing volumes of industrial methylated 
spirit (IMS) (Solmedia) in deionised H2O (100%, 90%, 70%, 50%) for two minutes in 
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each step and rinsed in deionised H2O. Samples were then stained in Ehrlich’s 
Haematoxylin (Solmedia) for 10 minutes followed by a 10-minute rinse under 
running water and then a two-minute rinse in deionised H2O. Sections were placed in 
acid alcohol (1% HCl in 95% IMS) for 15 seconds followed by another 10-minute 
rinse under running water and a two-minute rinse in deionised H2O. Tissue was then 
stained in 0.5% aqueous Eosin (Lamb) for 5 minutes and washed for two minutes in 
deionised H2O. Samples were dehydrated in increasing IMS in deionised H2O 
concentration steps (70%, 90%, 100%, 100%) for two minutes each. Slides were 
immersed in Histoclear II™ twice for 5 minutes and then mounted using Neo-
mount® mounting medium (Merck Millipore), coverslipped and left to dry overnight 
in a fume hood. 
2.3.2  Trichrome Staining 
Trichrome staining again consists of Haematoxylin and Alcian Blue dyes however the 
process has an additional staining step in Sirius Red. By exposing tissue to Sirius Red, 
collagen-containing structures, such as bone and connective tissue are darkly stained 
red. This staining method was used for nasal gland analysis as bone appears in the 
craniofacial regions during later embryonic stages. 
 
Slides were dewaxed by immersion in Histoclear II™ twice for 10 minutes. Tissue 
was then rehydrated by decreasing volumes of IMS in deionised H2O (100%, 90%, 
70%, 50%) for two minutes in each step and rinsed in deionised H2O. Samples were 
stained in 1% Alcian Blue dissolved in 3% acetic acid (Analytical Reagents) pH2.5 
for 10minutes followed by a 10-minute rinse under running water and a two-minute 
rinse in deionised H2O. Slides were then immersed in Ehrlich’s Haematoxylin for 10 
minutes followed by another 10-minute rinse under running water and a two-minute 
rinse in deionised H2O. For staining differentiation, samples were then placed in 2.5% 
phosphomolybdic acid (Fluka Biochemica) for 10 minutes and washed in deionised 
H2O. Slides were then left soaking in 0.5% Sirius Red in saturated Picric Acid (BDH) 
for one hour. Sections were rinsed twice in 0.5% acetic acid in deionised H2O and 
blotted dry. Tissue was then put through two 5-minute steps in 100% IMS and two 5-
minute steps in Histoclear II™. Slides were mounted using Neo-mount® mounting 
medium, coverslipped and left to dry in a fume hood overnight. 
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2.4  Genetic Determination of Animals 
2.4.1  Postnatal and Adult Ear Clipping 
Collection of ear tissue from postnatal or adult mice was carried out in the BSU, New 
Hunts House, Guy’s Campus by either Alex Huhn (Craniofacial Development 
Department, King’s College London) or myself. A forceps and ear punch (VetTech 
Solutions Ltd.) were sprayed with 70% ethanol and dried thoroughly. Equipment was 
then passed through a Bunsen burner flame to sterilise and left to cool to RT. Animals 
were gently, yet securely held by the scruff of the neck and a small piece of ear tissue 
was collected using an ear punch. This tissue was transferred into a sterile labelled 
1.5ml eppendorf tube and brought to the Craniofacial Development laboratory. 
2.4.2  Isolation of Genomic DNA 
Genomic DNA was extracted from embryonic tail clips or postnatal and adult ear 
clips. Purification steps were carried out by either Andrew Donkin (Craniofacial 
Development Department, King’s College London) or myself. Tissue clips were 
digested overnight in 0.5mg/ml Proteinase K in DirectPCR® tail or ear lysis buffer 
(Peqlab) at 55°C on a hotblock (Techne Dri-Block). The next day, samples were 
heated to 85°C for 45 minutes to inactivate the Proteinase K. Samples were allowed 
to cool to RT. 
2.4.3  Polymerase Chain Reaction 
Prior to the preparation of samples for the polymerase chain reaction (PCR), all 
equipment was sterilised by U.V light exposure using a PCR Workstation (Alpha 
Laboratories). To labelled PCR tubes DNA template samples, Fgf10 oligonucleotide 
primers (Sigma), Kapa 2G robust hot start ready mix (Kapa Biosystems) and PCR 
grade nuclease-free H2O (Promega) were added in the following volumes per 1.5ml 
eppendorf: 
DNA template 0.5µl 
Fgf203 primer  0.625µl 
Fgf204 primer  0.625µl 
Fgf233 primer  0.625µl 
Fgf234 primer  0.625µl 
Kapa ready mix 6.25µl 
Nuclease-free H2O 3.25µl 
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The Kapa 2G robust hot start ready mix contains all the vital ingredients for 
successful DNA amplification including DNA polymerase, MgCl2 and dNTP (dATP, 
dTTP, dGTPand dCTP) nucleotides. Primers used to detect wildtype Fgf10 locus 
were 5’-GAGGAAATGCTGCGCACAATGTATACTCGG-3’ (Fgf203 forward 
primer) and 5’-GGATACTGACACATTGTGCCTCAGCCTTTC-3’ (Fgf204 reverse 
primer) while the mutant Fgf10 locus was detected by primers 5’-
GCTTGGGTGGAGAGGCTATTC-3’ (Fgf233 forward primer) and 5’-
CAAGGTGAGATGACAGGAGATC-3’ (Fgf234 reverse primer) of the neo-cassette 
insert (Sekine et al., 1999). In addition to the collected DNA template sample tubes, a 
negative control tube containing a DNA template from a CD1 strain mouse, and a 
positive control tube containing a DNA template from an Fgf10 +/- mouse was 
processed using the same techniques as sample tubes. PCR was then carried out in a 
G-storm Thermal Cycler under the “Kapa 2g Robust” program for suitable conditions 
for DNA samples. 
 
Following PCR, 2.5µl of 5x Green GoTaq® Reaction Buffer (Promega) was added to 
each tube and 8.5µl of amplified DNA was run in a 2% agarose gel to confirm PCR 
products. 
 
2.4.4  Agarose Gel Electrophoresis 
To test the presence of nucleic acid fragments in a sample, agarose gel electrophoresis 
was routinely carried out using either a 1 % or 2% agarose gel. Firstly, 0.5g or 1.0g of 
agarose (Eurogentec) was weighed out and diluted in 50ml of Tris-acetate-EDTA 
(TEA) buffer for a 1% or 2% gel respectively. Agarose powder was dissolved in TAE 
by heating the solution for two minutes on high power in a microwave with 
intermittent swirling. Once the powder had dissolved, the gel was cooled by running 
cold water over its glass container while swirling. Once cool, but not solid, 1µl of 
ethidium bromide (Fischer Scientific) was added and the gel was mixed. Ethidium 
bromide fluorescently labels nucleic acids so they can be visualised under U.V light. 
The gel was poured into a mould and a comb inserted to form individual wells. Gel 
was left to completely solidify at RT for 30 minutes. 
 
Once solid, the gel was removed from its mould and placed gently in an 
electrophoresis tank (Scie-Plas HU6 Mini) and TAE was poured into the tank until the 
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gel was covered. To the first well of the gel, 7µl of DNA ladder (NEB Biolabs 
Quickload 1kb ladder for DNA and Promega 100bp ladder for RNA) was added. To 
the other wells 7µl of nucleic acid-containing samples were loaded. In the case of 
amplified DNA from tissue clips, these were loaded after Green Buffer addition (see 
section 2.4.3). For DNA and RNA samples isolated from plasmid DNA, 2µl of 
nucleic acid sample was added to 3µl of H2O and 2µl of Blue Loading Dye (Promega) 
and loaded into each well. The lid was placed on the electrophoresis tank and an 
electric current was triggered by turning the tank on. This current passes from the 
cathode to the anode of the tank, causing the nucleic acid samples to migrate south 
toward the anode. The electric current was usually run at 110V for 30 minutes 
however time was reduced significantly to approximately 5-10 minutes for more 
fragile RNA samples. When complete, the gel was carefully removed from the tank 
and placed in a U.V transilluminator (UVP). The door was closed securely and the 
U.V light turned on to visualise bands. Images were captured and printed on a 
Mitsubishi P91 printer. 
2.5  Molecular Biology 
2.5.1  Bacterial Plasmid DNA Transformation and Amplification 
Before bacterial cell transformation with plasmid DNA was carried out, a Lysogeny 
Broth (LB) medium and a LB agar were prepared and autoclaved (Table 2.2). For 
growth of bacterial colonies, LB agar plates were prepared containing the antibiotic 
Ampicillin (Sigma). Solid LB agar was heated in the microwave until all agar had 
turned to liquid. This liquid LB was placed in a 50°C waterbath for 30-60 minutes to 
ensure agar dropped to that temperature. At 50°C Ampicillin will not be denatured, 
yet the agar can remain as a liquid. Ampicillin was added at a concentration of 
200µl/1ml of agar and the solution was mixed by swirling. On a clean bench next to a 
lighted Bunsen burner, approximately 30mls of agar was poured into 9cm petri dishes 
(Sterilin, Fisher Scientific). Lids were partially placed on petri dishes and they were 
left to solidify for 30 minutes next to the lighted Bunsen burner. Once solidified, lids 
were placed fully on the dishes, plates were turned upside down, wrapped in 
Parafilm® M (Fluka Biochemica) and stored at 4°C. By storing upside down, any 
condensation that forms in the dishes will be restricted to the underside of the lid and 
will not collect on the LB agar. 
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Table 2.2 Composition of LB medium and LB agar used for bacterial 
amplification and growth. 
LB medium 
NaCl 1% 
Bacho-Tryptone (Oxoid) 1% 




Bacto-Yeast Extract 0.5% 
Bacteriological Agar (Sigma) 2% 
 
Competent bacteria cells (DH5®α, Invitrogen) were removed from -80°C storage and 
left to thaw on ice for 30 minutes. To introduce plasmid DNA into bacterial cells (i.e 
transform) 1µl of plasmid DNA was added to 30µl of competent cells in a DNase and 
RNase free 1.5ml eppendorf tube. To ensure no bacterial antibiotic resistance, a 
control tube containing 1µl of autoclaved H2O in 30µl of competent cells was 
prepared and processed in the exact same conditions as the plasmid DNA. To enhance 
competency and create pores in the bacterial cell walls, eppendorfs were subjected to 
heat shock by placing in a 42°C waterbath (Grant) for 45 seconds. Tubes were then 
put back on ice and left for a further two minutes. 
 
To each tube, 900µl of LB medium was added and tubes closed tightly. Tubes were 
then shaken vigorously in an ISF-1-W Kuhner shaker for one hour at 37°C. In these 
conditions, bacterial growth is stimulated. To each agar plate, 100µl of transformed 
bacterial cells was added and spread all around the agar using a sterile bacteria 
spreader. Lids were placed on dishes and were left to dry at room temperature for 15 
minutes. Once dry, plates were turned upside down and incubated overnight at 37°C. 
By incubating upside down, bacterial colonies are encouraged to grow individually. 
 
Following overnight incubation, bacterial plates were checked for colonies. As 
control plates were not incubated with antibiotic resistant containing plasmids, no 
colonies could grow due to Ampicillin in the LB agar. To a 15ml Falcon tube, 5ml of 
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LB medium with 5µl of Ampicillin was added. Close to a lighted Bunsen burner, a 
single colony of bacteria was collected from each agar plate using a pipette tip and the 
tip was placed in the tube with the LB medium. The tube was closed loosely and left 
to shake vigorously over night at 37°C. The following morning, tubes containing a 
milky broth verified positive bacterial growth. To keep stock of plasmid containing 
bacteria, 300µl of the bacteria-LB medium solution was collected and added to 700µl 
of glycerol (Sigma) and stored at -20°C. The remaining bacterial cells were spun 
down at 4,000rpm for 10 minutes to form a bacterial cell pellet and the supernatant 
was discarded. 
2.5.2  Bacterial Plasmid DNA Extraction and Purification 
Using a QIAprep® Miniprep kit (Qiagen), DNA was extracted from bacteria and 
purified. The process first involves re-suspension of the bacterial cells in TE buffer 
with added RNase A (P1 buffer). EDTA in the TE buffer chelates cations such as 
Mg2+ and Ca2+ which are needed for proper DNase activity, while the RNase destroys 
any RNA contamination within the bacterial cell sample. Cells are then lysed in 
alkaline conditions in P2 buffer, a solution containing 200mM NaOH and 1% SDS. 
Following the break up of the bacterial cell wall, the alkali denatures both 
chromosomal and plasmid DNA. The third step involves the washing of cells in a 
solution containing Guanidine-HCl and potassium acetate (KOAc). This acidic KOA 
re-natures plasmid DNA but allows the precipitation of chromosomal DNA from the 
solution. Tubes were then spun for 10 minutes at 13,000rpm to collect debris as a 
pellet and leave plasmid DNA suspended in the supernatant. This supernatant was 
then poured through a QIAprep spin column, and spun for 1 minute at 13,000rpm. 
This step binds the plasmid DNA to the silica gel membrane within the column 
allowing any other contaminants to pass through the column as flow through, which is 
then discarded. Column walls were then washed with PB buffer, a solution containing 
5M Guanidine-HCl and 30% isopropanol, which eliminates any possible nuclease 
activity and spun down at 13,000 rpm for one minute, discarding the flow through. 
Another wash in PE buffer, a solution containing 10mM Tris-HCl (pH 7.5) and 80% 
ethanol, which solubilizes smaller pieces of DNA other than the target plasmid, 
removing them from the wall of the column. Columns were again spun for 1 minute at 
13,000rpm and flow through discarded. Deionised H2O was then added to the column 
and let sit for one minute, followed by a spin at 13,000rpm for one minute. Flow 
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through containing pure plasmid DNA was collected and plasmid samples were stored 
at -20°C. 
2.5.3  Linearization of Plasmid DNA 
As plasmid DNA is circular, it must be linearized using a restriction enzyme 
downstream of the target sequence in order for a RNA probe to be transcribed. To 
carry out this digestion, 2µl of plasmid DNA was incubated on a hotblock at 37°C for 
two hours along with 2µl of restriction enzyme buffer, 0.2µl of 10mg/ml Bovine 
Serum Albumin (BSA), 13.8µl of deionised H2O and 2µl of appropriate restriction 
enzyme (Table 2.3). To confirm the linearization of DNA, 2µl of cut DNA was run on 
a 1% agarose gel, next to 1µl of uncut plasmid in the same gel. 
2.5.4  Preparation of Digoxygenin(dig)-labelled Riboprobes 
To generate a dig-labelled RNA probe from the linearized DNA template, cut plasmid 
DNA was incubated with the following reagents: 
 
DEPC treated H2O 7.5µl 
5 x transcription buffer 4µl 
0.1M DTT 2µl 
Dig-U NTPs 2µl 
RNase inhibitor 0.5µl 
Linearized plasmid DNA 3µl 
Appropriate polymerase (Table 2.3) 1µl 
 
DNA templates being transcribed with the polymerases T3 and T7 were incubated for 
one hour at 37°C, while those requiring SP6 polymerase were incubated at 42°C. 
After one hour, another 1µl of appropriate polymerase was added and the reaction was 
incubated for another one-two hours. After incubation 2µl of DNAse1 was added and 
all tubes were left on the hotblock for 15 minutes. The presence of RNA was then 
tested by running 2µl of the sample in a 1% agarose gel. RNA was then precipitated 
by adding 100µl of DEPC treated H2O, 10µl of 4M lithium chloride (LiCl) and 300µl 
of ice cold ethanol to the mixture and the sample was left overnight at -20°C. 
Following precipitation, probes were spun down for 10 minutes at 13,000rpm. RNA 
pellets were identified in the bottom of the tube and supernatant was removed 
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carefully using a pipette fitted with a filter tip. The probe pellet was then washed with 
70% ethanol in DEPC treated H2O for five minutes. Probes were spun down again for 
another 10 minutes and supernatant discarded carefully. Tubes were allowed to air dry 
for 5 minutes. The pellet was then diluted in 30µl of DEPC treated H2O and stored at 
-20°C. 
 















Fgf7 pGEM3 EcoR1 SP6 Dr. I. Mason 
(Mason et al. 
1994) 
Fgf10 pBluescript SK 
(+) 
BamH1 T3 Dr. I. Mason 




both IIIb and 
IIIc isoforms) 
pBluescript KS HindIII T3 Dr. K. Peters 
(Peters et al., 
1992) 
Spry1 pBluescript II EcoR1 T7 Dr. G. Martin 
(Minowada et 
al., 1999) 
Pea3 pGEM3 XbaI SP6 Dr. J. Hassell 
(Xin et al., 
1992) 
 
2.5.5  In Situ Hybridisation of Embryonic Tissue with Dig-labelled Riboprobes  
For in situ hybridisation with dig-labelled riboprobes, embryonic nasal and tracheal 
tissue was prepared as outlined in section 2.2. Using a forceps cleaned with RNase 
Away (Molecular Bioproducts) and rinsed with DEPC treated H2O, slides were 
transferred to glass coplin jars that had been baked at 200°C. All steps of this protocol 
were carried out rocking gently at RT, unless otherwise stated. 
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Sections were dewaxed in two washes of Histoclear II™ for 10 minutes and tissue 
rehydrated in decreasing concentrations of ethanol in DEPC treated PBS (100%, 95%, 
90%, 80%, 70%, 50%, 30%) for 5 minutes each. Sections underwent two 5-minute 
DEPC PBS washes and were fixed for 30 minutes in PFA. Tissue was washed in 
Proteinase K buffer (20mM Tris/HCl and 1mM EDTA pH7.2) containing 10µg/ml of 
Proteinase K. Proteinase K is a broad-spectrum serine protease that can digest any 
contaminating nucleases that may attack nucleic acids. Slides were put in a 5 minute 
DEPC PBS wash followed by a 30 minute fixation step in PFA and another two 5 
minute washes in DEPC PBS. Samples were then washed in 2x saline-sodium citrate 
(SSC) buffer, to control stringency of washing steps. Tissue was washed in 
Tris/Glycine Buffer (100mM Trizma-base, 100mM glycine), while the hybridisation 
solution was prepared in the fume hood (Table 2.4). 
 
Table 2.4 Composition and volumes of reagents required to make 10ml of 
hybridisation solution. 
DEPC treated H2O 1.7ml 
5M NaCL 1.5ml 
10x PE 1ml 
10% BSA 100µl 
5% Heparin 100µl 
10mg/ml tRNA 100µl 
Formamide 5ml 
10% SDS 500µl 
 
To prepare samples for hybridisation with dig-labelled riboprobes, slides were 
incubated in hybridisation buffer for 3 hours at 55°C. Before the end of this step, 
riboprobes were prepared at a concentration of 2µl probe/300µl hybridisation 
solution. Probes were denatured by heating at 85°C for 5 minutes. In a fume hood, 
slides were carefully removed from the coplin jars using RNase free forceps and 
placed in a humid chamber. To each slide 300µl of probe solution was added to each 
slide and a sterile coverslip placed on top. Remaining hybridisation solution was 
poured on the tissue paper in the humid chamber to prevent drying out of slides. The 
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lid was placed over the humid chamber and wrapped tightly with Parafilm® M to 
airlock the container. Samples were then incubated at 55°C overnight. 
 
The next day, slides were removed from the humid chamber in the fumehood and 
placed in a coplin jar. Samples underwent a series of washes in SSC at different 
concentrations and temperatures (Table 2.5). After this series, tissue was washed in 
NTE (0.5M NaCl, 10mM TrisHCl pH7.0, 5mM EDTA pH8.0) at 37°C for 10 minutes 
followed by a 10 minute wash in NTE with 10µg/ml RNase A at 37°C. Another wash 
in NTE was carried out at 37°C for 15 minutes followed by a rinse in 2xSSC at RT. 
Slides underwent hourly washes in 2xSSC at 50°C, 1xSSC at 55°C and 1xSSC at 
60°C, followed by a 30 minute wash in 1xSSC at RT. Tissue was then blocked for 
one hour in 10% Boehringer Blocking Reagent (BBR) (Roche) in Maleic Acid Buffer 
(100mM maleic acid (Analytical Reagents), 150mM NaCl, 0.1% Tween-20) 
(MABT). Slides were then removed from the coplin jars and placed in a fresh humid 
chamber with tissue paper soaked in deionised H2O. To each slide, 300µl of 1:5000 
anti-digoxygenenin alkaline phosphatase conjugated antibody (Roche) in 1% BBR in 
MABT was added and a coverslip placed on top. Slides were then incubated 
overnight at 4°C. 
 
Table 2.5 Times and temperatures of SSC washes carried out on the second day 
of in situ hybridisation. 
Reagent Time Temperature 
2xSSC 20 minutes Room temperature 
2xSSC 20 minutes Room temperature 
2xSSC 20 minutes 50°C 
1xSSC 20 minutes 55°C 
1xSSC 20mintues 60°C 
1xSSC 10 minutes Room temperature 
 
Slides were removed from the humid chamber and placed in coplin jars where they 
underwent three 10 minute washes and one 20 minute wash in Tris-buffered saline 
(50mM Tris-HCl pH7.4, 150mM NaCl) with 0.1% Tween® 20 (Sigma) rocking at 
RT. Tissue was then put through three 10 minute washes in freshly made NTM 
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(100mM NaCl, 100mM Tris-HCl pH9.5, 50mM MgCl2). Slides were then tapped dry 
on tissue paper and placed in a humid chamber with tissue paper soaked in deionised 
H2O. To each slide 300µl of BM-purple staining solution was added and slides were 
coverslipped. The lid of the humid chamber was placed on tightly to block out any 
light and slides were left at RT. Slides were checked twice a day for development of 
BM-purple. If BM-purple was coming up slightly purple in colour, solution was 
refreshed. Once tissue sections had developed showing mRNA localisation and 
staining, slides were washed in two 10 minute washes in PBS, fixed for 20 minutes 
with PFA and put through a further three 10 minute washes in PBS. Slides were 
mounted with Aquatex® mounting medium (Millipore), coverslipped and left to dry 
at RT. Once dry, slides were stored at RT in slide boxes.  
 
Sections were observed under a light microscope (Nikon Eclipse 80i) and images 
taken with a Nikon Digital Sight DS-Fi1 camera. Image collages were created using 
Adobe Photoshop CS5.1. 
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3. Anterior Nasal SMG Development 
3.1 Introduction 
3.1.1 The Nasal Glands and Their Secretions 
The nose is one of the initial entry points of inhaled air into the respiratory system. 
Therefore the epithelial lining cells of the upper respiratory tract are exposed to the 
highest concentrations of inhaled toxins and debris. It is the anterior nasal glands, 
along with the goblet cells of the respiratory epithelium (RE) that provide the first line 
of defence within the airway. The function of these respiratory glands is to secrete 
mucus into the nasal cavity where it traps airborne pathogens within inspired air, 
preventing them from progressing to the lower airway tubes and lungs. These mucous 
secretions also play an important role in warming and humidifying air, preventing the 
drying out of delicate respiratory tissue. The nose is the principal organ for sense of 
smell, and it is also believed that the mucus produced by the respiratory glands 
dissolves odorant molecules to help them be picked up by olfactory stimulation 
(Getchell and Getchell, 1992). Unlike humans, mice are obligate nasal breathers, 
therefore the nose and nasal environment of these animals are critical in maintaining 
respiratory health and homeostasis. For that reason, they provide an ideal model to 
study respiratory nasal gland development and function. 
3.1.2 The Nose 
In order to understand the developmental locations and progressions of the anterior 
nasal glands, the structure of the nose must be understood. In humans and rodents, the 
nose can be divided into three main areas known as the vestibule, the respiratory 
region and the olfactory region (Figure 3.1, A). The nasal vestibule is the opening site 
of the nose and is lined with a stratified squamous epithelium. Moving into the nasal 
cavity a transition into a RE occurs (Figure 3.1, A). Gross et al. (1982) showed that in 
mice the RE accounts for 47.5% and 45% of the total surface area of the nasal cavity 
in 7 week and 16 week old mice respectively. The periphery of the RE stops suddenly 
and the epithelium becomes olfactory in nature. In the same study the olfactory 
epithelium (OE) accounted for 45% and 47% of the nasal surface area in 7 week and 
16 week old mice respectively (Gross et al., 1982). The primary functions of the RE is 
to moisten and protect the cavity while the OE houses an enrichment of olfactory 
receptor neurons, required for the sense of smell (Popp and Martin, 1984; Purves et 
al., 2004). The RE and OE are supplied with mucosal secretions by goblet cells and 
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the respiratory submucosal glands, and the Bowman’s glands respectively (Bojsen-
Moller, 1964; Frisch, 1967). 
 
To appreciate the morphology of the nasal cavity, the capsule can be divided into the 
medial and lateral walls (Figure 3.1, B and C). The medial wall of the cavity is a 
simple plane of tissue that covers either side of the cartilaginous nasal septum (Figure 
3.1, C). Shelves of bone known as conchae or turbinates curve the lateral wall of the 
cavity (Figure 3.1, B and C). The most anterior shelf is referred to as the superior 
concha, the middle shelf as the medial concha while the lower shelf is called the 
inferior concha (Figure 3.1, B and C). By protruding from the lateral wall, these 
conchae create channels within the nasal chamber over which air can flow. These 
channels are known as meatuses and adopt the same name as their overlying concha 
(Figure 3.1, B and C). Additionally, there are four pairs of connected air filled cavities 
found in the nose, known as the paranasal sinuses (Figure 3.1, C). The lining of these 
spaces is continuous with the nasal RE and OE and secretions are drained directly or 
indirectly into the nose (Figure 3.1, C, black dotted line).  The maxillary sinus is the 
largest of the sinuses and is located lateral to the main nasal chamber (Figure 3.1, C). 
The frontal sinuses are the second largest of the group and are found above the eyes 
and between the eyes lie the ethmoidal sinuses (Figure 3.1, C). A fourth pair of 
sphenoid sinuses is found behind the eyes and nasal cavity. The function of the 
paranasal sinuses is disputable however it is believed they decrease the weight of the 
skull as well as warming and humidifying inspired air with their mucosal secretions. 
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Figure 3.1 Anatomy of the nose and paranasal sinuses. 
A) Sagittal view of the three distinct areas of the nose; vestibule, respiratory and 
olfactory regions. (B) Sagittal view of the lateral wall showing the curved concha and 
the inter-conchal meatuses. (C) Frontal section through the nasal chamber showing 
the position of the medial walls (yellow) on either side of the septum (S). Image 
shows the location of the superior concha (SC), the medial concha (MC) and the 
inferior concha (IC) of the lateral wall (orange) and their underlying meatuses. The 
frontal image also delineates the location the paranasal sinuses. SM=superior meatus; 
MM=middle meatus; IM=inferior meatus; FS=frontal sinus; ES=ethmoidal sinus; 
MS=maxillary sinus. Dotted black lines indicated opening of sinuses into nasal cavity 
found at a more caudal plane. 
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3.1.3 Morphology of the Anterior Nasal Glands 
It has been referenced in the literature that Broman (1921) first described the 
topography of the anterior nasal glands and created plastic reconstructions of the 
glands and ducts of rodents (Bojsen-Moller, 1964; Grüneberg, 1971). According to 
the manuscripts published in the mid-twentieth century, it was Broman (1921) who 
categorised and named the nasal glands into different groups based on their location 
and timing of when they first arose (Bojsen-Moller, 1964; Grüneberg, 1971). 
Although mentioned and reviewed in these early anatomical studies, the work of 
Broman has been described as “lost in recent literature” (Bojsen-Moller, 1964). 
Considering this, his primary names and descriptions of the glands have continued 
throughout the years and his work undoubtedly provided the backbone of future 
research on anterior respiratory gland development. 
3.1.3.1 Lateral Nasal Gland 1 or the Steno’s Gland 
The lateral nasal gland 1, more commonly called the Steno’s Gland, is the largest of 
the nasal glands (Grüneberg, 1971). The gland is located beneath the wall of the 
maxillary sinus and releases its product into an extremely long excretory duct, which 
opens into the nasal cavity near the nasal vestibule. The Steno’s gland, analogous to 
the anterior nasal gland in humans, is classified in some animals as solely serous in 
nature however in others it is seromucous (Moe and Bojsen-Moller, 1971; Bojsen-
Moller, 1967). In dogs the Steno’s gland is considered to play a principal role in 
thermoregulation while in marine birds it is primarily a salt gland (Wells and 
Widdicombe, 1986; Butler, 2002). Studies in rodents have elucidated that its secretion 
contains bactericidal proteins indicating an essential role in airway protection (Moe 
and Bojsen-Moller, 1971).  
3.1.3.2 The Lateral Nasal Glands 
The lateral nasal glands (LNGs) are found throughout the lateral wall of the nasal 
chamber. Similar to the Steno’s gland they have long ducts that open into the airway 
lumen close to the nasal vestibule, however, these glands are found within the 
submucosa of the lateral wall at more caudal locations. Up to 40 lateral nasal glands 
have been described in rabbits while approximately 20 have been reported in adult 
mice (Bojsen-Moller, 1964). Further research and descriptive analysis of this subset 
of glands is extremely lacking. 
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3.1.3.3 The Medial Nasal Glands 
The medial nasal glands (MNGs) are found within the submucosa of the medial wall 
on either side of the septum. Their long ducts open at rostral locations while their 
glands progress caudally and are seen anterior to the vomeronasal organ in rodents. 
These glands have been previously described in the rat, which can have four to five 
MNGs project into the septal mesenchyme (Bojsen-Moller, 1964). The MNGs have 
been described as having serous acini by light microscopy (Kerjaschki, 1974). 
3.1.3.4 The Maxillary Sinus Glands 
The maxillary sinus glands are located anterior and posterior to the maxillary sinus 
and drain their secretions directly into the sinus cavity through short wide tubules. 
Investigation of these glands in the rat showed that they are solely serous in nature 
(Vidić, 1971). 
From the literature currently cited, it is evident that interest and investigation into the 
anterior nasal glands is significantly lacking in recent times. Due to the roles played 
by the respiratory glands in a number of diseases and nasal conditions, it is crucial we 
understand their exact involvement and behaviours. Current studies avoid the SMGs 
of the upper airway however and concentrate more so on those of the 
tracheobronchial tree. As the anterior SMGs are different in nature, separate 
exploration of their development and function is imperative. 
3.1.4 Mechanisms of Lumen Formation 
The morphogenesis of epithelial tubes is a huge field of current research. Strategies 
used to create hollow epithelial tubes can be species specific and even tissue specific. 
Epithelial tissue has distinct characteristics such as (A) tight cell-to-cell adhesion, (B) 
unique inter-cellular junctions, (C) distinct apical-basal polarity and (D) a basement 
membrane on which the epithelial cells lie (reviewed in Andrew & Ewald 2010). 
When an epithelium undergoes branching morphogenesis, modulations of all these 
features must be made in order to allow cells to carry out successful organogenesis. 
One of these modulations is ductal formation, where a hollow tube through which 
liquid or gas can be transported successfully must be created. There are two main 
developmental strategies that have been reported to complete tubulogenesis in 
branched structures.  
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3.1.4.1 Formation of Tubes with Preformed Lumens 
The first method of tubulogenesis is the process by which epithelial tubes elongate 
with preformed lumens. This combination of epithelial placode invagination and 
lumen expansion is known as “budding” and occurs during development of the 
mammalian lung, as described in Chapter 1. The same mechanisms can be seen in the 
developing salivary gland of the fruit fly, Drosophila melanogaster (Kerman et al., 
2006). During Drosophila gland invagination, cells of the gland placode undergo 
apical constriction. With this process, also referred to as the “purse string model”, 
nuclei of placodal cells relocate to a basal position within the cell, allowing the apical 
regions of the cell to contract and form wedge-shaped cells (Baker & Schroeder 1967; 
Ettensohn 1985; Myat & Andrew 2000). This change in cell shape leads to the 
infolding of the epithelial sheet and a pit is formed. It has also been suggested that this 
strategy requires increased cell adhesion and changes to the underlying extracellular 
matrix (Hogan and Kolodziej, 2002). A continual wave of cell-shape change spreads 
to the more anterior placodal cells, leading to further internalization of these cells. 
This causes orthogonal elongation of the gland duct, without the occurrence of 
apoptosis (Myat and Andrew, 2000; Hogan and Kolodziej, 2002). 
3.1.4.2 Formation of Tubes from Solid Epithelial Cords 
Another method by which lumens form is referred to as ‘canalization’ and can be seen 
during mammalian salivary gland development, as outlined in Chapter 1, as well as 
the developing mammary gland (Humphreys et al., 1996; Melnick and Jaskoll, 2000). 
Following the condensation of unpolarised epithelial cells into a placode, a solid cord 
of cells extends into the underlying mesenchyme. Usually around the onset of 
branching morphogenesis, small spaces, or microlumena will begin to form within the 
epithelial stalk. These spaces then merge later in development to form one continuous 
lumen. The processes by which these original microlumena, as well as successional 
lumen formation occurs, are unclear, however contrasting hypotheses suggest the 
mechanism involves either programmed cell death (PCD) or PCD independent 
mechanisms.  
3.1.4.3 Apoptosis and Lumen Formation 
To maintain homeostasis in a multi-cellular organism, a constant balance between cell 
division and cell death is maintained. To carry out this function, PCD or apoptosis is a 
fundamental signalling process that occurs in all tissues throughout adult life. It is 
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also employed during development to help shape newly formed tissues. An example 
of apoptosis can be seen during limb morphogenesis where large areas of 
undifferentiated mesodermal cells undergo apoptosis to sculpt out digits in the 
developing limb (Hurle et al., 1996). 
 
Once PCD is triggered by either external or internal stimuli, a cascade of factors 
within the cell itself drives the eradication of the cell. These factors are part of either 
the “intrinsic” pathway triggered by internal stimuli, or the “extrinsic” pathway 
initiated by external intercellular information (Figure 3.2). The most frequent internal 
stimulus is irreparable DNA damage, which activates the tumour repressor molecule 
p53 in the nucleus. P53 translocates into the cytosol and activates the pro-apoptotic 
Bcl-2 protein Bax (Chipuk et al., 2004). Bax permeabilises the membrane of 
mitochondria leading to the leaking of apoptotic molecules, principally cytochrome c, 
from the organelle into the cytoplasm (Reed, 1997; Green and Reed, 1998; Schuler et 
al., 2000) (Figure 3.2). In the cytosol, cytochrome c binds to Apoptosis Protease 
Activating Factor 1 (APAF-1) and inactive Caspase-9 (Zou et al., 1999). The 
formation of this protein complex causes hydrolysis and the inhibitor domain of 
Caspase-9 dissociates and Caspase-9 is cleaved (Figure 3.2). This activation of 
Caspase-9 triggers a cascade of the “effector” Caspases (Caspase-3, 6 and 7), the 
proteins that are responsible for the cleavage of DNA, destruction of cytoskeletal 
proteins and consequently the demise of the entire cell (Li et al., 1997; Porter and 
Jänicke, 1999) (Figure 3.2). 
 
The “extrinsic” apoptotic pathway is triggered by external stimuli such as infection, 
environmental stresses (e.g. O2 depletion, cell-to-cell junction detachment), growth 
factors and hormones. Almost every cell in the body houses Tumor Necrosis Factor 
Receptors (TNFR) in their cell membrane. A subset of six receptors from this family 
are known as the “death receptors” and are responsible for triggering apoptosis within 
the cell following binding with their respective ligands. Fas and TNFR1 are the 
principal death receptors that bind to their extracellular ligands Fas-L and TNF 
respectively. Ligand-receptor binding leads to the activation of the common 
intracellular motif of both Fas and TNFR known as a “death domain” (Itoh and 
Nagata, 1993). Upon activation of Fas, the cytosolic adaptor protein Fas-associated 
protein with Death Domain (FADD) is recruited along with the inactive form of 
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Caspase-8, forming what is known as the “death inducing signal complex” (DISC) 
(Figure 3.2). When TNFR is activated DISC is formed with the addition of Tumor 
Necrosis Factor Receptor Type 1-associated Death Domain protein (TRADD). 
Hydrolysis of the inhibiting region of Caspase-8 occurs, cleaving and activating 
Caspase-8, which then triggers the Caspase cascade and thus the final stages of PCD 
(Figure 3.2). 
 
During murine mammary gland development, microlumen within the duct begin to 
fuse at approximately E18 (Hogg et al., 1983). At this stage peripheral luminal cells 
remain intact and will become the epithelial lining. Additionally, PCD is seen to begin 
in excess cells at a distance from the lumen (Hogg et al., 1983). Over the next 24 
hours, apoptosis spreads and is seen within the basal cells of the epithelial cord (Hogg 
et al., 1983). It is suggested that this method occurs to eliminate unnecessary cells 
within the mammary gland duct, as an epithelial lining of only one-three cells thick is 
required (Hogg et al., 1983). Apoptosis has also been reported to cavitate the terminal 
end buds of the mammary gland (Humphreys-Beher, 1996). 
 
It has been suggested that apoptosis plays a similar role during submandibular 
salivary gland (SMDG) lumen formation, with canalization of microlumen first seen 
within the main ducts during the Early Canalicular stage at E15.5, and identified in 
the terminal end buds approximately a day later at the Late Canalicular stage (Jaskoll 
and Melnick, 1999). By the Terminal Bud stage at approximately E18.5, these 
microlumen begin to coalesce to from one contiguous lumen (Jaskoll and Melnick, 
1999). PCD detection within the epithelium was seen to mirror lumen formation. At 
E15.5 many apoptotic cells were identified in the main ducts and some within the 
terminal end buds (Jaskoll and Melnick, 1999). By E17.5, at the Early Terminal Bud 
stage, PCD was more prevalent within the end buds, and apoptotic cells were less 
prevalent in the main ducts (Jaskoll and Melnick, 1999). In SMDG in vitro organ 
culture, PCD has been detected in the mesenchyme adjacent to the developing gland, 
while some apoptotic cells were seen within the branching epithelium, in newly 




Figure 3.2 The intrinsic and extrinsic apoptotic pathways. 
The intrinsic pathway is triggered by an intracellular stimulus. This activates pro-
apoptotic molecules in the cytosol, such as Bax, which permeabilise the outer 
membrane of mitochondria. Cytochrome c is released into the cell where it binds to 
APAF-1 and inactive proCaspase-9. Caspase-9 autoactivates by hydrolysis of its 
inhibiting region. The cleaved Caspase-9 functions in activating the Caspase cascade 
that recruits Caspase-3, 6 and 7, which are responsible for DNA fragmentation and 
the destruction of the cell. The extrinsic pathway involves activation by an 
extracellular ligand that binds to a transmembrane death receptor. The DISC within 
the cell, containing FADD, TRADD and inactive proCapsase-8, is activated. Caspase-
8 then cleaves and initiates the Caspase cascade. 
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3.1.4.4 Non-apoptotic Lumen Formation 
The involvement of the nervous system on salivary gland function has long been 
known (Pavlov, 1906). While it is well established that development and 
differentiation of epithelial structures is influenced by a number of environmental 
cues from surrounding mesenchyme and endothelial tissue, more recent research has 
elucidated a role for the parasympathetic nervous system during salivary gland 
regeneration (Proctor and Carpenter, 2007) and morphogenesis (Knox et al., 2010; 
Ferreira and Hoffman, 2013). A recent study demonstrated that the parasympathetic 
submandibular ganglion (PSG) nerve supply is imperative for both lumen formation 
and lumen expansion of the SMDG (Nedvetsky et al., 2014). It was described that this 
method of nerve-induced canalization is independent of PCD mechanisms. Although 
some apoptotic cells were identified in SMDG lumens, as previously described 
(Walker et al., 2008), successful lumen cavitation occurred in SMDGs cultured with 
the pan-caspase inhibitor Z-VAD-FMK (Nedvetsky et al., 2014). Furthermore, E17 
salivary glands in Bax null mutant mice were phenotypically normal, having 
undergone successful lumen formation (Nedvetsky et al., 2014). As opposed to PCD 
hollowing out SMDG ducts and end buds, the findings of this study demonstrated that 
this process was mediated, at least in part, by the PSG nerve supply. When nerve 
outgrowth and innervation were inhibited in in vitro culture lumen formation was 
disrupted (Nedvetsky et al., 2014). Inhibition of the neurotransmitter Vasoactive 
Intestinal Peptide (VIP), and its receptor VIPR1, gave rise to defective luminal cell 
aggregations, and exogenous VIP protein application caused narrow ducts in SMDG 
in vitro culture (Nedvetsky et al., 2014). Therefore it appears that VIP released by the 
PSG regulates SMDG cord hollowing. 
 
It has been reported that nerves ensheath the acini of the Steno’s gland in both dogs 
and rats (Bast, 1924; Moe and Bojsen-Moller, 1971), however innervation patterning 
or lumen formation mechanisms have not been investigated in the developing 
respiratory glands.  
 
3.1.5 Progenitor Cell Populations 
In recent times, research has focused on the role of progenitor cells during 
development, homeostasis and repair of complex 3D epithelial structures. Considering 
the constant exposure of the respiratory airways and lungs to airborne pathogens, it is 
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critical to characterize different stem and progenitor cell niches within respiratory 
epithelium, to elucidate their roles in airway disease, and to unveil solutions for gene 
therapy. Compared to other structures such as the skin and intestine (Clayton et al., 
2007; Doupe et al., 2012), the lungs have a slow rate of cell turnover. Following 
injury however, the pulmonary system undergoes rapid repair. To date, research has 
shown that different populations of progenitor cells may found in distinct regions of 
the pulmonary system, suggesting that differential niches of progenitors are recruited 
in the trachea, bronchioles and alveoli (Kim, 2007; Rawlins and Hogan, 2006; 
Rawlins et al., 2009). This is complimented by the fact that the airway lining changes 
in a proximal-distal fashion. As outlined in Chapter 1, the upper airways have a 
ciliated pseudostratified epithelium. Within this epithelium lie secretory goblet and 
Clara cells. Additionally, mitotically active basal cells are found closest to the 
basement membrane, however unlike epithelial cells, they have no luminal contact. 
Moving further down the pulmonary system to the bronchi in mice, or the bronchioles 
in humans, a transition to a simple columnar epithelium with a mixture of ciliated 
cells, non-ciliated secretory Clara cells, and neuroendocrine cells are found. No basal 
cells are identified in these distal airways. Finally, the epithelia of the lungs are 
composed of Type I and Type II pneumocytes. 
 
Advances in lineage tracing techniques have allowed the establishment of possible 
heterogeneous progenitor cell populations within the airway (Rawlins and Hogan, 
2006; Rawlins et al., 2009). For example, using a Scgb1a1-CreERTM knock in mouse 
to trace the lineage of Scgb1a1 positive Clara cells within the mouse lung, it was 
shown that Clara cells act as long-term progenitors in the distal bronchioles, giving 
rise to ciliated cells during development and adult homeostasis (Rawlins et al., 2009). 
In the trachea however, the Clara cells act more so as transit amplifying cells in 
response to injury, while their long-term progenitor population is composed of 
Scgb1a1 negative basal cells (Rawlins et al., 2009).  
 
It has been shown in a number of epithelial structures such as the tongue, stomach and 
skin, that keratin 5 (K5) expression, usually paired with K14 expression, is seen 
within the most basal undifferentiated cells of complex epithelia, closest to the 
basement membrane (Rentrop et al., 1986; Schweizer et al., 1988; Lersch and Fuchs, 
1988). The keratins are a family of 20 intermediate filament proteins essential for the 
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construct of the cells cytoskeleton (Fuchs, 1983). In the anterior trachea of mice, K5 
is expressed in the basal cells while K14 is detected in specific groups of these cells 
(Rock et al., 2009, 2010). More recent studies have elucidated that these basal cells 
are multipotent progenitor cells within the human and mouse airways (Hong et al., 
2004; Cole et al., 2010; Rock et al., 2010). Considering this however, little is known 
of the differentiation of these basal cells, as well as their role in airway disease 
pathogenesis. Borthwick et al. (2001) showed high K5 promoter activity within the 
ductal cells of the tracheal SMGs using a K5βgal6000 transgenic mouse. Using 
lineage tracing analysis, it was elucidated that K5+ basal cells of the tracheal 
respiratory epithelium gave rise to both secretory and ciliated cells during 
development (Rock et al., 2009). Additionally the same K5 positive cells gave rise to 
these cells types during tissue repair after injury (Rock et al., 2009).  
 
3.1.6 Aims of Study 
• To delineate anterior nasal gland development and distinguish the temporal 
localisation of each gland type during both duct elongation and gland branching 
stages using histological and optical projection tomography methods.  
 
• To culture the nasal glands in vitro, to follow their dynamic development. 
 
• To analyse the relationship between lumen formation, programmed cell death and 
innervation in the anterior nasal glands. 
 
• To investigate possible basal cell progenitor populations within the nasal 
epithelium and the SMGs during critical developmental stages.  
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3.2 Materials and Methods 
3.2.1 Immunofluorescence Analysis 
3.2.1.1 Primary and Secondary Antibody Addition 
Paraffin wax sections were dewaxed in three 10 minute washes of Histoclear and 
rehydrated in decreasing ethanol concentrations at RT (Table 3.1). Tissue underwent 
one wash in PBS and was put through an antigen retrieval wash of 30 minutes in Tris-
EDTA buffer (pH 9.0) at 95°C. Samples were left for 90 minutes to cool down to 
room temperature (RT). Sections then underwent one 10 minute wash in PBS 
followed by 20 minutes in PBS with 0.5% Triton® X-100 (Sigma-Aldrich, T9284). 
Slides were transferred to a lidded moist container known as a humid chamber. To 
each slide, 150µl of blocking solution (10% goat serum and 1% BSA in PBS with 
0.1% Triton® X-100) was added and tissue was blocked for one hour at RT. Sections 
were incubated overnight at 4°C with appropriate primary antibodies in blocking 
solution in the humid chamber (Table 3.2). Three one-hour washes in PBS were 
carried out, followed by a one-hour incubation in the humid chamber with suitable 
secondary antibody in blocking solution at RT (Table 3.2). Sections then underwent 
six five-minute washes in PBS in a coplin jar wrapped in tinfoil to omit light. Slides 
were mounted with Fluoroshield™ with DAPI (Sigma-Aldrich) mounting medium 
and cover slipped. Slides were put in a dry chamber that omitted all light, and kept at 
4°C. 
3.2.1.2 Confocal Microscopy 
Once the slides were dry, sections were scanned using a Leica TCS SP5 confocal 
microscope and Leica Application Suite Advanced Fluorescence (LAS-AF) software. 
Selected sections were scanned using the 10x, 20x or 40x lenses to capture specific 
stages of gland development. Images were saved in both .lif and .tif formats, and scale 
bar measurements were set by LAS-AF software. Images were collected as collages 
and labelled using Adobe Photoshop CS5.1 software and saved in .jpeg format. 
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Table 3.1 Ethanol concentrations for paraffin wax rehydration for 
immunofluorescence analysis. 
Ethanol Concentration Time of Wash 
100% 10 minutes 
100% 10 minutes 
100% 10 minutes 
90% 10 minutes 
70% 10 minutes 





















































3.2.2 In Vitro Organ Culture 
3.2.2.1 Collection of Fresh Tissue 
It is very important to imitate a tissue’s natural environment in vitro to ensure 
successful growth and development during organ culture. To provide growth factors 
and hormones, a supportive culture medium is crucial. For in vitro organ culture of 
the anterior nasal glands, a complete culture medium was made up using Advance 
Dulbecco’s Modified Eagle Medium F12 (DMEM F12) (Invitrogen) with added 1% 
Glutamax™ (Invitrogen) and 1% Penicillin-Streptomycin (Invitrogen) antibiotics. 
 
E14.5 CD-1 embryos were collected (described in Chapter 2) and transferred to ice 
cold culture medium. These ages were chosen as the Steno’s gland has elongated and 
the LNGs are budding at E14.5. Stages after initial bud formation were chosen to 
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ensure correct location of the nasal glands as buds could be identified under the 
microscope. 
3.2.2.2 Organ Culture Equipment Preparation 
Before beginning the culturing technique all instruments (scissors, forceps, tungsten 
wire) were cleaned thoroughly with 70% ethanol in dH2O and allowed to dry at RT. 
Instruments were then sterilised in a Germinator 500™ for approximately 30 seconds 
and allowed to cool at RT before using. Throughout the culturing process, these steps 
were repeated to ensure instrument sterility. 
Organ culture dishes were then prepared. These consisted of a Falcon™ central well 
organ culture dish (BD-Falcon 35-3037) containing 2mls of autoclaved H2O in its 
most outer well and 1ml of DMEM-F12 in its central well. An autoclaved metal grid, 
with a central hole removed, was then placed on top of the central well. Lids were 
placed on the culture dishes while tissue was being prepared. 
3.2.2.3 Tissue Dissection and Culturing 
A rostral-caudal incision, using a tungsten needle, was made through the mouth 
between the maxilla and the mandible (Figure 3.3, A). This isolated the nasal region, 
eyes and anterior brain from the rest of the embryo. Following this, brain tissue was 
removed and the remaining tissue was placed, palatal shelf down, on a clean 
mounting disk (Figure 3.3, B). Excess medium was removed from the disk using filter 
paper. The mounting disk was then placed on the table of a McIlwain tissue chopper 
(MTC/2, Mickle Laboratory Engineering). With the blade force set to maximum, 
tissue was then cut into sagittal 300µm thick sections using the chopper (Figure 3.3, 
C) (Alfaqeeh and Tucker, 2013). Tissue slices were then immediately transferred to a 
petri dish containing pre-chilled medium and observed carefully under a Leica MZFiii 
dissection microscope. For the Steno’s gland, complete slices containing the Steno’s 
duct were chosen for culture (Figure 3.4, A). This was decided upon as the Steno’s 
gland duct migrates through a large mesenchymal area of the middle concha and the 
whole duct was attempted to be isolated (Figure 3.4, A). With the culture of LNG 
buds, the middle conchal lip of tissue, of which the LNG buds arise, was dissected 
and kept for culture (Figure 3.4, B). This conchal lip was chosen, as it contains the 
exact epithelium of which the LNGs bud from, therefore other irrelevant tissue could 
be discarded (Figure 3.4, B). 
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Tissue sections were carefully transferred to small pieces of nucleopore filters (VWR) 
(Figure 3.4, C). Approximately three sections of tissue were placed on each filter and 
adequate space between each section was ensured. Filters were then placed on top of 
metal grids within organ culture dishes, allowing underlying medium to gently touch 
the filter (Figure 3.4, C). This ensures tissue is nourished by the underlying medium 
but not immersed in the liquid itself. Lids were put back on and dishes were placed in 
a 5% CO2/95% O2 Nuaire™ DH Autoflow-CO2 Air-Jacketed incubator. The dishes 
were then incubated for four days at 37°C. Dishes were removed from the incubator 
every 24 hours to take pictures at RT. Tissue sections were photographed with a Leica 
DFC300 Fx camera, and placed immediately back in the incubator after each photo 
was taken. 
3.2.3 Optical Projection Tomography (OPT) 
Tissue mounting and OPT optics were carried out by Dr. Alistair Edgar (Craniofacial 
Development and Stem Cell Biology, King’s College London). Whole head samples 
from E17.5 CD1 mice were fixed overnight in 4% PFA at 4oC. Samples underwent 
two 30 minutes washes in PBS followed by permeabilisation in 0.1% Triton in PBS 
for 3 hours, rocking at RT. Heads were equilibrated in PBS, embedded in 1% low-
melting point agarose (Invitrogen) and glued on magnetic aluminium mounts with 
ethyl 2-cyanoacrylate. Solidified agarose surrounding samples was cut at sharp angles 
to remove any excess gel. Samples were then dehydrated in 100% methanol and 
cleared in a mix of one-part benzyl alcohol to two-parts benzyl benzoate (BABB).  
 
Specimens were imaged in a Bioptonics 3001 OPT scanner (Bioptonics, Edinburgh, 
UK) at a pixel size of 3.2 µm. Single images were acquired at 0.9o intervals. White 
light shadow and fluorescence emission images were collected by a CCD camera. 
Three-dimensional (3D) reconstructions were generated using N-Recon Software 
(Skyscan) and channel overlays were rendered using Bioptonics Viewer. Rendered 
frames were concatenated into movie clips using QuickTime Pro (Apple). Epithelial 
autofluorescence was used as a means to identify ducts and glands in 3D videos.  
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Figure 3.3 Dissection and tissue sectioning of E14.5 mouse heads for in vitro 
organ culture of anterior nasal glands.  
(A) The head of freshly collected embryos is dissected (along red dotted line), 
isolating the maxilla and nasal region. (B) Brain tissue is removed and the remaining 
anterior head is placed on a chopping mounting disk, with the palatal shelf facing 
down. (C) Using a tissue chopper, tissue is sectioned into 300µm sections. These 
sections are then inspected and gland buds identified. Appropriate sections are then 






Figure 3.4 Isolated nasal tissue sections and culturing method for E14.5 anterior 
nasal glands. 
(A) Illustration of chosen nasal section for Steno’s gland duct (yellow) organ culture. 
As the Steno’s duct moves through a large plane of the nasal region, whole 300µm 
sections were cultured to follow its development. (B) Appearance of nasal sections 
containing the elongating gland buds of LNG2 (2) and LNG3 (3). From this, the 
protruding lip of tissue jutting from the middle concha, of which the LNG buds are 
located, was dissected (red dotted line) and cultured. (C) Central well slice organ 
culture method used to culture nasal glands in vitro. Isolated tissue is placed on a 
nucleopore filter, which is suspended above a bath of DMEM-F12 medium by a piece 
of sterile steel gauze. The outer well of the culture dish contains autoclaved H2O, to 
ensure tissue does not dry out during incubation period. Scale bar = 500µm. 
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3.3 Results 
3.3.1 Anterior Nasal Gland Development 
3.3.1.1 Positioning of the SMGs Within the Nasal Region 
The anterior nasal glands have long ducts that open close to the nares but their distal 
branched glands are located in more caudal heterogeneous locations at the back of the 
nasal cavity. Considering this, we investigated the anterior nasal glands in 3D using 
an OPT approach of late stage E17.5 CD1 embryonic heads (n=3), to understand the 
layout and morphology of these glands. It was difficult to visual glands in the whole 
head due to their location deep within the nasal capsule (Figure 3.5, A), although the 
MNGs could be observed when viewed down the cranial midline (Figure 3.5, B and 
C). We therefore turned to analysis of sagittal frames collected through the entire 
head by OPT (Figure 3.6). Using this method, glands could be followed from their 
opening locations, along their ducts and eventually to their distal branched gland 
(Figure 3.6). Having established the general layout of the glands by OPT we could 
then turn to histological methods to further understand the pattern of nasal gland 
development. 
3.3.1.2 Steno’s Gland Development 
Between E12.0 and E12.5 the Steno’s duct buds from the respiratory epithelium 
anterior (REA) on the septal side at the nasal vestibule (n=5) (Figure 3.7, A-D). The 
budding of the duct occurs as the pseudostratified REA dips inwards and invaginates 
into the underlying mesenchyme (Figure 3.7, A-D). As the bud arises, an indentation 
in the REA is formed (Figure 3.7, C-D). At E13.5 duct elongation proceeds over the 
superior nasal meatus and distally extends through the mesenchyme of the middle 
concha (n=4) (Figure 3.7, E-H). The REA indentation continues as the Steno’s duct 
lumen, simultaneously with the growing duct. A day later at E14.5, the distal tip of 
the duct has reached the mesenchyme below the respiratory epithelium of the 
maxillary sinus cavity (n=4) (Figure 3.7, I-L). At this location, duct elongation ceases 
and the Steno’s gland begins to branch distally over the next 24 hours (Figure 3.7, J - 
red brackets).  
 
At E15.5 the extending gland branches and end buds were apparent (n=4) (Figure 3.8, 
A-C). Branching of the Steno’s gland continued over the next 3 days. The first sign of 
acinar cell differentiation was observed at E16.5 (n=3) (Figure 3.8, D-F). Alcian blue 
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stained mucus was evident in some acinar cells of the developing gland as well as 
within the lumen of the more proximal Steno’s duct (Figure 3.8, inset image F). 
Continual branching proceeded through to E17.5, when the Steno’s gland is observed 
to be much larger and acini more numerous (n=6) (Figure 3.8, G-I). At this stage the 
majority of acinar cells were now producing mucus as indicated by Alcian Blue 




Figure 3.5 Morphological analysis of the anterior nasal glands using 3D OPT. 
(A) Some nasal gland ducts are observed in the sagittal view of the 3D E17.5 mouse, 
however they are difficult to identify to which subset of glands they belong. The 
medial nasal glands can be identified when viewing down the midline of the 






Figure 3.6 Morphological analysis of the anterior nasal glands using single 
sagittal frames of E17.5 heads by OPT. 
(A) The Steno’s duct opening located in the rostral nasal regions close to the nares, 
and (B) the Steno’s gland, found more caudally beneath the maxillary sinus. (C) The 
ducts of LNG2, LNG3 and LNG5 extend in parallel to the nasal cavity with their 
glands branching (D) above the Steno’s gland. The MNG ducts (E) and glands (F) are 
observed within the mesenchyme of the nasal septum. (G) The MSG branches close 




Figure 3.7 Steno’s duct elongation. 
(A-D) The epithelial budding of the Steno’s duct is seen between E12.0 and E12.5 
from the respiratory epithelium anterior (REA). (E-H) By E13.5, the Steno’s duct 
elongates over the nasal cavity and caudally extends through the mesenchyme of the 
medial concha. (I-L) By E14.5 the distal tip of the Steno’s duct has reached the 
mesenchyme beneath the maxillary sinus to the location of where the Steno’s gland 








Figure 3.8 Branching of the Steno’s gland. 
(A-C) The Steno’s gland begins to branch from the Steno’s duct between E15.0 and E15.5. 
The first signs of end buds are seen at E15.5. (D-F) Further branching continues and end 
buds have begun to differentiate into acini by E16.5. Mucus production is visible in some 
acinar cells (blue arrows) and inside the Steno’s Duct (inset image F). (G-I) By E17.5 the 
Steno’s gland is continually branching and acinus differentiation is well established with 
most acinar cells producing mucus (blue arrows). Respiratory epithelium (RE); olfactory 
epithelium (OE); maxillary sinus cavity (MS); Steno’s gland (yellow arrows and dotted 
line); MSG (red dotted line); LNG2 (green dotted line). Division of RE to OE shown by 





3.3.1.3 Lateral Nasal Gland Development 
In this study four LNGs, LNG2-LNG5, were identified to bud, elongate and branch 
during embryonic stages. All the LNGs budded from the respiratory epithelium 
posterior (REP) that covers a lip of tissue that protrudes from the rostral end of the 
middle concha (Figure 3.9). LNG2 was the first to undergo bud initiation between 
E13.5 and E14.0 from the REP at the nasal vestibule closest to the nares (Figure 3.9 
and Figure 3.10 B-D). Unlike the Steno’s gland duct, which dips into the underlying 
mesenchyme forming a dent in the REA, the budding of LNG2, and all the LNGs, 
involved the invagination of a solid swelling of cells from the REP into the 
mesenchyme. At E14.5, LNG2 had caudally extended as a solid cord of cells through 
the mesenchyme of the middle concha (Figure 3.10, F-H). At this stage LNG3 was 
observed to be at the late bud stage, having extended slightly from the REP at a 
location anterior to the distal tip of the extending LNG2 duct, and just beneath the 
opening of the Steno’s duct into the airway lumen through the REA (Figure 3.9 and 
Figure 3.10, F-H). Additionally at E14.5, LNG4 and LNG5 were observed to be 
budding from the REP covering the most rostral side of the middle concha, and caudal 
to the distal end of the LNG2 duct respectively (Figure 3.10, F-J).  
 
By E15.5, the duct of LNG2 had reached its final destination beneath the maxillary 
sinus, above the branching Steno’s gland (Figure 3.11, A-C). The duct of LNG3 had 
elongated parallel to that of LNG2, with its distal tip found rostral to the end of the 
arrested LNG2 duct (Figure 3.11, A-C). LNG4 had elongated posteriorly through the 
middle concha and its distal tip had emerged in the mesenchyme below the enclosing 
cartilage of the nasal capsule (Figure 3.11, D-E). The LNG5 duct had elongated 
caudally through the middle concha and arrests rostral to the ends of LNG2 and 
LNG3 (Figure 3.11, F-G). LNG5 sat adjacent to a curve in the nasal cartilage, which 
shall be referred to as the nasal cartilage grove. 
 
By E16.5, LNG2 had branched distally above the Steno’s gland, showing the 
formation of end buds (A-C). The beginning of lumen formation within the acini of 
LNG2 was apparent at this stage (Figure 3.12, C – white arrows). No mucus 
production was evident in acinar cells of LNG2 at this stage. The distal tip of LNG3 
duct had reached the caudal end of the middle concha, where it was found lying 
rostral to the branching LNG2 (Figure 3.12, A-C). LNG3 had begun branching 
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morphogenesis as the first signs of end buds were observed (Figure 3.12, C – green 
arrows). LNG4 was at a similar stage of development with the formation of end buds 
noted at its distal end below the nasal cartilage capsule (Figure 3.12, D-F). The duct 
of LNG5 had elongated through the middle concha beneath the respiratory 
epithelium, parallel to the ducts of LNG2 and LNG3, and had arrested close to the 
location of the nasal cartilage groove, where it began branching over the next 24 
hours (Figure 3.12, G-I).  
 
By E17.5, LNG2 had undergone extensive branching and cells had arranged into 
distinct acini (Figure 3.13, A-C). The distal gland of LNG3 had also undergone 
similar branching and clear lumens were identified within acini (Figure 3.13, A-C). 
No cellular differentiation was evident at E17.5 in both the LNG2 and LNG3 as no 
mucus staining was detected by Alcian Blue staining. LNG4 had formed numerous 
branches and terminal end buds and cavitation had begun within acini (Figure 3.13, 
D-F). LNG5 had begun to form distal epithelial gland buds close to the nasal cartilage 
grove and lumen formation had progressed from the duct to acini (Figure 3.13, G-I). 
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Figure 3.9 Budding locations of the lateral nasal gland ducts from the 
protruding lip of the middle concha. 
The LNG2 bud is first seen at E13.5 arising from the REP at the most rostral 
area of the conchal lip. It will extend caudally though the middle concha as 
development continues. At E14.5, LNG3 arises from the anterior area of the lip, 
underneath the opening of the Steno’s duct through the REA, and will extend 
caudally adjacent to the duct of LNG2. At E15.5, LNG4 initiates below the 
origin of the LNG2 and extends posteriorly through the mesenchyme of the 
concha where it will eventually branch beneath the nasal cartilage capsule, 
anterior to the palatal shelf. LNG5 also initiates at E15.5, where it will elongate 
adjacent to the ducts of LNG2 and LNG3. Gland buds (2-5) shown in green, 
direction of future extending duct shown by red arrows. Schematic is taken at a 







     
 
Figure 3.10 Lateral nasal duct elongation during E13.5 and E14.5 of 
development. 
(A) Sagittal (S) and horizontal (H) planes through an E13.5 mouse head showing the 
location of the LNG2 bud. (B) Horizontal schematic representation of LNG2 budding 
from the middle conchal lip. (C) Sagittal histological section showing the location of 
the middle conchal lip and the LNG2 bud in the nasal region. (D) The epithelial bud 
of LNG2 at E13.5. (E-F) Schematics showing location and appearance of the 
elongated LNG2 and the budding LNG3-5 at E14.5. (G-H) At E14.5 the LNG2 has 
elongated caudally as a solid stem. LNG3 has budded and begun to elongate and 
LNG4 is seen at a slightly earlier budding stage. (I-J) LNG5 is at its initial bud 





Figure 3.11 Lateral Nasal Gland duct elongation at E15.5. 
(A) Schematic showing the progression of the LNGs by E15.5. (B-C) A sagittal 
section shows the distal tips of LNG2 and LNG3 ending within the mesenchyme 
above the branching Steno’s gland (yellow). (D-E) LNG4 has elongated posteriorly 
with its distal tip emerging below the nasal cartilage capsule. (F-G) LNG5 has 
elongated parallel to the ducts of LNG2 and LNG3 however the end of this duct is 






Figure 3.12 Onset of Branching of the LNGs at E16.5. 
At E16.5 the LNGs begin branching of their distal glands. (A-C) LNG2 is the first to 
undergo branching between E15.5 and E16.5. At E16.5 many terminal end buds are 
apparent and cavitation has begun within the gland acini (C - white arrows). LNG3 
has also begun to branch at E16.5 as seen by the appearance of end buds (C – green 
arrows). (D-F) At E16.5 the onset of branching of the LNG4 beneath the nasal 
capsule is evident (F – green arrows). (G-I) The distal tip of LNG5 has not begun to 
branch at E16.5. A clear lumen is seen in the ducts of LNG2 and LNG3 at this stage 
(I – white arrows). A,D,G scale bar = 500µm; B,E,H scale bar = 250µm; C,F,I scale 






Figure 3.13 Branching of the LNGs at E17.5. 
At E17.5 all the LNGs are seen to have undergone branching of their distal glands. 
(A-C) LNG2 and LNG3 have branched and formed distinctive acini with lumens. (D-
F) LNG4 has formed branches and terminal end buds and lumen formation has just 
begun within acini. (G-I) LNG5 has also begun to branch with a clear lumen seen 
within its duct and lumen formation at its initial stages within acini. A,D,G scale bar 






3.3.1.4 Medial Nasal Gland Development 
Medial nasal gland (MNG) development was easier to follow compared to that of the 
LNGs. All MNGs budded from the respiratory epithelium covering either side of the 
nasal septum of the medial wall and elongated and branched within the mesenchyme 
of the septum (Figure 3.14, A-R). MNG1 and MNG2 were the first to bud between 
E14.0 and E14.5. At E14.5 ducts of these two medial glands had elongated (Figure 
3.14, A-F). By E15.5 these ducts had elongated into the central area of the septum 
while MNG3 had budded and elongated to the midline of MNG1 and MNG2 (Figure 
3.14, G-L). Through another plane of mesenchyme it is clear that branching of MNG1 
had begun by E15.5 (Figure 3.14, inset image L). Branching had progressed by E16.5 
in MNG1 and end bud formation was also underway in MNG2 (Figure 3.14, M-O). 
MNG3 had elongated adjacent to the ducts of MNG1 and MNG2 at E16.5 (Figure 
3.14, M-O) and began its branching over the next 24 hours. At E17.5, MNG1, 2 and 3 
had all branched, with branches and terminal end buds all crossing over one another 
(Figure 3.14, P-R). MNG4 had also elongated and begun its branching at E17.5, 
indicated by the presence of end buds (Figure 3.14, P-R). 
3.3.1.5 Maxillary Sinus Gland Development 
The maxillary sinus glands budded and branched from the respiratory epithelium at 
both the anterior and posterior walls of the maxillary sinus. They did not have a long 
gland duct like the other anterior nasal glands, they rather branched within the 
mesenchyme close to the epithelium. The anterior and posterior sinus glands 
underwent the same developmental patterning so for expediency the development of 
only the posterior MSG will be explained. At E14.5, no evidence of a MSG was seen 
(Figure 3.15, A-C) however by E15.5 branching of the MSG was apparent close to the 
respiratory epithelium (Figure 3.15, D-F). At this stage the MSG was observed to 
invaginate into the mesenchyme with preformed lumens within the branching 
epithelium. Branching of the MSG epithelium continued over the next two days of 
embryonic development with lumens constantly present within the end buds (Figure 
3.15, G-L). 
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Figure 3.14 Medial nasal gland development. 
(A-F) The development of the medial nasal glands begins between E14.0-E14.5 with 
the budding and elongation of the ducts of MNG1 and MNG2. (G-L) The MNG1 and 
MNG2 ducts elongate to the central septal area by E15.5 and branching has initiated 
at the distal tip of MNG1 (inset image L). MNG3 has also budded and elongated, with 
its distal end adjacent to the midline of the MNG1 and MNG2 ducts (G-I). (M-O) 
Branching of MNG1 has progressed by E16.5 with an array of branches and terminal 
end buds apparent at this stage. MNG2 has also begun branching. The distal tip of 
MNG3 has extended close the branching ends of the other MNGs. (P-R) Branching 
continues in all the MNGs in the central region of the septum. MNG4 has emerged by 
E17.5 has an elongated duct and the onset of branching has begun. Column 1 scale 





Figure 3.15 Maxillary sinus gland development. 
Maxillary sinus gland initiates between E14.5 and E15.5. (A-C) No MSG primordium 
is evident at E14.5. (D-F) At E15.5 the MSG is seen to have invaginated and 
branched into the mesenchyme close to its opening in the respiratory epithelium. The 
MSG continues to branch and grow at E16.5 (G-I) and E17.5 (J-L). MSG = red, 
Steno’s gland = yellow, LNG2 = green. MS = maxillary sinus cavity. Column 1 scale 




3.3.2 In Vitro Organ Culture of the Anterior Nasal Glands 
In vitro organ culture is an invaluable technique that allows ex vivo manipulation of 
organ development. We attempted to culture the Steno’s gland and the Lateral nasal 
glands using the slice organ culture method to follow gland development in vitro and 
to allow future experimentation and manipulation of anterior nasal gland 
development. 
 
Following dissection of nasal tissue at E14.5, development of both the Steno’s gland 
(Figure 3.16, A-D) and LNG2 and LNG3 (Figure 3.16, E-H) could be followed in 
culture. The Steno’s gland began its first stages of gland branching after 24 hours 
(Figure 3.16, C) of organ culture and continued to branch after 48 hours (Figure 3.16, 
D). At the time of collection at E14.5, LNG2 had begun elongation, and the LNG3 
bud had initiated its extension into the underlying mesenchyme (Figure 3.16, E and 
F). Following 48 hours of culture, both LNG ducts had elongated and branching of 
distal LNG glands has begun (Figure 3.16, G). Branching of the LNG glands 
continued successfully over the next 48 hours (Figure 3.16, H). 
 
3.3.3 Lumen Formation and Apoptosis During Gland Development 
As described above (see 3.3.1), different sets of anterior nasal glands undergo 
different mechanisms to ensure successful lumen formation within gland ducts. While 
the Steno’s gland and MSG develop with preformed lumens, the LNG and MNG 
ducts form lumens approximately two days after they bud and begin elongation. To 
elucidate if apoptosis plays a role in lumen formation, investigation into the activation 




Figure 3.16 In vitro organ slice culture of the E14.5 anterior nasal glands. 
(A-D) Culture of the Steno’s gland duct collected at E14.5. (A) Illustration of the 
nasal tissue section that has the Steno’s duct incorporated. (B) Appearance of Steno’s 
duct on day of dissection. Duct has elongated caudally and contains a lumen. (C) 
After 24 hours the tip of the Steno’s duct appears to have undergone initial gland 
budding. (D) Gland branching has continued on day 2 of culture. (E-H) Culture of 
LNG2 and LNG3 at E14.5. (E) Illustration of the nasal tissue section containing the 
LNG buds. From these sections the middle conchal lip was removed and cultured. (F) 
Extent of LNG duct elongation on day of collection. LNG2 has elongated caudally 
while LNG3 has undergone initial budding. (G) After 48 hours both LNGs have 
elongated and undergone branching of their distal glands. (H) Branching can be 
followed clearly and has continued to form distal LNG gland after 96 hours of culture. 
Scale bars = 500µm. 
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3.3.3.1 Apoptosis During Steno’s Gland Development 
At E12.5, the Steno’s bud had invaginated into the underlying mesenchyme from the 
REA. Caspase-3 positive apoptotic cells were detected in the epithelium of the duct 
close to the duct opening at the REA into the airway lumen (n=2) (Figure 3.17, A). At 
E14.5 (n=2), when the duct had elongated caudally, no apoptotic cells were found in 
the proximal Steno’s duct opening but activated Caspase-3 was observed in cells 
between the REA and REP (Figure 3.17, B). At the distal Steno’s duct, some 
apoptosis was detected (Figure 3.17, C). At E15.5, an odd apoptotic cell was found 
within the REA near the Steno’s duct opening (n=2)(Figure 3.17, D). At this same 
stage the distal Steno’s gland had begun branching morphogenesis. Apoptosis was 
seen was observed in some cells dispersed throughout the proximal (Figure 3.17, G) 
and middle (Figure 3.17, H) Steno’s duct, and within acini of the branching Steno’s 
gland (Figure 3.17, I). By E18.5 no apoptosis was detected within the Steno’s duct 
(n=2). 
3.3.3.2 Apoptosis During Lateral Nasal Gland Development 
Between E14.5-E15.0, when LNG2 and LNG3 had budded and elongated, the ducts 
were seen as a solid cord of cells (Figure 3.18, A-B, LNG3). No apoptosis was 
detected in these ducts at this stage. An odd Caspase-3 positive cell was detected 
within the REP and the distal tip of LNG3 however (Figure 3.18, A-B, white arrows). 
At E14.5 when LNG4 is initiating, no apoptosis was seen within this epithelial bud. 
At E15.5, lumen formation was noted within the proximal ducts of LNG2, 3 and 5 
(Figure 3.18, C-D). No Caspase-3 was expressed in any cells of the ducts. Some 
apoptosis was found at the distal tip of LNG5 at this stage (Figure 3.18, D, white 
arrows). By E16.5, when LNG2 and LNG4 have begun distal gland branching, 
lumens had formed in all of the LNG ducts (Figure 3.18, E). An odd Caspase-3 
positive cell was noted in the forming end bud of LNG2 (Figure 3.18, F), however 
none were found within the branching gland of LNG4 (Figure 3.18, G). 
3.3.3.3 Apoptosis During Medial Nasal and Maxillary Sinus Gland Development 
By E14.5-E15.0, lumen formation is underway in MNG1. No apoptosis was detected 
in the MNG1 ducts however at this stage (Figure 3.19, A-B). By E15.5, some 
Caspase-3 positive cells were seen in the duct and the budding distal end of MNG1 
only (Figure 3.19, C-D). No apoptosis was occurring in the other MNG ducts at E15.5 
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(Figure 3.19, C-D). At E16.5, an odd apoptotic cell was detected in the proximal 
opening of MNG2 (Figure 3.19, E), however no Caspase-3 positivity occurred in the 
rest of the ducts of all the MNGs at this stage (Figure 3.19, F). An odd Caspase-3 
positive cell was identified within the branching gland of MNG1 at E16.5 (Figure 
3.19, G). 
 
As the MSGs are undergoing initial budding and branching between E14.5-E15.0 no 
apoptotic cells were apparent (Figure 3.19, H). By E15.5, the branched MSGs were 
evident (Figure 3.19, I). No apoptosis was detected within gland acini, however 
Caspase-3 positive cells were observed within the respiratory epithelium of which the 
gland is branching from (Figure 3.19, I, white arrows). Similarly at E16.5 as the MSG 
continues branching, no apoptosis was detected within the gland itself but an odd 




Figure 3.17 Activated Caspase-3 during Steno’s Gland development.  
(A) Apoptosis is seen in proximal epithelial cells of the invaginated Steno’s duct at 
E12.5. (B-C) As the Steno’s duct elongates apoptotic cells are seen at the base of the 
REA close to the opening of the duct into the airway lumen (B). At the distal tip of 
the duct some apoptotic cells are identified (C). (D-F) At E15.5 an odd apoptotic cell 
is seen in the epithelium near the opening of the Steno’s duct (D). At the distal end of 
the Steno’s duct apoptosis is evident in the duct at the location of the branching gland 
(E). Some Caspase-3 expression was seen sparingly in cells within the new epithelial 
buds (F). By E16.5, the overall amount of apoptotic cells seemed reduced with an odd 
Caspase-3 positive cell seen throughout the gland from the duct opening (G), mid-





Figure 3.18 Activated Caspase-3 during Lateral Nasal Gland development.  
(A-B) Between E14.5 and E15.5, as LNG2 and LNG3 bud and elongate as solid cords 
of cells, no apoptosis is seen within the future duct structures. An odd Caspase-3 
positive cell was noted within the distal tip of LNG3 (B, white arrow). (C-D) Lumen 
formation is underway in the LNGs by E15.5. Sporadic expression of Caspase-3 was 
seen however only in the distal end of LNG5 (D, white arrows). (E-G) Lumens are 
clear within the ducts of the LNGs by E16.5, yet no Casapse-3 was seen in ductal 
cells. In the budding gland of LNG2, an odd apoptotic cell was noted (F, white 








Figure 3.19 Activated Caspase-3 during Medial Nasal and Maxillary Sinus gland 
development. 
(A-C) No apoptosis is seen within MNG1 between E14.5-E15.0. (C-D) An odd 
Caspase-3 positive cell was seen within the duct and end bud of MNG1 at E15.5. No 
apoptosis was seen in the other MNGs. (E-G) One apoptotic cell was seen in the 
proximal opening of MNG2 at E16.5. All other MNG ducts were apoptosis free. An 
odd Caspase-3 positive cell was seen in the branched MNG1 gland. (H-J) During 
MSG gland development no apoptosis was seen in gland cells, but rather within the 






3.3.4 Progenitor Cell Populations and Nerve Innervation During Anterior Nasal 
Gland Development 
To gain more knowledge of the characteristics of the nasal glands during development 
we decided to investigate progenitor cell populations within the glands using the basal 
epithelial cell progenitor marker K5. As previous research has indicated a role of 
epithelial-nerve interactions during gland development, particularly during lumen 
formation, we also looked at the nerve innervation of the glands, by Neurofilament 
protein detection.  
3.3.4.1 Keratin-5 and Neurofilament Detection During Steno’s Gland Development 
As the nasal pit forms and the middle conchal lip arises at E12.5, K5 expression was 
detected within cells of the respiratory epithelium at the most rostral location of the 
nasal vestibule (n=2)(Figure 3.20, A). As the respiratory epithelium runs more 
caudally and forms the Steno’s duct, K5 expression was absent in basal epithelial 
cells of both the epithelium of the conchal lip and the Steno’s duct (Figure 3.20, B). 
As development proceeded to E13.5, K5 expression was seen all throughout the REP 
of the conchal lip (n=2)(Figure 3.20, C and D). No K5 expression was found in the 
REA however, or in any of the basal cells of the Steno’s duct (Figure 3.20, D and E). 
At a more caudal position, some K5 expression began to become apparent within the 
respiratory epithelium of the maxillary sinus at E13.5 (Figure 3.20, F). No innervation 
was detected associated with the Steno’s duct during E12.5 and E13.5 of duct 
elongation. This suggests that a K5+ progenitor cell population, as well as nerve 
innervation, is not required for the outgrowth and elongation of the Steno’s duct. 
By E14.5, K5 expression had spread throughout the REA and all throughout the 
Steno’s duct (n=2)(Figure 3.21, A-D). Expression was more intense within the basal 
cells of the respiratory epithelium of the maxillary sinus above where the Steno’s 
gland duct had arrested elongation (Figure 3.21, B and C, pink arrows). At E14.5, 
innervation seemed to have developed close to the Steno’s duct with rich 
neurofilament expression seen in close proximity to the medial and proximal end of 
the duct (Figure 3.21, C and D, green arrows). No innervation was detected more 
rostral near the duct opening into the nasal cavity. This indicates that there is an 
arrival of nerve innervation just prior to the branching of the distal Steno’s gland, 
suggesting that nerves may play a role in branching morphogenesis.  
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At E15.5, the Steno’s duct had begun to branch distally into the Steno’s gland. K5 
expression was clearly identified within ductal cells and some expression was 
apparent within the branching acini (n=2)(Figure 3.22, A-C, pink arrows). Innervation 
surrounded the proximal Steno’s duct and gland while branching occurred (Figure 
3.22, A-C, green arrows). By E18.5, K5 expression was strong in the basal cells of the 
respiratory epithelial cells of the maxillary sinus (n=2)(Figure 3.22, D-E). K5 
expression was not detected in a consecutive line of cells close to the basement 
membrane of the olfactory epithelium however was expressed sporadically in some 
cells of the olfactory epithelium (Figure 3.22, D, blue dotted line).  Ductal cells and 
distal gland acinar cells of the Steno’s gland had clear K5 expression at E18.5 (Figure 
3.22, E-F). By this stage, innervation was evident throughout the distal Steno’s gland 
(Figure 3.22, E-F). 
 
3.3.4.2 Keratin-5 and Neurofilament Detection During Lateral Nasal Gland 
Development 
By E14.5, as the LNG have budded and begun elongation, K5 was expressed 
throughout the RE of the nasal cavity. By E14.5-E15.0, LNG2-5 had budded and most 
had elongated as ducts. As they did so, K5 was seen within the basal cells of all the 
LNGs (Figure 3.23, A-D). Innervation is also detected in close proximity to each 
LNG at this early stage of duct elongation (Figure 3.23, A-D). At E15.5, the LNGs 
proceeded more caudally with K5 expression still strong in the basal cells of each 
duct (Figure 3.24, A-C). LNG2 had begun to branch at E15.5 and K5 was expressed 
within some cells of the branching gland buds (Figure 3.24, C). As all glands have 
branched by E18.5, K5 is seen more widespread throughout the terminal end buds of 
each gland (Figure 3.24, D-G). Innervation was also detected throughout each gland 





Figure 3.20 Keratin-5 (red) and neurofilament (green) expression during early 
Steno’s gland duct development. 
(A-B) K5 expression is seen in the most rostral respiratory epithelium of the middle 
concha at E12.5. No K5 is seen within the cells of the Steno’s duct. (C-F) K5 has 
spread throughout the REP by E13.5 but is absent in the REA (C-D). No K5 is seen 
within the cells of the Steno’s duct (E). Some K5 expression is seen within the 
epithelium of the maxillary sinus (F). No innervation was detected associated with the 
Steno’s duct during E12.5 and E13.5 of duct elongation. REA – respiratory 
epithelium anterior; REP - respiratory epithelium posterior, Steno’s duct = yellow 
dotted line. Scale bar = 50µm. 
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Figure 3.21 Keratin-5 (red) and neurofilament (green) expression during Steno’s 
gland development at E14.5. 
(A-D) By E14.5, K5 expression has spread all throughout the RE of the nasal cavity. 
K5 expression has also spread throughout the basal cells of the Steno’s duct (B-D). 
Innervation is now seen in close proximity to the distal end of the Steno’s duct (C-D). 
REA – respiratory epithelium anterior; REP – respiratory epithelium posterior; 
maxillary sinus epithelium (white dotted line); Steno’s gland – yellow dotted line; 








Figure 3.22 Keratin-5 (red) and neurofilament (green) expression during Steno’s 
gland branching morphogenesis. 
(A-C) As the Steno’s gland branches at E15.5, K5 expression is seen in distal branching end 
bud cells. Innervation has also spread to envelop the branching buds (B and C, green arrows). 
(D) At E18.5, K5 is expressed in basal cells of the respiratory epithelium of the maxillary 
sinus however sporadic detection is seen in cells of the olfactory epithelium. (E-F) K5 
expression is found within acinar cells of the Steno’s gland and basal cells of the duct while 
nerves are seen wrapped through the distal gland at E18.5. RE - respiratory epithelium (white 
dotted line); OE – olfactory epithelium (blue dotted line); Steno’s gland – yellow dotted line; 
pink arrows – K5 expression; green arrows – neurofilament expression. Image D scale bar = 




3.3.4.3 Keratin-5 and Neurofilament Detection During Medial Nasal Gland 
Development 
Similarly to the LNGs, the MNGs begin budding and elongating at about E14.0. At 
E14.5, as the MNG ducts extend, K5 was detected within ductal basal cells (Figure 
3.25, A-C). Nerves were also seen to be in close proximity to the MNG ductal cells as 
each duct was elongating (Figure 3.25, A-C). At E15.5, rich K5 expression was 
observed within the ducts of MNG1-3, as well as clear innervation between the 
elongating ducts (Figure 3.25, D-F). Some K5 expression was found within the distal 
branching epithelial tip of MNG1, with nerves seen close by (Figure 3.25, F). By 
E18.5, when all the MNGs have branched as glands, K5 expression was clear in 
ductal cells and distal acinar cells (Figure 3.25, G-I). Innervation was prominently 
associated with the MNG ducts (Figure 3.25, G) and within the distal glands (Figure 
3.25, I). 
3.3.4.4 Keratin-5 and Neurofilament Detection During Maxillary Sinus Gland 
Development 
K5 expression was prominent within basal cells of the RE as the MSG branched 
immediately from the epithelium. At E14.5-E15.0 budding of the MSGs had begun. 
K5 expression arrested within the basal cells of the RE in the location of the 
branching gland but was observed in some distal epithelial cells of the gland itself 
(Figure 3.26, A). A day later at E15.5, branching of the gland continued, again with 
some K5 expression within gland cells (Figure 3.26. B-C). The first sign of nerve 
innervation of the MSG was observed at E15.5 (Figure 3.26, C, green arrows). By 
E18.5, the MSG was undergoing continual branching, yet no K5 expression was 
observed within gland acini cells (Figure 3.26, D-E). Some nerves were detected close 
to acini cells (Figure 3.26, D-E), however not as much as was detected in the other 




Figure 3.23 Keratin-5 (red) and neurofilament (green) expression during 
lateral nasal gland development at E14.5. 
(A-D) K5 expression is seen in the basal cells of all budding and elongating 
LNGs between E14.5 and E15.0. Innervation indicated by neurofilament 
expression is also seen close to all elongating LNGs. Innervation = green 





Figure 3.24 Keratin-5 (red) and neurofilament (green) expression during 
lateral nasal gland development at E15.5 and E18.5. 
(A-C) K5 is maintained within ductal cells during LNG elongation and seen within the 
branching gland buds of LNG2 at E15.5 (C). (D-G) At the later stage of E18.5, K5 has 
spread into terminal end bud epithelial cells of all the branched LNGs and innervation is 
rich around each distal gland. Nerves are also seen to run parallel to the ducts of LNG2, 







Figure 3.25 Keratin-5 (red) and neurofilament (green) expression during Medial 
nasal gland development. 
(A-C) K5 expression is seen within all MNG ducts at E14.5. Innervation is also seen 
in close proximity to the elongating ducts. (D-F) As development continues to E15.5, 
K5 expression continues within the MNG ducts and also spread to the distal 
branching tip of MNG1 (F). Nerves are seen associated with all ducts. (G-I) At E18.5, 
K5 positivity is seen within distal gland acini of each MNG (I). Nerves are also 
evident close to MNG ducts and within the distal glands. Innervation = green arrows. 







Figure 3.26 Keratin-5 (red) and neurofilament (green) expression during 
Maxillary Sinus Gland development. 
(A) K5 is strong within basal cells of the RE. Some K5 expression is seen in distal 
MSG gland cells (pink arrows). (B-C) Branching has continued and some K5 is still 
seen within gland cells (pink arrows). Innervation is also evident close to MSG acini 
(green arrows). (D-E) No K5 is seen within MSG gland cells by E18.5. Innervation is 
seen however not very many nerves were noted close to the MSGs (green arrows). 





3.4.1 Anterior Nasal Gland Development 
In the mid-twentieth century, researchers analysed and delineated anterior nasal gland 
topography and physiology (Brunner, 1942; Bojsen-Moller, 1964), however modern 
investigation of these respiratory glands is severely lacking. Although their scattered 
arrangement can be complex, with their long ducts and branched glands distributed 
throughout different regions of the nasal mucosa, the importance of these glands 
cannot be ignored. With an estimated 150 glands per cubic millimetre of nasal 
mucosa reported in adult humans (Brunner 1942), the nasal glands play a critical role 
in maintaining airway homeostasis as they provide the first line of defence within the 
respiratory system. Previous studies have named and described the temporal location 
of the glands in mice, and other mammals (Brunner 1942; Bojsen-Moller 1967; Moe 
& Bojsen-Moller 1971; Bojsen-Moller 1964), however these manuscripts fail to give 
descriptive explanations and illustrative aids to help the researcher locate and 
differentiate all groups of glands. The aim of this study was to thoroughly investigate 
and describe the patterning of the anterior nasal glands in a mouse model, in the hopes 
to clarify the development and arrangement of the glands and encourage future 
research into their cellular and molecular behaviours. 
3.4.1.1 The Steno’s Gland 
The orifice of the budding Steno’s duct can be clearly identified in the mouse at E12.5 
as the REA invaginates into the underlying mesenchyme forming an indentation in 
the epithelium. Steno’s duct elongation can then be followed over the next 48 hours, 
as the duct proceeds with a distinctive lumen. This has already been stated by 
Grüneberg (1971) however no histological or illustrative description was provided. 
We have shown in these results the temporal location of the budding and elongating 
Steno’s duct as well histological evidence of its appearance. Through schematic 
diagrams we have also explained the craniofacial planes of which the Steno’s duct 
elongates, in the hopes to clarify its journey for future studies.  
 
The distinct morphological stages of Steno’s gland development have also been 
categorised into different stages, where general time frames are provided for 
investigation into bud formation, duct elongation, distal gland branching and acinar 
differentiation (Table 3.3). This categorization will hopefully aid research into the 
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delineation of different cellular mechanisms occurring during these different stages of 
gland morphogenesis. 
 
Table 3.3 Approximate stages of the distinct morphological events of anterior 
nasal gland development. 
Gland Name Approx. age of 
budding 
Approx. age of 
initial lumen 
formation 
Approx. age of 
onset of branching 
Steno’s Gland E12.0 - E15.5 
LNG2 E13.5 E14.5-E15.0 E16.5 
LNG3 E14.0-14.5 E15.0 E16.5 
LNG4 E14.5 E15.5 E16.5 
LNG5 E14.5 E15.5 E17.0 
MNG1 E14.0 E14.5 E15.5 
MNG2 E14.5 E15.5 E16.5 
MNG3 E15.5 E16.5 E17.0 
MNG4 E16.0 E17.5 E17.5 
MSG E14.5-E15.0 - E15.0 
 
3.4.1.2 The Lateral Nasal Glands 
Bojsen-Moller (1964) reviewed anterior nasal gland development and reported that up 
to 20 LNGs had previously been described in mice. From this current study, we report 
the first five LNGs (Steno’s gland and LNG2-5) are found to bud and elongate during 
embryonic murine development. This suggests that continual LNG budding and 
branching occurs during postnatal development. Unlike the Steno’s gland, LNG2-5 
appeared to follow a similar developmental mechanism by elongating as a solid cord 
of cells, which hollow out approximately 24 hours after initial bud formation, to form 
a lumen. Distal LNG glands also began to branch 48 hours subsequent to gland 
budding. Although developing similarly, LNG2, 3 and 5 elongated caudally and 
branched close to the Steno’s gland, while LNG4 elongated posteriorly and branched 
below the nasal cartilage capsule. This suggests that LNG4, although structurally 
similar to the other LNGs, could be following a different molecular signal that attracts 
its elongating gland duct in a posterior direction, compared to a caudal attractant 
guiding its other LNG counterparts. By delineating this directional differentiation 
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between the LNGs, a model system is proposed to understand different mechanisms 
of cellular proliferation and chemo-attractant interactions. Regardless of this 
difference in spatial-temporal development, all the LNGs appeared to follow the same 
pattern of cavitation and branching morphogenesis.  
3.4.1.3 The Medial Nasal Glands  
Development of the medial nasal glands was relatively simple to follow as their ducts 
elongated and branched through the clear plane of mesenchymal tissue on either side 
of the nasal septum. The orifices of their ducts were found on the vestibular side of 
the nasal septum. The MNGs have been previously described in the rat, which can 
have four to five MNGs project into the septal mesenchyme (Bojsen-Moller, 1964). 
The rat MNGs do not stain with Periodic-Acid Schiff (PAS) or Alcian Blue staining 
(Bojsen-Moller, 1964). Analysis of the four MNGs of the mouse have also been 
carried out (Broman, 1921; Kerjaschki, 1974). These glands have previously been 
reported to be exclusively made up of serous cells (Bojsen-Moller, 1964; Kerjaschki, 
1974) and in this study, no Alcian Blue staining was seen within their acini, 
suggesting these glands are exclusively serous in nature. While all the MNGs look 
similar and undergo comparable developmental strategies, investigation into their 
ultrastructure has delineated distinguishable differences between these glands 
(Kerjaschki, 1974). It has been shown that MNG4, shows homologous characteristics 
to serous salivary glands, with its gland cells having common characteristics as serous 
cells, however MNG1-3 stand alone as their own distinct gland type (Kerjaschki, 
1974). What differentiates MNG1-3 from the fourth is that they possess “light” and 
“dark” endpiece cells within their glandular acini when analysed by electron 
microscopy (Kerjaschki, 1974). These “light” and “dark” cells have been described in 
the Bowman’s glands of the olfactory epithelium, where “light” cells contain 
electron-dense serous secreting vesicles while the “dark” cells contain electron-lucent 
mucous secreting vesicles (Getchell and Getchell, 1992). These compositional 
differences of these glands may also explain why in this study we see MNG1-3 
elongate and branch in the same plane and at similar time points, when MNG4 arises 
in the more rostral septum and develops slightly later. While all are considered 
‘Medial Nasal Glands’, for future studies it is advised to be aware of their differences.  
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3.4.1.4 The Maxillary Sinus Gland  
The maxillary sinus glands differed from their other nasal gland counterparts, as they 
began branching morphogenesis immediately after bud formation, giving rise to a 
tubulo-alveolar gland close to the respiratory epithelium. This structure allows the 
MSG to drain its secretion directly into the sinus cavity through its short and wide 
excretory ducts. Research on the MSG in rat found it to be an exclusively serous 
gland (Vidić and Greditzer, 1971) and begins its development at embryonic day 16 
(Vidić, 1971). In the mouse, we have shown that the MSG undergoes a similar 
method of development as in the rat however is first seen to bud from the epithelium 
of the maxillary sinus at approximately E15.0. This gland then rapidly branches over 
the next three days of embryological development, moving through the submucosa of 
the maxillary sinus in both an anterior-posterior and a left-right direction. By E17.5, 
the peripheral edge of the MSG can be first seen in the first sagittal section entering 
the nasal cavity, while its anterior and posterior edges can be seen to extend around 
the maxillary sinus. No Alcian Blue staining was present in the MSG, suggesting that 
this gland is exclusively serous in nature. 
3.4.2 Lumen Formation in the Anterior Nasal Glands 
3.4.2.1 The Steno’s Gland and Maxillary Sinus Gland Develop with Preformed 
Lumens 
From our analysis, it is clear that both the Steno’s gland and the MSG, although 
different in nature, develop with preformed lumens in their ducts, a method similarly 
seen in the developing lung (see Chapter 1). Lung bud outgrowth follows the budding 
pattern driven by apical constriction similar to that described in the Drosophila 
salivary system (Burri and Moschopulos, 1992; Meyer et al., 2004). PCD has been 
shown to play an important role in the modelling of developing lung tissue in fetal 
and postnatal rodents, however apoptosis is absent within the lung epithelium during 
initial stages of budding and branching (Kresch et al., 1998). This indicates that 
apoptosis does not play a part in lumen formation and that lumen expansion is a 
sufficient method to create a distinct hollow space within the lung. 
 
In this study, some apoptotic cells were seen within the epithelium of the Steno’s duct 
and gland. Many Caspase-3 positive cells were seen in the ductal epithelium close to 
its orifice at E12.5 when the duct is undergoing initial elongation. This PCD could 
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possibly be triggered to help carve out a clear opening into the nasal cavity, as it is 
seen in the most proximal cells, to aid in mucous expulsion out of the gland duct. A 
similar mechanism is seen in early mammary gland development as at E18 apoptosis 
is seen in excess epithelial cells at a distance from the newly formed lumen (Hogg et 
al., 1983). This PCD then continues to spread to the basal cells of the forming tube 
(Hogg et al., 1983). It is suggested that this method occurs to eliminate unnecessary 
cells within the mammary gland duct, as an epithelial lining of only one-three cells 
thick is required (Hogg et al., 1983). 
 
Another noticeable area of apoptosis was seen in the distal Steno’s duct at E15.5. 
These Caspase-3 positive cells were located close to the distal formation of end buds 
as the Steno’s gland begins morphogenesis, and it is suggested that this helps cavitate 
regions of the duct where future branches will form, allowing the flow of mucous into 
the main collecting duct. A few apoptotic cells were seen throughout the Steno’s duct 
and gland through all stages of development but due to their sporadic nature it is 
thought that these are undergoing normal tissue homeostasis mechanisms. 
 
No Caspase-3 positive cells were seen within the MSG during any stages of branching 
morphogenesis suggesting that apoptosis does not play a role in MSG development 
and that this gland may adopt a method of tubulogenesis similar to that seen in the 
Steno’s duct and mammalian lung. 
3.4.2.2 Apoptotic Canalization does not Occur in LNGs and MNGs 
As the LNGs and MNGs begin their first stages of branching morphogenesis as solid 
cords of epithelium, it was hypothesised that these tubes undergo canalization to form 
ductal structures. While this has been reported in mammalian tissues such as the 
mammary gland end buds and salivary gland ducts (Humphreys et al., 1996; Melnick 
and Jaskoll, 2000), it does not seem to occur in the anterior nasal glands. By analysis 
of Caspase-3 within the gland cells during their branching morphogenesis, no 
significant amount of apoptosis was detected in the LNGs and MNGs during any 
stages of development. As these glands form lumens within the first 24 hours 
following budding, it is suggested that they undergo alternative methods of 
tubulogenesis. For example, the method of cord hollowing is observed in the gut of 
zebrafish (Wallace and Pack, 2003; Ng et al., 2005). Through this process, cells of the 
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cord undergo weak polarization and form cell-to-cell junction complexes with 
neighbouring cells. Polarization leads to the formation of a small lumen in the apex of 
each cell. These lumena then merge to form one large lumen in the centre of the duct. 
During this process no apoptosis is recruited to help lumen formation (Wallace and 
Pack, 2003; Ng et al., 2005).   
 
In the LNGs and MNGs, detection of Caspase-3 seemed to occur randomly in a few 
cells through different planes of the glands indicating sporadic apoptosis was 
occurring. This suggests that PCD is not required to create a luminal space but may be 
adopted to maintain a clear duct. This strategy is seen in three-dimensional cell 
models using kidney epithelial cell lines (Martín-Belmonte and Yu, 2008). When 
MDCK cells were grown in Matrigel, an environment that promotes rapid cell 
polarization, cells rearrange to form a luminal space, like in cord hollowing. When 
cultured in collagen, which slows down the rate of polarization, apoptosis was 
recruited for lumen formation, similar to the cavitation process (Martín-Belmonte and 
Yu, 2008). To test this hypothesis in vivo, polarization of LNG and MNG glands cells 
could be analysed by immunofluorescent labelling using polarization markers such as 
Claudins and Integrins, to delineate if cell polarization is occurring within gland cells. 
Additionally, using the culture method described in this chapter, glands could be 
grown in vitro and exposed to polarization inhibitors, such as the Rho-associated 
kinase (ROCK) inhibitor Y27632, to delineate if a switch from cord hollowing to 
cavitation occurs. 
 
Furthermore, the observation that innervation is present during all stages of LNG and 
MNG stalk elongation, however absent during duct extension of the Steno’s gland, 
compliments the recent finding that a nerve supply is essential for successful lumen 
formation within the SMDG ducts (Nedvetsky et al., 2014). A model process of four 
distinct stages was proposed to ensure cavitation within SMDG ducts (Nedvetsky et 
al., 2014). Firstly, proliferation and aggregation of luminal cells along the midline of 
the epithelial stalk is observed. Polarisation of these cells then lead to the formation of 
microlumena within the epithelial stalk, due to the reorganization of cells (Nedvetsky 
et al., 2014). As development continues, these microlumena coalesce to form one 
continuous lumen, which then undergoes expansion to form a distinct hollow duct 
(Nedvetsky et al., 2014). It was shown that this method of lumen formation was 
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independent of PCD and relied on the neurotransmitter vasoactive intestinal peptide 
(VIP) for successful cavitation (Nedvetsky et al., 2014). Due to the rich nerve supply 
associated with the LNGs and MNGs during their stalk elongation and ductal 
formation stages, we hypothesise that a similar mechanism of lumen formation may 
be adopted in these glands, as to that of the SMDG.  
 
Thus, as different groups of nasal glands undergo different processes of 
tubulogenesis, they provide a valuable model system for the study of molecular and 
cellular mechanisms required for cell rearrangement and lumen formation. 
 
3.4.3 Progenitor Cell Populations in the Anterior Nasal Glands 
As the Steno’s gland budded and elongated during the first two days of development 
(E12.5-E14.5), K5 expression was absent in the REA, of which it protrudes, and the 
cells of the Steno’s duct itself. By E14.5, K5 had spread in a wave along the 
rostral/caudal axis, and was seen all throughout the RE of the nasal cavity. This wave 
now ensured K5 was expressed in the basal cells of both the REA and the entire 
elongated Steno’s duct. The onset of this wave of expression delineates that K5 was 
not required for initial Steno’s duct budding and elongation, however as the distal 
Steno’s gland began to branch at E15.5, a reservoir of K5 positive cells were present 
at the distal duct. K5 positive cells have been identified as progenitor cells in tracheal 
epithelium, postnatal mammary gland and prostate development (Rock et al., 2009; 
Sun et al., 2010; Shen et al., 2008). Knox et al. (2010) showed through lineage tracing 
experiments that K5+ cells are also progenitor cells of developing embryonic SMDGs 
and that depletion of K5 proliferation, by innervation removal, leads to a reduction in 
salivary gland terminal end buds. As development progressed, innervation was 
apparent surrounding the buds of the branching Steno’s gland. K5 expression is seen 
within ductal and endbud epithelial cells of the salivary gland by the Pseudoglandular 
stage at E13.0 (Lombaert et al., 2011). No studies have investigated earlier K5 
expression during prebud or initial bud stage however, so a direct comparison with 
the Steno’s gland duct stage cannot be made. It has been shown that the EGFR 
antagonist PD168393 (PD), and the epithelial muscarinic receptor inhibitor 4-DAMP 
(DAMP, N-2-chlorethyl-4-piperidinyl diphenylacetate) both completely inhibit 
proliferation, and thus differentiation, of K5+ basal progenitor cells in the salivary 
gland (Knox et al., 2010). Application of these inhibitors to Steno’s gland cultures at 
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E14.0, when distal gland budding is about to begin, would delineate if K5 is critical 
for distal Steno’s gland branching, 
 
By E13.5, when the first signs of LNG gland budding occurred, K5 expression was 
seen within the basal cells of the REP. By E14.5, when the MNGs began budding, 
again basal cells of the REA were K5+. As a result of this rostral/caudal wave of K5 
expression, epithelial buds of both LNGs and MNGs expressed K5 at this initial stage 
of development. Whether these progenitor cells are critical for bud formation can be 
tested using the PD and DAMP culture methods described above. It may be plausible 
that K5 progenitor cell populations are not required for structures that bud and 
elongate by the ‘budding’ mechanism, however may be critical to maintain epithelial 
cell condensations of those branching structures that develop by the elongation of 
solid cords. As the distal Steno’s gland may cleft and bud with solid branches, this 
would also explain why K5+ cells were present close to the distal end buds.  
 
Additionally, we report that no nerves were detected in close proximity to the 
elongating Steno’s duct between E12.5 and E14.5. After E14.5, neurofilament 
expression detected innervation close to the midline and distal end of the Steno’s duct 
as it began gland branching, a similar time as to when K5 expression was detected in 
the distal Steno’s gland. In comparison, nerves were detected in close proximity to the 
developing LNGs and MNGs during all stages of budding, stalk elongation and 
branching morphogenesis. Due to the timing of K5 expression within ductal cells, and 
the development of proximal nerves, it is suggested that signalling from the nerve 
supply may play a role in the expression of K5 in the basal epithelial progenitor cells. 
This nerve-epithelial interaction is well established in the mouse SMDG (Knox et al., 
2010; Lombaert et al., 2011). In ex vivo SMDG culture experiments where the 
parasympathetic submandibular ganglion (PSG) was removed, K5 expression in gland 
end buds and ducts reduced to less than 25% compared to those cultured with an 
intact PSG (Knox et al., 2010). Furthermore, culture of PSG-free SMDGs with 
carbachol, an acetylcholine analogue, increased the K5 progenitor cell population and 
rescued, to some extent, salivary gland morphogenesis (Knox et al., 2010). 
Considering this, we suggest that due to the development of nerves mirroring the 
wave of K5 positivity running through the nasal epithelium, innervation may be 
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required to induce and maintain K5 progenitor cell expression in the branching stages 
of Steno’s gland development and all stages of LNG and MNG morphogenesis. 
 
K5 expression was never seen in the epithelial cells of the maxillary sinus gland. 
Strong K5 expression was present all throughout the basal cells of the RE of the 
maxillary sinus, and the entire nasal cavity. Due to the MSG having short ducts and 
branching close to the RE, it is expected that the K5+ basal cells of the RE provide 





4. The Role of FGF Signalling During Nasal SMG Development 
4.1 Introduction 
Considering the importance of the submucosal glands (SMGs) in maintaining airway 
homeostasis and the significant role they play in a number of respiratory diseases, 
very little is known about the signalling molecules and intercellular cues that shape 
these branched organs. Looking at other structures that develop in a similar fashion, 
such as the mammalian lung, submandibular salivary gland (SMDG), hair follicles 
and teeth, dynamic expression of conserved signalling pathways such as Bone 
Morphogenetic Proteins (BMPs), canonical Wnt/βcatenin, and Eda/Edar, are all 
recruited to tightly control cellular and morphological changes that occur during 
budding, extension and in some cases, branching of epithelial tissue (Thesleff, 2003; 
Cardoso and Lü, 2006; Jaskoll and Melnick, 2006; Rishikaysh et al., 2014). As 
outlined in Chapter 1, previous studies have delineated the requirement for these 
pathways during SMG development. In the case of the development of the tracheal 
glands, Bmp4 expression is widespread throughout the mesenchyme beneath the 
airway epithelium during stages of bud induction and extension, while later, as glands 
are branching, Bmp4 expression is restricted to mesenchymal cells surrounding the 
newly forming gland end buds (Rawlins and Hogan, 2005). Signalling through the 
Eda/Edar pathway is also essential as tracheal SMGs are absent in Tabby male adult 
mice as well as crinkled mice, which are knockouts of Eda and Edaradd respectively 
(Rawlins and Hogan, 2005). Research on the anterior nasal glands also show that 
some, but not all of these glands are absent in the Tabby mouse (Grüneberg, 1971). 
Furthermore Lef-1 and Wnt signalling are required for early nasal gland bud initiation 
(Duan et al., 1999; Driskell et al., 2004, 2007). The involvement of Wnts during later 
stages of duct elongation and gland branching of the nasal glands however has not 
been investigated. 
 
As covered in Chapter 1, it is evident that the role of Fgf10, and its receptor Fgfr2b, 
is pivotal for cell proliferation, epithelial growth and extension of stalks during 
development of many branched organs (Sekine et al. 1999; Bellusci, Grindley, et al. 
1997; Jaskoll et al. 2005 and Chapter 6). Fgfs are also required for successful tracheal 
gland morphogenesis as hypoplastic glands are observed in Fgf10 +/- adult mice 
(Rawlins & Hogan, 2005 and Chapter 5). Expression of downstream readout genes 
and target transcription factor expression within branching epithelial structures has 
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also emphasised the role FGF signalling during branching morphogenesis (Zhang et 
al., 2001; Liu et al., 2003). Considering this, we wanted to investigate the role FGF 
signalling plays during embryonic nasal gland development.  
4.1.1 Aims of Study 
• To delineate expression patterns of mesenchymal Fgf10 and Fgf7 mRNA and 
epithelial Fgfr2 mRNA during stages of duct elongation and gland branching in 
each of the embryonically developing nasal glands. 
• To investigate the expression patterns of the downstream readout Spry1 and the 
target ETS domain transcription factor Pea3, to understand where FGF signalling 
is active.  
• To highlight the role of Fgf10 in nasal gland development by investigating gland 
phenotypes in WT, Fgf10 +/- and Fgf10 -/- embryos. 
• To uncover the role played by Fgfr2b signalling during gland development by 











4.2.1 FGF Signalling and Anterior Nasal Gland Development 
To follow temporal localisation of Fgfs during normal gland development, in situ 
hybridisation was adopted to locate expression of Fgf10 and its receptor at duct 
elongation and gland branching developmental stages. Additionally, detection of other 
Fgfs signalling through the FGFR2b receptor, along with downstream target and FGF 
signalling readout genes Spry1 and Pea3. 
4.2.1.1  Fgf10 and Fgfr2 Expression During Anterior Nasal Gland Development 
At E13.5, as the Steno’s duct is elongating through the mesenchyme of the middle 
concha, Fgf10 expression was detected distal to the end of the extending duct (n=1) 
(Figure 4.1, D). At the same stage Fgfr2 mRNA was found in the distal epithelial 
cells of the extending duct (n=1) (Figure 4.1, G). A day later, when the Steno’s duct 
has reached the area below the maxillary sinus, Fgf10 expression was observed 
throughout the mesenchyme (n=2) (Figure 4.1, E – yellow arrow). This is where the 
Steno’s gland begins to branch over the next 24 hours. Fgfr2 expression was found 
within the distal cells of the elongated Steno’s duct at E14.5 (n=2) (Figure 4.1, H). 
When the Steno’s gland was branching at E16.5, Fgf10 expression was apparent 
throughout the mesenchyme surround the end buds of the gland (n=2) (Figure 4.1, F). 
Fgfr2 mRNA was evident within the epithelial cells of the gland buds during this 
stage of branching morphogenesis (n=2) (Figure 4.1, I). 
 
At E14.5 the duct of LNG2 had begun its elongation through the middle conchal 
mesenchyme and the bud of LNG3 was emerging from the epithelium of the middle 
conchal lip (Figure 4.2, A-B). At this stage Fgf10 was expressed in the conchal 
mesenchyme surrounding both the extending LNG2 (Figure 4.2, C) and the budding 
LNG3 (Figure 4.2, D). At this same stage, Fgfr2 is expressed in the ductal epithelial 
cells of the elongating LNG2 (Figure 4.2, E) and the within the cells of the LNG3 bud 
(Figure 4.2, F). As LNG2 and LNG3 were branching at E16.5, Fgf10 was expressed 
throughout the mesenchyme surrounding the developing end buds (Figure 4.3, C), as 
well as adjacent to the end of the LNG5 duct (Figure 4.3, D). Fgfr2 was expressed 
within the end bud epithelial cells of LNG2 and LNG3 (Figure 4.3, E) and within the 
distal duct of LNG5 (Figure 4.3, F). At E16.5, when the LNG4 duct is elongating 
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beneath the nasal septum, Fgf10 was expressed in the mesenchyme surrounding the 
extending duct (Figure 4.4, B) and Fgfr2 within the ductal cells (Figure 4.4, C). 
 
 
Figure 4.1 Fgf10 and Fgfr2 expression during Steno’s gland development. 
Trichrome stained sagittal sections of the distal Steno’s duct (A-B) and gland (C) at 
respective stages of development. (D) Fgf10 mRNA is detected in the mesenchyme 
adjacent to the elongating Steno’s duct at E13.5. (E) At E14.5, Fgf10 expression is 
seen all throughout the mesenchyme beneath the maxillary sinus epithelium in the 
location of where the Steno’s gland will branch. (F) At E16.5 when the Steno’s gland 
is undergoing continual branching, Fgf10 is seen in the mesenchyme surrounding the 
distal gland buds. (G) Fgfr2 expression is seen within the distal epithelial cells of the 
Steno’s duct at E13.5. (H) At E14.5, Fgfr2 mRNA is detected in the maxillary sinus 
epithelium and the distal epithelial cells of the Steno’s duct. (I) During gland 
branching stages at E16.5, Fgfr2 expression is evident in the distal epithelial cells of 
the gland end buds. Steno’s gland outlined in yellow; blue dotted line outlines the 




Figure 4.2 Fgf10 and Fgfr2 expression during LNG duct elongation. 
(A-B) Trichrome staining of the LNG2 duct (A) and LNG3 bud (B) at E14.5. (C-D) 
Fgf10 expression is found throughout the mesenchyme adjacent to the elongating 
LNG2 and surround the invaginating LNG3 bud. (E-F) Fgfr2 is expressed within the 









Figure 4.3 Fgf10 and Fgfr2 expression during LNG gland branching. 
(A) Trichrome staining of LNG2 and LNG3 branching glands. (B) Trichrome staining of 
the LNG2 and LNG3 ducts as well as the LNG5 elongating duct, at a more rostral plane. 
(C) Fgf10 expression is seen throughout the mesenchyme surrounding the branching LNG2 
and LNG3 buds. (D) Some Fgf10 expression is maintained in the mesenchyme close to the 
extended LNG2 and LNG3 ducts, as well as in the mesenchyme close to the extending 
LNG5 duct. (E) Fgfr2 expression is clearly seen in the branching epithelial buds of LNG2 
and LNG3. (F) Some Fgfr2 expression is seen within some epithelial cells od LNG2 and 
LNG3 and in the distal epithelial cells of the extending LNG5. LNGs outlined in green. 
Scale bar = 100µm. 
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Figure 4.4 Fgf10 and Fgfr2 expression during LNG4 development. 
(A) Trichrome staining of the elongating LNG4 (green outline) duct found beneath 
the nasal capsule. (B) Fgf10 is expressed in the mesenchyme below the nasal capsule 




Fgf10 is expressed throughout the mesenchyme of the nasal septum at E14.5 when the 
MNG gland ducts are elongating (Figure 4.5, C). At this stage Fgfr2 expression is 
noted in the epithelial cells of the extending MNG1 duct (Figure 4.5, E). At the 
branching stages of the MNGs at E16.5, Fgf10 still surrounds the extending glandular 
branches and Fgfr2 is expressed within the gland buds (Figure 4.5, D & F) 
 
Similar to all the other nasal glands, Fgf10 is seen throughout the mesenchyme 
adjacent to the MSG primordium at E14.5 (Figure 4.6, C), with Fgfr2 expression seen 
within the maxillary sinus epithelium from which the MSG buds (Figure 4.6, E). 
When the MSG is branching at E16.5, Fgf10 expression is maintained throughout the 
epithelium adjacent to branching MSG end buds (Figure 4.6, D). At this same stage, 
Fgfr2 expression is lost within the maxillary sinus epithelium however it is apparent 






Figure 4.5 Fgf10 and Fgfr2 expression during MNG Development. 
(A) Trichrome stained tissue section through the nasal septal mesenchyme at E14.5 
and (B) through the branched MNGs at E16.5. (C) A section through the septum 
showing Fgf10 expression all throughout the mesenchyme adjacent to the elongating 
MNGs. (D) Fgf10 is expressed in the mesenchyme surrounding the branching MNGs 
at E16.5. (E) Fgfr2 is expressed in the distal tip of the elongating MNG1. (F) Fgfr2 
mRNA is detected in the distal tips of the branching glandular buds. MNG1 duct 






Figure 4.6 Fgf10 and Fgfr2 expression during maxillary sinus gland 
development. 
(A) Trichrome staining of the position at which the MSG is about to begin its initial 
budding at E14.5. (B) Trichrome staining of the branching MSG at E16.5. (C) Fgf10 
is expressed throughout the mesenchyme surrounding the MSG primordium. (D) By 
E16.5 when the MSG is branching Fgf10 is seen in the mesenchyme surrounding the 
branching MSG end buds. (E) Fgfr2 is expressed in the maxillary sinus epithelium of 
which the MSG buds at E14.5. (F) By E16.5, Fgfr2 expression is lost from the 
maxillary sinus epithelium but seen within the distal end buds of the MSG. Red dotted 
line outlines the MSG; orange dotted line outlines the maxillary sinus lumen. Scale 





4.2.1.2  Spry1 and Pea3 Expression During Anterior Nasal Gland Development 
Spry1, a negative-feedback regulator of tyrosine kinase signalling, and an immediate 
target of FGF signalling, was expressed in the distal epithelial cells of the elongating 
Steno’s duct at E14.5 (n=2) (Figure 4.7, A). At E15.5 (n=1), when the Steno’s gland 
was branching, Spry1 was seen again within the epithelial cells of the extending gland 
buds and maintained within buds during continual branching at E16.5 (n=2) (Figure 
4.7, C and E). At these same stages, Pea3, a downstream target of the MAPK 
signalling pathway, was also expressed in the epithelial cells of the extending Steno’s 
duct at E14.5 (n=1) (Figure 4.7, B) and within the budding glands at both E15.5 (n=1) 
and E16.5 (n=2) (Figure 4.7, D and F). 
 
Similar expression patterns of Spry1 and Pea3 were seen during LNG development. 
Both genes were expressed within the peripheral epithelial cells of LNG4 as it buds at 
E14.5 (Figure 4.8, A and B). At late E15.5, Spry1 and Pea3 expression was observed 
in cells of the newly forming gland buds of the branching LNGs (Figure 4.8, C and 
D). This expression was maintained within the end buds at E16.5 (Figure 4.8, E and 
F). 
 
Again, expression of Spry1 and Pea3 during MNG1 duct elongation was restricted to 
the distal cells of the extending duct (Figure 4.9, A and B). As the MNGs continue 
formation and elongation at E15.5, some Spry1 and Pea3 was expressed within the 
newly budding glands (Figure 4.9, C and D). As the MNGs successional branching 
occurs at E16.5, Spry1 and Pea3 are expressed in the distal epithelial bud cells 
(Figure 4.9, E and F). 
 
At E14.5, just before the MSG begins its budding and immediate branching, Spry1 
expression was seen throughout the basal epithelial cells of the maxillary sinus 
epithelium and some of the underlying mesenchyme (Figure 4.10, A). At the same 
stage of E14.5, Pea3 was expressed by some cells of the maxillary sinus epithelium 
from which the MSG will bud (Figure 4.10, B). By E15.5 when MSG branching was 
evident, Spry1 was seen in the distal epithelial bud cells (Figure 4.10, C). Some Pea3 
expression was also seen within these distal cells (Figure 4.10, D). Spry1 expression 
was maintained in the gland buds during continual branching at E16.5 (Figure 4.10, 




Figure 4.7 Spry1 and Pea3 expression during Steno's gland development. 
(A-B) Spry1 and Pea3 expression is evident in the distal type of the elongating 
Steno’s duct at E14.5. (C) At E15.5 Spry1 expression is seen within the epithelial 
gland buds of the branching Steno’s gland. (D) Pea3 is expressed in the most 
peripheral epithelial cells of the branching Steno’s gland. (E-F) Expression of both 
Spry1 and Pea3 is maintained in the gland buds as branching continues at E16.5. 










Figure 4.8 Spry1 and Pea3 expression during LNG development. 
(A-B) As LNG4 is budding Spry1 and Pea3 expression is detected in the distal 
epithelial cells of the bud. (C-D) At E15.5, Spry1 and Pea3 expression is localised to 
the branching epithelial buds of the distal glands. (E-F) This was again seen at E16.5 





Figure 4.9 Spry1 and Pea3 expression during MNG development. 
(A-B) At E14.5 when the MNG1 duct is elongated Spry1 and Pea3 expression is seen 
in the distal tip of the ducts. (C-D) A day at E15.5 the distal cells of the newly 
forming gland buds express Spry1 and Pea3. (E-F) As continual gland branching 










Figure 4.10 Spry1 and Pea3 expression during MSG development. 
(A) At E14.5 priors to MSG budding Spry1 is seen within the maxillary sinus 
epithelium (blue outline) as well as some of the underlying mesenchyme. (B) Some 
Pea3 expression was seen within some cells of the maxillary sinus epithelium of 
which the MSG will bud. (C) As the MSG (red outline) is branching at E15.5, Spry1 
expression is seen in the distal end bud epithelial cells. (D) Slight Pea3 expression 
was also seen in these distal bud cells. (E) At E16.5 when continual branching of the 
MSG occurs Spry1 expression is evident in the gland buds. (F) Pea3 expression is 
also seen in the end buds of the MSG glands and in the surface of the maxillary sinus 
epithelium. Orange dotted line outlines the maxillary sinus epithelium. Steno’s gland 




4.2.2 Fgf10 is Critical for Early Steno’s and Maxillary Sinus Gland Development 
To define the role of Fgf10 in anterior nasal gland development, we analysed the 
gland phenotype in WT (n=3), Fgf10 +/- (n=5) and Fgf10 -/- (n=5) mice at E17.5 
when the majority of the anterior nasal glands have elongated and branched. 
Investigation of the Steno’s gland showed that this gland was completely absent in 
Fgf10 -/- mice (Figure 4.11, G-I). The gland did develop however in Fgf10 +/- 
animals, as its duct elongated to the correct location underneath the maxillary sinus 
and branching of the gland occurred (Figure 4.11, D-F). The amount of branches of 
the Steno’s gland was reduced however in the Fgf10 +/- (Figure 4.11, E and F) 
compared to WT littermates (Figure 4.11, B and C). Additionally, the MSG was 
absent with complete loss of Fgf10 (Figure 4.11, I). Similarly to the Steno’s gland, the 
MSG did develop in Fgf10 +/- mice however branching was noticeably reduced 
(Figure 4.11, F) compared to that observed in WTs (Figure 4.11, C). 
 
4.2.3 Fgf10 is Critical for Steno’s Gland Duct Invagination 
At E12.5 when the Steno’s gland duct arises from the respiratory epithelium anterior 
(REA) and invaginates into the mesenchyme of the middle concha, an epithelial pit 
was observed in both WT (n=3) and Fgf10 +/- (n=3) mice (Figure 4.12, A & B). At 
the same stage in Fgf10 -/- mice however, no pit was apparent arising from the REA 
yet a slight swelling indicating formation of an epithelial placode was observed (n=3) 
(Figure 4.12, C). This phenotype indicated that FGF10 signalling is critical for the 




Figure 4.11 The Steno’s gland and MSG are absent in Fgf10 -/- mice. 
Frontal and sagittal sections through the nasal cavity at E17.5. The Steno’s duct (A) 
and gland (B-C) are well established in WT animals at E17.5, as well as the MSG (C – 
red line). (D-F) The glands have developed in Fgf10 +/- littermates however reduced 
branching is evident. (G-I) The Steno’s duct (G) and gland (H-I), and the MSG (I) are 
completely absent in the Fgf10 -/- animal. The LNG ducts extend to their correct 
location in the Fgf10 -/- however branching of the distal glands is severely defective 
(H-I). Steno’s gland = yellow; MSG= red; LNG2&3=green; asterisks represent absent 
gland. Column1 scale bar=50µm, Column2 and 3 scale bar=100µm. 
 
 
Figure 4.12 Fgf10 expression is required for initial Steno’s bud invagination 
(A) Indentation of the Steno’s gland duct is observed in WT animals at E12.5 (B) Similar 
development is seen in Fgf10 +/- littermates as the Steno’s duct dips into the underlying 
mesenchyme.  (C) No ductal pit is found in the Fgf10 -/- mouse. An epithelial placode 




4.2.4 Fgf10 is required for Successful Branching of the Lateral and Medial Nasal 
Glands 
The LNGs are found in both Fgf10 +/- and -/- mice at E17.5. Their ducts have budded 
and elongated to the correct locations when compared to WT specimens (Figure 4.13, 
A-F). Branching of the distal glands was affected however with a slight reduction 
observed in the heterozygotes (Figure 4.13, D-E) and a more significant reduction in 
branches in the homozygotes (Figure 4.13, G-H). When the MNGs have elongated 
and branched throughout the septal mesenchyme in WTs at E17.5 (Figure 4.13, C), in 
Fgf10 +/- mice they developed to the same stage, however fewer gland branches were 
observed (Figure 4.13, F). In Fgf10 -/- littermates, the MNGs were severely defective 
with ducts elongating, yet were truncated with considerably reduced branches (Figure 
4.13, I). 
 
4.2.5 Fgfr2b is Critical for Steno’s Gland, MSG, LNG4 and MNG Development 
To elucidate if other FGF ligands working through the same receptor as FGF10 were 
critical for nasal gland development, the gland phenotype was investigated in Fgfr2b 
knockout mice at E18.5 (n=2). Similarly to Fgf10 homozygous mutants, the Steno’s 
duct (Figure 4.14, A-B) and gland (Figure 4.14, C-D) were completely absent in 
Fgfr2b -/-. Furthermore, similar to the Fgf10 -/- phenotype, the MSG was also absent 
in the Fgfr2b knockout (Figure 4.15, C-D). Additionally, unlike the Fgf10 -/- 
phenotype, the MNGs were also absent with complete loss of Fgfr2b (Figure 4.15, A-
B). This indicates that other FGFs that bind to FGFR2b with high affinity are required 
for MNG duct elongation and branching. 
 
Investigation of LNG development showed that the LNG2 duct budded and elongated 
in Fgfr2b deficient mice however branching of the distal LNG2 gland was severely 
truncated (Figure 4.14, C-D). A similar phenotype is seen with LNG3 as its duct 
(Figure 4.14, C-D) and a reduced distal gland (Figure 4.16, A-B) were found in 
Fgfr2b deficient animals at E18.5. Interestingly, loss of Fgfr2b leads to the complete 
absence of LNG4, as observed underneath the nasal cartilage capsule at E18.5 (Figure 
4.16, C-D), suggesting that other FGFs that bind to FGFR2b are required for LNG4 
development. LNG5 developed similarly to that of LNG2 and LNG3, as its duct 
extended to the correct location however branching of the distal gland was defective 
(Figure 4.16, E-F).  
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Figure 4.13 Fgf10 expression is required for the branching of the distal LNG and 
MNGs. 
(A) Gland branches of LNG3 and 5, and the duct of LNG2, are found beside the nasal 
cartilage groove in WT animals. (B) LNG4 has extended beneath the nasal septum 
and has branched extensively. (C) MNG1-3 are well established in the WT at E17.5, 
and MNG4 has elongated and begun branching. (D-F) A similar phenotype is seen in 
Fgf10 +/- littermates, however branching of all of the distal glands is slightly reduced. 
(G) Branching is severely defective in LNG3 and 5 in the Fgf10 -/- animal. (H) LNG4 
has extended and undergone some branching but again the number of branches is 
significantly reduced. (I) Ducts of MNG1-3 have elongated in the Fgf10 -/- mouse at 
E17.5 however branches extending from the distal duct are severely truncated. Scale 






Figure 4.14 Fgfr2b expression is critical for Steno’s gland development. 
(A-B) Frontal sections of E18.5 nasal tissue shows the Steno’s duct present in WT (A) 
and absent in Fgfr2b -/- animals (B). The duct of LNG3 is found in both WT and 
Fgfr2b deficient mice. (C) The distal LNG2 and Steno’s gland are seen clearly in WT. 
(D) The Steno’s gland is completely absent in Fgfr2b -/- mice. LNG2 is found in 
Fgfr2b -/- animals however branching of the gland is extremely defective, with only 
truncated end buds found (D). Asterisks indicate absence of the Steno’s gland. Scale 








Figure 4.15 Fgfr2b expression is critical for Medial and Maxillary Sinus Gland 
development. 
(A-B) The MNGs are completely absent in Fgfr2b -/- mice compared to their WT 
littermates. (C-D) The MSG develops from the maxillary sinus epithelium in WTs 






Figure 4.16 Fgfr2b expression is critical for LNG4 formation and LNG3 and 
LNG5 distal gland branching. 
Frontal histological sections of E18.5 embryos. (A-B) The LNG3 duct extends to the 
same location in Fgfr2b -/- mice however branching of the distal gland is severely 
reduced. (C-D) Both LNG4 glands are found below the nasal cartilage capsule in WT 
animals, however are completely absent with the loss of Fgfr2b. (E-F) The LNG5 
duct develops in Fgfr2b -/- mice yet branching of a distal gland is truncated. Asterisks 







4.2.6 Fgf7 Expression During Anterior Nasal Gland Development 
Considering the absence of the MNGs in the Fgfr2b -/- mouse, yet the presence of 
MNG ducts and primary branches in the Fgf10 homozygous embryo, we decided to 
investigate the expression pattern of Fgf7 during normal gland development, as this 
ligand is closely related to FGF10 and also binds to FGFR2b with high affinity. 
 
Fgf7 was not found in the mesenchyme surrounding the Steno’s gland during any of 
the duct elongation stages (Figure 4.17 A-C) or gland branching (Figure 4.17, D). 
Fgf7 expression was observed surrounding the nasolacrimal duct (NLD) and this was 
used as a positive control of gene expression (Figure 4.17, A and D inset image). No 
Fgf7 expression was associated with LNG or MSG development (Figure 4.18 A-D). 
Unlike the other anterior nasal glands however, Fgf7 expression was observed 
throughout the septal mesenchyme at E14.5 (n=2)(Figure 4.18, E). As the MNG ducts 
were elongating Fgf7 expression was maintained in the anterior septal mesenchyme 
close to the elongating ducts (n=2)(Figure 4.18, F). These results suggest that MNG 




Figure 4.17 Fgf7 expression during Steno’s gland development. 
(A) At E13.5, the mesenchyme surrounding the maxillary sinus is absent of Fgf7, 
however Fgf7 expression was found surrounding the NLD at this stage (arrow). (B) 
No Fgf7 expression is detected adjacent to the distal tip of the Steno’s duct at E13.5. 
(C) At E14.5 no Fgf7 expression is associated with the elongating Steno’s duct. (D) 
When the Steno’s gland is branching at E15.5 no Fgf7 is observed near the branching 
gland. Fgf7 expression is still maintained in the mesenchyme surrounding the NLD 




Figure 4.18 Fgf7 expression during anterior nasal gland development. 
(A) Fgf7 expression is not found associated with the elongate LNG2 and 3 ducts or 
(B) the budding LNG5 at E15.5. (C) Fgf7 expression is not associated with the 
epithelium where the MSG will bud at E14.5 or (D) surrounding the branching MSG 
at E15.5. (E) At E14.5, a section through the nasal septum shows Fgf7 expression 
throughout the mesenchyme. (F) At E15.5, Fgf7 expression is seen in the anterior 
mesenchyme of the nasal septum close to the elongating MNG ducts. A-D scale bar = 








4.3.1 Fgf10 is Essential for Anterior Nasal Gland Branching Morphogenesis 
The anterior nasal glands provide a wonderful model for studying branching 
morphogenesis due to their long duct elongation stage and subsequent gland 
branching. This allows the investigation of different pathways and signalling 
molecules involved in these distinct stages of organogenesis. In this study, it was 
elucidated that Fgf10 is essential for gland branching of all of the anterior nasal 
glands. Although branching of the glands occurs in an array of temporal locations, 
expression of Fgf10 mRNA was seen throughout the mesenchyme surrounding the 
gland end buds of all glands during their branching stages. This expression pattern of 
Fgf10 is similar to that seen during mammalian lung development as Fgf10 mRNA is 
localised to the mesenchyme surrounding newly developing lung buds (Bellusci, 
Grindley, et al., 1997). In the lung, Fgf10 has been shown to trigger cell proliferation 
and act as a chemoattractant (Bellusci, Grindley, et al., 1997; Park et al., 1998), and 
the expression pattern described in our study suggests a similar role in nasal SMG 
development. Examination of the Fgf10 mutant mouse also emphasised that with one 
copy of Fgf10 present in the heterozygotes, branching of the nasal glands occurs 
however is slightly reduced and in the complete absence of Fgf10 in the 
homozygotes, gland branching is seriously defective with only the presence of 
severely truncated end buds at the distal ductal tips. The heterozygous phenotype 
observed is consistent with the lacrimal gland and salivary gland aplasia present in the 
mouse model and human LADD syndrome (Entesarian et al. 2007 and Chapter 6). As 
the number of branches is reduced in the Fgf10 +/- animals, this suggests that Fgf10 
is involved in cleft formation and branch extension. This hypothesis is supported by 
similar research using other branching models. When the submandibular salivary 
gland (SMDG) is cultured ex vivo with antisense oligonucleotides for FGFR2b, 
glands develop with a decreased amount of gland branches, however this phenotype 
can be rescued by the addition of FGF10 (Steinberg et al., 2005). Furthermore, ex vivo 
culture of lung, lacrimal and the SMDG with WNT3A has been shown to inhibit 
clefting and reduce the number of epithelial branches (Dean et al., 2005; Patel et al., 
2011). It is understood that this stimulation of the canonical Wnt pathway regulates 
Fgf10 levels, as knockdown of β-catenin leads to upregulation of Fgf10 in both the 
lacrimal gland and the lung (Dean et al., 2005). Using in vitro culturing methods of 
the SMDG, Koyama et al. (2008) showed that epidermal growth factor (EGF) was the 
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main cause of cleft formation as it increased the number of branches when cultured 
with normal salivary glands, and stimulated clefting in those glands that had been 
cultured without mesenchyme. Culture of mesenchyme-free glands with FGF10 did 
not stimulate cleft formation, however it did result in the elongation of stalks and the 
expansion of endpieces (Koyama et al., 2008). Furthermore, branch elongation in the 
presence of FGF10 has been shown to be independent of the MAPK pathway, and 
potentially works through the PLCγ pathway (Koyama et al., 2008). It is therefore 
suggested that Fgf10 plays a similar role in the growth and proliferation of anterior 
nasal glands during branching morphogenesis. This hypothesis is supported by the 
phenotype shown by both the LNGs and the MNGs in the Fgf10 knockout mouse. 
While branching morphogenesis is significantly defective, truncated branches do form 
in these glands suggesting that Fgf10 is essential for elongation and expansion of 
gland branches as opposed to the formation of clefts from the ducts or primary 
branches. To delineate this further, in vitro slice culture of the nasal glands could be 
employed and exposed to the MEK inhibitor U0126 and PLCγ inhibitor U73122 to 
investigate the influence this has on branching morphogenesis of the distal nasal 
glands. 
 
Expression patterns of Spry1 and Pea3 were restricted to the most distal epithelial 
buds of the branching end buds in all of the anterior nasal glands. This coincides with 
reports for other branching organs. Spry1 expression has been reported in the 
branching lung buds between E11.5 and E14.5 (Zhang et al., 2001), and similarly 
seen in the distal epithelial buds and ducts of the SMDG during morphogenesis (Patel 
et al., 2011). Pea3 expression was observed from E10.5-E18.5 in the most peripheral 
endodermal cells of the extending lung buds, as well as some expression found in the 
mesoderm (Liu et al., 2003). A similar expression pattern of this ETS domain 
transcription was also seen in SMDG branching morphogenesis, where Pea3 
expression was restricted to the distal epithelial buds and not found in the ductal 
structures (Patel et al., 2011). While Spry expression is a downstream read out of FGF 
signalling, it also plays a critical role in negatively regulating growth factor signalling 
from both the FGF and EGF families (Kramer et al., 1999; Reich et al., 1999). Spry1 
expression, as well as Fgfr2 expression, appeared more widespread than Pea3 
expression, in nasal gland epithelial buds of consecutive tissue sections. This suggests 
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that while many cells within the buds are receiving an FGF signal, only the peripheral 
Pea3 positive cells are triggering nuclear transcription factor activation leading to 
changes in cell behaviour. 
4.3.2 Fgf10 Plays a Heterogeneous Role in Early Anterior Nasal Gland 
Development 
The complete absence of the Steno’s gland in the Fgf10 -/- mouse indicates this 
growth factor’s pivotal role in the development of this structure. As explained in 
Chapter 3, this gland differs from the others as it buds approximately 24 hours earlier 
than the onset of the rest of the nasal glands and it also invaginates into the 
mesenchyme at its bud stage as an epithelial indentation, as opposed to a solid 
swelling of cells. If other branching structures that employ the same invaginating 
mechanism are considered, it is clear that Fgf10 plays a similar role. As described 
before, the lung develops through a similar mechanism and agenesis of the lung 
occurs in Fgf10 -/- mice (Min et al., 1998; Sekine et al., 1999). The lacrimal gland of 
the eye also undergoes this tubular invagination from the conjunctival epithelium 
(Kammandel et al., 1999; Makarenkova et al., 2000). At approximately E13.5 when 
the lacrimal bud arises on the temporal side of the eye, Fgf10 expression is seen in the 
periocular mesenchyme adjacent to the budding gland and distal to the tip of the gland 
as it is elongating at E14.5 (Makarenkova et al., 2000). Investigation of Fgf10 -/- mice 
at E18.5 showed the complete absence of the lacrimal gland (Makarenkova et al., 
2000), a phenotype similar to that seen of the Steno’s gland. A similar function for 
Fgf10 however is employed in budding structures that arise as solid cords of cells. As 
mentioned before the SMDG arises at the Initial Bud stage at E12.5 in the Fgf10-null, 
however any epithelium structure is absent by E13.5 (Jaskoll et al. 2005). This shows 
similarity to the Steno’s bud phenotype shown in the E12.5 Fgf10 -/-, as a swelling of 
the epithelium is seen however no duct primordia successfully invaginates into the 
underlying mesenchyme. Furthermore, Fgf10 expression in the lateral plate mesoderm 
is essential for the outgrowth of the limb bud from the apical ectoderm (Ohuchi et al., 
1997; Min et al., 1998; Sekine et al., 1999). 
 
The absence of the MSGs in Fgf10 -/-  is conclusive with the establishment that Fgf10 
is essential for branching morphogenesis, as these glands refrain from ductal 
formation and rather branch immediately from the maxillary sinus epithelium. 
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Apparent Fgf10 expression surrounding the maxillary sinus, along with Fgfr2b and 
downstream targets Spry1 and Pea3 within the maxillary sinus epithelium and 
branching MSG end buds respectively, also confirm its significant role. It must be 
highlighted that MSG bud branching is solely tubular in nature, therefore adopting a 
branching mechanism similar to the ductal formation of the Steno’s gland, however 
different to the gland formation of the salivary glands and all the other anterior nasal 
glands. 
 
Expression of Fgf10 mRNA in the mesenchyme adjacent to, as well as Fgfr2 within 
the epithelium of both the LNGs and MNGs as their ducts are budding and 
elongating, was shown in this study by in situ hybridisation. While this suggests 
Fgf10 is involved in early LNG and MNG bud outgrowth and duct elongation, its 
function is not critical however as these same ducts bud and elongate in the Fgf10 -/- 
mouse. Due to the complexity of biological regulatory networks, removal of one or 
some of its elements does not necessarily contribute to its overall collapse (Jeong et 
al., 2000; Albert et al., 2000). Furthermore, expression of Spry1 and Pea3 during 
budding, duct elongation and branching of these glands highlights involvement of 
FGF signalling. Therefore, although the development of LNG and MNGs proceed 
without Fgf10, it cannot be ruled out that Fgf10 does not play a role in early stages of 
their normal organogenesis. Their early ductal morphogenesis is unaffected however, 
with loss of Fgf10 alone. This establishes that the function of Fgf10 is conserved 
among some branching structures, however this role is not applicable to all biological 
cases. 
4.3.3 Other Signalling Molecules are Essential for Anterior Nasal Gland 
Development 
While the absence of Fgf10 inhibited the complete development of the Steno’s gland 
and the MSG, the LNGs and MNGs successfully budded, elongated as ducts and 
underwent some primary branch formation. This suggests that these glands either 
predominantly rely on other signalling factors for their early development, or 
compensation is made by other factors in the Fgf10 knockout. A likely candidate for 
recruitment is Fgf7. The amino acid core of Fgf7 shows over 60% sequence identity 
with that of Fgf10, making it the most structurally similar growth factor to Fgf10 
(Yamasaki et al., 1996). Biological functions are also conserved between these two 
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mesenchymally expressed Fgfs, emphasised by both their ligands having high affinity 
to FGFR2b and their interplay seen during branching morphogenesis of other 
structures. During mouse lung development, Fgf7 is not expressed in the lung 
mesenchyme during early endoderm branching at E11.5 however Fgf7 transcripts are 
detected when the lung is undergoing extensive branching between E13.5-E14.5 
(Bellusci, Grindley, et al., 1997). Early studies using culture of mesenchyme-free 
endoderm with FGF7 protein showed that it stimulates endoderm stalk extension by 
inducing cell proliferation (Cardoso et al., 1997). Bellusci, Grindley, et al. (1997) 
elucidated that prolonged exposure to FGF7 only gave rise to stalk expansion in the 
mesenchyme-free lung cultures, while when cultured with FGF10, expansion was first 
induced followed by additional budding. While Fgf7 expression was not as evident as 
that of Fgf10 in the periocular mesenchyme during normal in vivo lacrimal gland 
development, application of an FGF7 bead to lacrimal gland explant cultures induced 
ectopic gland bud formation, similarly to FGF10 protein application, however not at 
as high a rate (Makarenkova et al., 2000). In comparison, culture of SMDGs with 
FGF7 only gave rise to moderate stalk extension and instead induced epithelial bud 
enlargement (Koyama et al., 2008). Inhibition of salivary gland branching by 
FGFR2b antisense oligonucleotides was also rescued by the addition of exogenous 
FGF7 which stimulated cell proliferation and end bud formation (Steinberg et al., 
2005). A role of Fgf7 during MNG ducts may be employed for successful expansion 
of the primary MNG buds or for duct elongation. The localisation of Fgf7 mRNA in 
the nasal septum mesenchyme from E14.5-E15.5 when the MNG ducts are budding, 
elongating and beginning to branch as well as the absence of these glands in the 
Fgfr2b -/- mouse at E18.5, suggest that Fgf7 function may be utilised by these 
developing glands. To elucidate the precise role of FGF7 during anterior nasal gland 
development, their phenotype should be investigated in the Fgf7 knockout mouse 
(Guo et al., 1996). If Fgf7 plays a compensatory role when functional Fgf10 is lost, 
qPCR for Fgf7 levels in nasal septal tissue in WT, Fgf10 +/- and Fgf10 -/- animals at 
different stages of MNG development could be carried out to explore if there is an 
upregulation of Fgf7 expression. Furthermore, to uncover an Fgf7-Fgf10 interaction, a 
double knockout mouse model of these two genes could be used and all anterior nasal 
glands investigated. Considering that LNG4 is also absent in the receptor knockout, 
the development of this gland using these suggested methods is also encouraged. 
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LNG2, LNG3 and LNG5 all bud and elongate as ducts to the presumptive branching 
location independent of FGFR2b signalling. It is possible that these glands rely more 
so on Ectodysplasin A signalling as Grüneberg (1971) described a severe phenotype 
of the lateral nasal glands in the Tabby mouse. While the glands are numbered in this 
study according to the times at which they arise, it is difficult to interpret whether 
Grüneberg’s labels correspond to the labels we have used in our current work as there 
are no detailed schematic or histological images provided (Grüneberg, 1971). The 
paper does however state that the LNG3 bud arises in the Tabby, yet it does not 
progress after this stage. In contrast, LNG2 and LNG4 are said to not develop at all in 
the absence of Eda signalling (Grüneberg, 1971). With the help of the detailed 
developmental and morphological descriptions of the anterior nasal glands outlined in 
Chapter 3, it would be interesting to return to the Tabby, as well as the downless and 
crinkled mouse models, to uncover the precise role of the Ectodysplasin A pathway 
during development of each gland. 
 
As described in Chapter 1, more recent studies have shown that activation of the 
canonical Wnt pathway occurs in early anterior gland development with Lef-1 mRNA 
and protein expression observed at gland bud initiation stage (Driskell et al., 2004, 
2007). Inconsistencies arise in these studies however. Firstly, it is not explained which 
nasal gland is investigated in these studies. From the images and time points stated it 
appears that the bud studied could be that of LNG3 or LNG5. Secondly, it is stated 
that Lef-1 mRNA is expressed in this nasal gland bud at E16.5 (Driskell et al., 2004) 
while the LEF1 protein is expressed in the bud at E15.5 (Driskell et al. 2007). This 
order of RNA and protein expression could be explained if a different gland bud was 
investigated in each study. While this work has given valuable insight into Lef-1 
involvement in gland bud initiation, it cannot be said for certain if these results apply 
for all of the anterior nasal glands. Also, the role of Wnt signalling during the later 
stages of nasal gland development has not been investigated. Using the Axin2lacz, it 
has been shown that Wnt/β-catenin signalling is restricted to the ductal structures of 
the developing SMDG, with its localisation seen at E14.5, during the 
Pseudoglandular stage, in the main gland duct and by E15.5 spreading into the 
smaller ducts (Patel et al., 2011). Wnt activity may be maintained in the ductal 
epithelial cells to ensure their long-range elongation before branching of a distal gland 
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occurs. Again, as it has been shown that Wnt signalling negatively regulates 
branching morphogenesis in other structures (Dean et al., 2005; Patel et al., 2011), 
this same strategy could be tested in the anterior nasal glands by in vitro culture of the 
gland ducts in the presence of the Wnt signalling inhibitor Dickkopf-related protein 1 
(DKK1). DKK1 interacts with the LRP6 coreceptor, inhibiting its recruitment in the 
binding of extracellular Wnt to the Frizzled receptor (Bafico et al., 2001; Semënov et 
al., 2001). Addition of DKK1 may stimulate gland ducts to branch prematurely due to 
the absence of Wnt signalling. This inhibition may also cause the upregulation of Fgfs 
in the nasal mesenchyme and downstream targets of FGF signalling within the nasal 
gland epithelium. 
 
From this study we want to emphasise that nasal SMGS not only adopt contrasting 
temporal locations and methods of development, they each employ different 
signalling factors and intracellular cues for their tightly controlled duct elongation and 






5. Tracheal SMG Development and Function 
5.1  Introduction 
5.1.1  The Tracheal SMGs 
Most of the tracheal SMGs are found in the anterior trachea above the first cartilage 
ring, adjacent to the cricoid cartilage, and spread posteriorly between the cartilage 
rings to the sixth ring in mice, but continue to the bronchi in humans (Sturgess and 
Imrie, 1982; Borthwick et al., 1999). The localisation of the SMGs allows the 
lubrication of the airway mucosa running from the upper and lower airways and 
provides a mucin-rich barrier against the environment. As outlined in Chapter 1, 
investigation into the tracheal SMGs has elucidated their role in a number of severe 
and life threatening respiratory diseases with SMG hyperplasia and mucus hyper-
secretion common to most (Reid, 1960; Oppenheimer and Esterly, 1975; Aikawa et 
al., 1992). CFTR, the defected gene in patients suffering from cystic fibrosis (CF), is 
primarily expressed in the serous cells and some of the ductal cells of the SMGs 
(Engelhardt et al., 1992).  While this suggests a functional defect in the glands of CF 
patients, defects in the developmental patterning of the SMGs in a CF mouse model 
has also been reported, suggesting an additional role during gland initiation 
(Borthwick et al., 1999). Despite the significance of SMG involvement in disease 
however, little research has focused on their normal patterning and the signalling cues 
required for their successful budding and branching. 
 
One paper in particular has examined the timed developmental patterning of the 
tracheal glands in postnatal mice (Rawlins and Hogan, 2005). Here it was reported 
that the first sign of tracheal SMG initiation was described at P2, with SMG buds 
invaginating from the airway epithelium into the mesenchyme in the anterior trachea 
(Rawlins and Hogan, 2005). These buds had undergone extension and branching by 
P4, while new buds were still forming. The branching glands already showed signs of 
mucus production at this stage (Rawlins and Hogan, 2005). By P7, early-formed 
glands were evidently secreting mucus. Gland buds continually formed until P14, 
however new gland initiation was reported to have ceased by P21 (Rawlins and 
Hogan, 2005). In this same study, gland phenotypes were compared in WT and Fgf10 
+/- postnatal pups. At this stage anterior glands above the first cartilage ring (C1) in 
the WT animals were highly branched structures while the smaller glands between the 
cartilage rings were seen to extend passed C6 (Rawlins and Hogan, 2005). In contrast 
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to this the anterior SMGS in the Fgf10 +/- animals were significantly smaller with 
fewer branches, and the posterior localisation of the glands between the cartilage rings 
was also reduced (Rawlins and Hogan, 2005).  
 
5.1.2  Tracheal SMG Mucus Secretion 
Mucus hyper-secretion from the SMGs is a characteristic of many respiratory diseases 
such as asthma and cystic fibrosis (Rogers, 2004; Rowe et al., 2005). Animal models 
have been indispensible tools in gaining insight into these disease abnormalities and 
aetiologies. A number of CF mouse models have been generated to understand the 
biological processes that lead to the severe mucus hyper-secretion of this disease. 
Ianowski et al. (2007) tested the physiological function of normal and CF glands 
using an optical method originally described in sheep (Joo et al., 2001). Using the 
mouse model, tracheas were dissected, covered in a mineral oil layer on their mucosal 
side and exposed to different gland stimulants, to test which would be the most 
effective to induce a secretory response (Ianowski et al., 2007). Results of these 
experiments showed that the cholinergic agonist carbachol was the most effective in 
stimulating gland secretion in both WT and CF tracheal SMGs (Ianowski et al., 
2007). As glands were triggered to secrete fluid, mucus bubbles formed within the oil 
layer, allowing secretion volumes and rates to be visualised.  
5.1.3  Aims of Study 
• To delineate the timed postnatal development of the tracheal SMGs with 
primary focus on the anterior glands adjacent to the cricoid cartilage. 
• To carry out more extensive analysis of the tracheal SMGs in adult Fgf10 +/- 
mice. 
• To investigate the early SMG phenotype in WT, Fgf10 +/- and Fgf10 -/- mice 
at gland initiation stages. 
• To analyse if a defective gland phenotype in Fgf10 +/- adult mice leads to a 
reduction in mucus secretion into the airway lumen, using previously reported 
optical methods (Ianowski et al., 2007). 
• If mutant glands produce less mucus, investigate if this compromises the 
pulmonary health of Fgf10 +/- animals by exposing these mice, and their WT 
littermates to airway sensitizers and allergens.  
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If a reduction in mucus negatively influences the mucocilliary barrier in Fgf10 +/- 
animals, these mice may be more likely to have a severe inflammatory response when 
exposed to airway irritants, than their WT counterparts. It is therefore important to 
understand the airway’s response to inhaled particles and allergens. 
 
5.1.4  The Airway and Allergy 
While the airway mucous, beating cilia and protective respiratory epithelium provide 
one of the first lines of defence against harmful airborne inhalants, the body’s 
immune system additionally aims to prevent invasion of harmful pathogens. 
Phagocytic cells and bactericidal enzymes within the airway mucous, as well as 
epithelial cell tight junctions, aim to protect underlying tissue from pathogen invasion. 
While this line of defence limits the passage of irritants, it has been shown that 
allergens can evade this epithelial-derived barrier, even in healthy animals (Holt et al., 
1981; Sedgwick and Holt, 1983). In this situation, when an allergen, bacteria or virus 
is inhaled and bypasses the mucus barrier, specific antigens on their surface are 
detected by antigen presenting cells (APC) such as macrophages, dendritic cells and B 
cells (Unanue, 1984; Steinman, 1991; Rodriguez-Pinto, 2005)(Figure 5.1). While 
some of these antigens are digested by the APCs by phagocytosis, others are broken 
down and fragments of the antigens are presented on the cell surface along with other 
proteins known as the Major Histocompatibility Complex II (MHCII)(Germain, 1994) 
(Figure 5.1). Presentation of the antigen fragments along with the MHCII is critical 
for antigen detection by T helper 2 (TH2) lymphocytes. Upon antigen recognition, TH2 
cells secrete cytokines (e.g Interleukin-4, -5 and -13), which leads to the recruitment 
of inflammatory cells, mainly mast cells and eosinophils, to the airways (Romagnani, 
1991) (Figure 5.1). TH2 cell activation additionally triggers B-cells to produce 
allergen-specific IgE antibodies (Romagnani, 1991). These IgE antibodies bind to 
specific receptors on the surface of mast cells, which are now sensitized to that 
particular antigen (Figure 5.1). Upon secondary exposure to the allergen, these IgE 
bound mast cells detect inhaled allergens, which cross-link the receptor bound IgE. 
Upon linking, mast cells release inflammatory mediators such as histamine and 
prostaglandins, which can cause local tissue responses such as vasodilation, venous 
permeability, fever and pain (Serafin and Austen, 1987; Metcalfe et al., 1997; Stone et 
al., 2010). These localised tissue responses also translate into allergic reactions such 
as sneezing, wheezing and itchy eyes. Repeated exposure to allergens can cause more 
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severe pulmonary reactions as the recruitment of mast cells and their inflammatory 
mediator release can lead to allergic rhinitis in the anterior airways as well as airway 
bronchoconstriction in the lower airways (Milián and Díaz, 2004). Additional 
research has also showed that TH2 cells induce mucus hyper-secretion (Cohn et al., 
1997). These repetitive inflammatory responses then lead to significant breathing 
difficulties due to airway remodelling and increased mucus production. 
 
5.1.5 Murine Allergic Sensitization 
As laboratory rodents do not instinctively develop asthma, researchers generally 
expose animals to inhalant allergens to provoke an asthmatic-like response. A 
traditional allergen used is ovalbumin (OVA) (Kumar et al., 2008). OVA is a 
glycoprotein found in large quantities in eggs of the chicken, Gallus gallus, that has 
been shown to trigger airway eosinophilia and pulmonary inflammation (Tomkinson 
et al., 2001). Inoculation of OVA alone, however, requires a great number of 
administrations to achieve sensitization so usually the antigen is administered in 
conjunction with an adjuvant. Inoculation of both these factors enhances airway 
hyper-responsiveness at a quicker and more effective rate (Nials and Uddin, 2008). 
 
One adjuvant that is used is tumor necrosis factor alpha (TNF-α). TNF-α is a cytokine 
that plays a critical role in the mediation of inflammatory response (reviewed in 
Brightling et al. 2008). Upon inhalation of airborne allergens, it is released primarily 
by macrophages and mast cells (Thomas, 2001). TNF-α triggers an influx of 
inflammatory cells such as T-cells, eosinophils and neutrophils, to the site of 
inflammation and also induces respiratory structural cell changes such as the 
upregulation of adhesion molecules within the respiratory epithelium (Brightling et 
al., 2008). The involvement of TNF-α in the asthmatic inflammatory response was 
highlighted by the detection of both TNF-α mRNA and protein in the airways of 
sufferers of asthma (Ying et al., 1991; Bradding et al., 1994). Research has since 
elucidated that TNF-α is a key player required for the recruitment of TH2 cells to the 
site of allergic response and have concluded that inhalation of recombinant TNF-α by 
healthy individuals leads to symptoms of airway hyper-responsiveness (Thomas et al., 
1995; Thomas and Heywood, 2002). Considering these revelations, studies have 
adopted intranasal TNF-α inoculation mechanisms, along with OVA, to establish 
animal models of airway sensitization (Zhao et al., 2013). 
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5.1.6  House Dust Mites and Pulmonary Response 
A common cause of allergic airway disease (AAD), as well as eczema, rhinitis and 
allergic conjunctivitis, is the exposure and sensitization to house dust mites 
(HDM)(Janson et al., 2001). HDM are minute eight-legged arthropods measuring 
approximately 300µm in length (Milián and Díaz, 2004). They prevail in all homes 
and fabrics as they feed on shed skin scales and organic detritus. Two common 
species of HDM, Dermatophagoides pteronyssinus and Dermatophagoides farina 
trigger pulmonary allergic response, with D. pteronyssinus predominating in the 
United Kingdom (Arlian et al., 2002).  
 
HDM secrete a plethora of allergens that arise from whole dust mites, mite eggs and 
faecal pellets (Thomas et al., 2002). The most common of these proteins belong to the 
group 1 allergens, also referred to as Der p I, which are cysteine proteases excreted in 
HDM faeces (Tovey et al., 1981; Chua et al., 1988). Inhalation of these allergens and 
detection of Der p I antigen triggers IgE mediated immunological hypersensitivity, 
described above (Greene and Thomas, 1992).  
 
Research has shown that children born with normal lung function are susceptible to 
developing asthmatic symptoms and reduced lung function within the first three to six 
years of life (Martinez et al., 1995; Lowe et al., 2005). Therefore an animal model 
investigating asthmatic progression is extremely valuable in understanding the 
pathogenesis of this allergic disease. Continuous intranasal exposure of adult mice to 
purified HDM extract for seven weeks gave rise to severe eosinophilic inflammation 
and an increase in T-cell activation and accumulation in the lung (Johnson et al., 
2004). Additionally, analysis of lung tissue showed airway remodelling and goblet 
cell hyperplasia (Johnson et al., 2004). Saglani et al. (2009) used the same 
experimental strategy to establish a suitable neonatal model of allergen sensitization 
and early asthma development. Again, intermittent exposure to HDM extract gave rise 
to increased eosinophilic inflammation in both the airway lumen and lung digest 
(Saglani et al., 2009). Lung tissue exposed to HDM extract also demonstrated a 
significant increase in inflammatory infiltrate in the peribronchial and perivascular 
areas however not within the lung parenchyma itself (Saglani et al., 2009). Other 
asthmatic phenotypes observed in HDM inoculated neonates included increased T-
cell count, higher IgE antibodies and airway remodelling characteristics such as 
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goblet cell hyperplasia and increased peribronchial collagen deposition (Saglani et al., 
2009). In conclusion, murine intranasal inoculation with HDM gives rise to similar 
pathophysiogical features as seen in humans with asthma and elucidated that 
inhalation of this environmentally relevant allergen provided an ideal model to study 




Figure 5.1 APC recognition and presentation of inhaled antigens. 
Antigens of inhaled allergens may pass through the mucosal-epithelial barrier where 
they are recognized by Antigen Presenting Cells (APC), such as macrophages or 
dendritic cells. Antigens are either digested by APCs or broken down and fragments 
presented to T-cells via the MHCII complex. Binding of T-cells to antigen fragments 
occurs via a T-cell receptor (TCR).  Upon antigen recognition, T-cells release 
cytokines to stimulate inflammatory cell recruitment. One response is that of B-cells 
which produce IgE antibodies specific to the inhaled allergen. These antibodies are 
released and bind to mast cell surface receptors. Repeated exposure to antigens is 
detected by these antibodies, causing mast cells to release inflammatory mediators 




5.2  Materials and Methods 
5.2.1 Cartilaginous Staining of Embryonic Tracheal Tissue 
Tracheas were dissected from E18.5 Fgf10 WT and Fgf10 +/- littermates and fixed 
overnight in 95% ethanol in deionised H2O at 4°C. After 24 hours of fixation, fat 
from tissue was removed by storing tracheas in 100% acetone overnight at RT. 
Followed by two rinses in 95% ethanol, tracheas were then placed in Alcian Blue 
solution (15mg Alcian Blue 8GX in 80ml 95% ethanol and 20ml glacial acetic acid) 
for 24 hours rocking at RT. Tissue was rinsed with 95% ethanol twice for 30 minutes 
and stored in 95% ethanol overnight at RT. The ethanol was poured off and tracheas 
were cleared in 1% Potassium Hydroxide (KOH) for 3-4 hours. Tissue then went 
through a series of 1% KOH and glycerol solutions, all at RT, until specimens were 
finally stored in 100% glycerol (Table 5.1). Tracheas were then observed and 
photographed using a Leica MZFLiii dissection microscope fixed with a Leica 
DFC300 Fx camera. 
 
Table 5.1 Concentration of 1% potassium hydroxide in glycerol solutions used in 
cartilaginous preparation of embryonic tracheal tissue. 
1% KOH:Glycerol Solutions Time 
80:20 4 hours 





5.2.2 Tracheal Mucus Secretion Analysis 
5.2.2.1  Tracheal Tissue Preparation 
Wildtype mice (n=4) and their Fgf10 heterozygous littermates (n=6) aged 7-8 weeks 
were culled by exposure to rising levels of CO2 and tracheas were immediately 
dissected. The thyroid gland and oesophagus were removed and the trachea was cut 
along the dorsal trachealis muscle (Figure 5.2, A). The following procedure was 
modified from the method used in (Ianowski et al., 2007). Using insect pins, the 
trachea was opened and pinned to a Sylgard® plate and the luminal mucosal surface 
was exposed (Figure 5.2, B). The mucosal side of each trachea was dried with an air 
spray and 5µl of mineral oil (Sigma) was added to the surface. Beneath the trachea, 
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2.5µl of D-MEM/F12 plus penicillin/streptomycin and 1% Glutamax (Invitrogen) 
medium was added to nourish the tissue during incubation (Figure 5.2, B). A damp 
piece of filter paper was also placed on the Sylgard® plate to provide a humid 
environment ensuring the oil layer would not dry out during incubation. Tracheal 
tissue was then placed in a 95% O2: 5% CO2 incubator at 37°C for 10 minutes. The 
exposed trachea was then placed, at RT, under a Leica MZFLiii dissection 
microscope fitted with a Leica DFC300 Fx digital camera. A further 2.5µl of DMEM 
medium containing 60µM of the cholinergic carbachol (Sigma) was added to the 
medium bath, giving a final concentration of 30µM carbachol stimulating the tracheal 
glands (Figure 5.2, B). Photographs of the anterior region of the trachea were taken 
every 30 seconds for 10 minutes to trace mucus bubble production. 
 
After 10 minutes of exposure to carbachol, the amount of mucus bubbles produced 
were counted to show the amount of gland openings within the tracheal mesenchyme. 
As glands were found to only be present between the cricoid cartilage and first two 
tracheal rings in Fgf10 +/- adults, bubbles only secreted in this area were chosen for 
the study. Viable bubbles for area measurement were those of which followed the 
criteria described in Ianowski et al. (2007): (a) a complete circular outline 
surrounding each mucus bubble as accurate measurements could be collected and (b) 
no fusion with adjacent droplets. For gland opening analysis, these criteria were not 
followed, as they were not required to count the amount of bubbles produced.  Area 
(µm3) and circumference (µm) of each bubble was calculated using ImageJ software.  
Additionally, the feret diameter, also known as the maximum caliper diameter, was 
measured for each bubble. This measurement is taken as the longest distance between 
two points of non-spherical shape. In this study, ferret diameter was calculated using 
ImageJ software. Overall trachea mucus secretion was calculated by the sum of all 
areas of each bubble per animal.  Statistics and graphs were calculated using 




               
Figure 5.2 Dissection and preparation of tracheal for mucus production analysis. 
(A) Adult tracheas were dissected and cut along the dorsal trachealis muscle. (B) 
Tracheal tissue was flattened out and pinned down onto a sylgard plate, exposing the 
mucosal side. Medium was added underneath the tissue, while mineral oil was added 
on top of the mucosal side and gland openings. After 10 minutes of incubation, 
medium containing carbachol was added to the current medium bath. Mucus bubble 
production was observed and recorded for 10 minutes. Axis labels: anterior (A); 
posterior (P); ventral (V); dorsal (D); left (L) and right (R). 
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5.2.3 Respiratory Challenge of Adult Mice with Ovalbumin and TNF-α  
5.2.3.1  Initiation of Respiratory Challenge and Tissue Treatment 
Six-nine week old Fgf10 WT and +/- littermates were briefly anaesthetized with 
100% IsoFlo® isoflurane (Abbott) using a Fluovac unit. This was carried out in the 
BSU, New Hunts House, Guy’s Campus, King’s College London. Animals were 
placed in the chamber and exposed to vaporized isoflurane for approximately 4 
minutes, or until mice were anaesthetized and a steady pace of breathing was 
maintained. Animals were held by scruffing the back of the shoulders. This 
positioning allows steady inhalation of nasal inoculant. Using a 200µl Eppendorf 
pipette, 50µl of either PBS control (WT n=2; Fgf10 +/- n=2) or 20µg/ml of TNF-α 
and 1000µg/ml Alexa Fluor® 488 ovalbumin conjugate (Life Technologies) in PBS 
(WT n=6; +/- n=9) was slowly released on the nose of each animal. Mice were held 
steadily until all liquid was inhaled and were then placed upright in their cages 
allowing inoculant to be sufficiently inhaled while animals recovered. Cages were 
returned to their normal storage rooms. After 6 hours, mice were culled by exposure 
to CO2 gas. In order for quick treatment following sacrifice, two mice were culled in 
the CO2 chamber at a time. Animals were removed from the chamber and placed on 
their back. The chest area was sprayed with 70% ethanol in deionised H2O to ensure 
there was no hair contamination during dissection. An incision was made through the 
chest to below the chin and skin was opened. Salivary glands were gently moved to 
the side to expose the anterior trachea. Extra care was taken during this step as not to 
cut any large blood vessels located throughout the neck area.  The connective tissue 
membrane surrounding the trachea was removed and a small incision was made 
through the submucosa of the trachea between the anterior cartilage rings. A syringe 
fitted with a 20µl pipette tip was inserted down into the tracheal tube.  The trachea 
and lungs were rinsed by flushing 1ml of PBS into the organs and then removing it 
again with the same syringe. This process is known as bronchoalveolar lavage (BAL) 
and in this case BAL fluid removed any residual OVA-Alexa-488 present in the 





The next day individual lungs were transferred into 24-well plates containing 0.5ml of 
DMEM culture medium containing 10% fetal calf serum (FCS) in each well. Lungs 
were cut up into small pieces using sharp scissors and 25µl of 10mg/ml collagenase 
type IV (Sigma) was added to each well. Lung tissue was incubated in a 95% air: 5% 
CO2 incubator at 37°C for 45 minutes. Cells were mixed thoroughly in medium by up 
and down pipette movements and transferred to 30ml sample tubes. Cells were 
washed with 20mls of Dulbecco’s PBS (Sigma) and spun down at 200g for 10minutes 
in a Hettich Rotanta 46R bench top centrifuge. PBS supernatant was poured off and 
discarded leaving cells and approximately 100µl of PBS in the sample tube. Another 
200µl of PBS was added to each tube and cells were shaken and left to sit for 5 
minutes. From this, 100µl of cloudy cell solution was carefully transferred to a 
Falcon™ round bottom FACS tube, making sure not to transfer any pieces of residual 
lung tissue. Cells were then fixed in 100µl 2% PFA overnight at 4°C. 
5.2.3.2 Fluorescence-Activated Cell Sorting (FACS) 
FACS or Flow Cytometry is a technology used to count, sort and measure physical 
properties of single biological particles. The method is usually used to characterise the 
size, internal complexity and relative fluorescence intensity of cells suspended in a 
liquid sample. The method relies on disaggregating cells from a tissue sample and 
staining them with fluorescently labelled antibodies specific for antigens present on 
the membranes of target cell types. Stained cells are then passed through a channel 
where they are exposed to laser illumination. As cells pass through the laser intercept, 
the fluorescently labelled antigens on their cell surface scatter light. This split light is 
collected by specific detectors, which translate the optical signal into that of an 
electronic one where it is analysed by a computer. 
 
Before each tube was loaded into the BD FACSCalibur™ (BD Biosciences), each 
sample was vortexed to re-suspend cells in solution. Analysis of samples began with a 
PBS control to set the gate for cell populations and to exclude autofluorescence and 
background staining. The samples of lung cells were then run through the FACS and 




5.2.4 Respiratory Challenge of Adult Mice with House Dust Mites (HDM) 
Every three days for three weeks CD1, Fgf10 WT and Fgf10 +/- animals were 
anaesthetized with isoflurane and given intranasal inoculations of PBS control, whole 
HDM (Allergon) or sonicated HDM in PBS (method outlined in section 5.2.3). Three 
concentrations of 25µg, 125µg or 625µg of HDM were administered in doses of 30µl 
in PBS. The last inoculation was given on Day 20 of challenge and animals were 
sacrificed 24 hours later on Day 21. Animals were culled by exposure to rising levels 
of CO2 and BAL was carried out (method outlined in section 5.2.3). With all HDM 
experiments BAL fluid was collected and analysed as the effect of HDM inoculation 
on lung inflammation was to be determined by the presence of immune cells within 
the respiratory airway. BAL fluid was collected in FACS tubes and stored at 4°C until 
analysis. Following BAL collection, the left lung lobe and trachea were dissected and 
transferred to ice cold PBS. Lung tissue was dried using an air stream and weighed. 
Both lung and tracheal tissue were fixed in 4% PFA and were processed for 
histological staining with H&E and Alcian Blue. 
 
To analyse airway inflammatory response, BAL fluid was spun down in a centrifuge 
for 5 minutes at 200g and 800µl of supernatant was discarded. Cells were re-
suspended in the remaining 200µl and washed with 2.5ml of 1% FCS in PBS. Fluid 
was again spun down in a centrifuge for 5 minutes at 200g and supernatant removed. 
Tubes were flicked to re-suspend cells and 10µl of antibody mix containing 0.1µg of 
each antibody (Table 5.2) in FCS-PBS was added to each tube. 
 
All anti-mouse antibodies used for FACS cell labelling were supplied by 
BioLegend®. To identify APC (macrophages and dendritic cells) 
FITC/AlexaFluor488-conjugated I-Ab and Granulocyte Receptor 1 (Gr-1) antibody 
was used. I-Ab is an alloantigen of the MHCII of APCs and Gr-1 is a cell surface 
receptor predominantly found in neutrophils. As this antibody will label macrophages, 
dendritic cells and neutrophils the application of an additional antibody CD11c 
conjugated to the dye PerCP-eF710® will label the APCs only, distinguishing them 
from the neutrophils. An antibody, conjugated to the fluorochrome phycoerythrin  
(PE), against the chemokine receptor CCR3 abundant on eosinophils was used to 
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identify these cells. Finally, to stain lymphocytes anti CD3 + B220-APC antibody was 
used. CD3 is expressed by all mature T-cells while B220 is expressed by B-cells.  
 
Cells were left at RT for 10 minutes and were washed with 2.5mls of 1% FCS in PBS. 
Cells were spun down for 5 minutes in the centrifuge at 200g, supernatant discarded 
and fixed with 200µl of 1% formaldehyde. 
 
FACS analysis was primarily carried out by Dr. Alistair Noble (Department of 
Asthma, Allergy and Respiratory Science, King’s College London). Using 
CellQuest™ software, two regions were set based on CD3 + B220-APC antibody 
detection. Cells negative for CD3 + B220-APC (eosinophils, neutrophils and 
macrophages/dendritic cells) were grouped into “Region 1” while positive for CD3 + 
B220-APC (T-Cells and B-Cells) were grouped into “Region 2”. Cells were then 
identified within these regions by antibody detection specific for each cell type (Table 
5.2). 
Table 5.2 Monoclonal antibodies and their conjugated fluorochromes used in 











Eosinophils - + - - 
Macrophages/Dendritic 
Cells 
+ - + - 
Neutrophils + - - - 
T-Cells - - - + 
B-Cells + - - + 
5.2.5 Statistical Analysis 
 
Statistical significance between experimental groups was calculated in the mucus 
bubble analysis, OVA-TNF administration and HDM inoculation experiments using a 
Student’s t-test. Graphs were generated using GraphPad Prism software.  
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5.3 Results 
5.3.1  Anterior Tracheal SMG Development 
As a first step in our aim to understand tracheal SMG development, early gland bud 
formation and extension stages were analysed in CD1 animals. All tissue sections 
were stained with Haematoxylin and Eosin with Alcian Blue and developmental 
stages were directed by previous studies (Thurlbeck et al., 1961; Keswani et al., 
2011). Stage 1 of development is the initial bud stage where an epithelium swelling is 
seen to immerge from the respiratory epithelium (RE) (Figure 5.3, A). Stage 2 is 
characterised by the epithelial bud elongating into the underlying mesenchyme and 
cavitation occurs within this stalk to form a lumen (Figure 5.3, B). This is followed by 
Stage 3 where canalized stalks begin to branch within the underlying mesenchyme 
(Figure 5.3, C), while Stage 4 is classified as the cellular differentiation stage, 
indicated by mucus production within the gland (Figure 5.3, D). Investigation began 
at P2 as it had been previously reported that at this age early tracheal SMG buds 
initiate (Rawlins and Hogan, 2005). At this stage while SMG buds were found in the 
anterior tracheal mesenchyme in dorsolateral positions (Figure 5.4, F), glands that had 
progressed to the branching and mucus producing stages were found in the ventral 
mesenchyme (Figure 5.4, E). This result suggested that ventral SMGs were forming at 
an earlier age. Considering this, we traced back to E18.5 tracheas, where the 
invagination of some of these ventral gland buds was apparent, indicating that SMG 
development begins embryonically in the ventral trachea.  At P0 ventral glands were 
observed at Stage 1 of budding, while others have extended and branched and had 
already begun Stage 3 of lumen formation (Figure 5.4, C). Furthermore, some gland 
buds were also found in more dorsolateral planes at P0 (Figure 5.4, D). By P1, 
branching continues in both the ventral and dorsal glands, as well as continued 
induction of new buds throughout the dorsolateral walls. By P4, the ventral and 
dorsolateral glands continued to undergo extensive branching and cellular 
differentiation (Figure 5.4, G and H).  
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Figure 5.3 Stages of tracheal SMG development 
(A) Stage 1: Tracheal SMG buds are first seen to invaginate from the RE into the 
underlying mesenchyme. (B) Stage 2: Elongation of the bud and cavitation of the 
epithelial stalk occurs. (C) Stage 3: Epithelial stalk undergoes clefting and branching 
(D) Stage 4: Cellular differentiation is observed indicated by mucus staining within 
the glands by Alcian Blue. AL= airway lumen, L= lumen, M= mucus. Scale bar = 
25µm. 
 
5.3.2  Anterior-Posterior Development of Tracheal SMGs 
The first signs of SMG formation in a posterior direction between the first and second 
cartilage rings was observed in the ventral trachea at P4 (Figure 5.4, G). At P8, 
established anterior glands were continuing their branching as well as new glands 
appearing between C2 and C3 and progressively at P12 glands were found between 
C3 and C4 in ventral cross-sections. At P15 glands had developed between C4 and C5 
and were producing mucus. Over these 10 days, it was noted that glands seemed to be 
developing in a gradient from the ventral to dorsal areas of the trachea, in conjunction 
with their posterior development. By P22, glands were well established and observed 
as posterior as C6, as previously reported in the mouse (Borthwick et al., 1999).  
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Figure 5.4 Normal postnatal tracheal SMG development. 
(A-B) Schematic representations of the ventral (A) and more dorsal (B) tissue 
sections cut through postnatal tracheal tissue. (C) Glands are seen to have reached the 
lumen formation stage in the ventral trachea by P0, while more dorsally they are seen 
at the branching stage (D). (E) At P2 ventral glands have continued to branch and 
cellular differentiation is indicated by mucus staining within gland lumens. Continued 
budding of new glands is seen in more anterior dorsal positions (F). (G-H) By P4 
glands have branched extensively in the ventral mesenchyme as well as in the dorsal 
trachea. Glands are also seen at the branching stage between C1 and C2 in the ventral 
trachea (G). CC=cricoid cartilage, C1=first cartilage ring, C2=second cartilage ring 
etc. Black arrow = developing gland, green arrow = lumen formation, blue arrow = 
mucus production. Scale bar=100µm. 
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5.3.3 Anterior and Posterior Tracheal SMGs are Reduced in Fgf10 +/- Adults 
It has previously been reported that there is an altered SMG phenotype in adult Fgf10 
+/- mice (Rawlins and Hogan, 2005). In this study it was elucidated that there was a 
reduction in branching of the anterior SMGs adjacent to the cricoid cartilage and a 
severe reduction in the posterior expansion of the glands between each tracheal 
cartilage ring (Rawlins and Hogan, 2005). We investigated adult WT (n=7) and Fgf10 
+/- littermates (n=6) to ensure a similar phenotype in our mouse line. Analysis 
concluded a reduction in anterior tracheal SMGs in heterozygous animals compared 
to their WT littermates (Figure 5.5 A-B). Using histological methods it was difficult 
to conclude whether this was a reduction in branching of each gland, a reduction in 
the amount of glands within the anterior mesenchyme, or collectively both of these 
phenotypes. Variation in severity of this reduction was seen in Fgf10 +/- mice 
however it was concluded that glands were always reduced in the heterozygous adults 
compared to WT littermates.  
Analysis of SMGs between tracheal cartilage rings also showed a notable reduction in 
the anterior-posterior presence of the glands (Figure 5.5 C). WT littermates showed 
continuous SMG development between each cartilage ring, reaching the mesenchyme 
between C6 and C7 in 3/7 animals and even between C7 and C8 in one specimen 
(Figure 5.5 C). Two more WTs showed glands extending between C5 and C6, 
however in one of these animals, glands were missing between C4 and C5. The final 
WT specimen showed continual gland extension from the anterior trachea to above 
the fifth cartilage ring, no SMGs between C5 and C6, however glands were observed 
between C6 and C7 (Figure 5.5 C). In the six Fgf10 +/- mice investigated, one adult 
had no glands past the first cartilage ring. Of the other five animals, two only showed 
small glands between C1 and C2 (Figure 5.5, C). Two more animals had glands past 
C1 and C2, with one of these showing another small gland past C5. Finally, the last 
Fgf10 +/- had glands between each of the first four rings (Figure 5.5 C).  In a 
previous study investigating tracheal SMG formation in the Tabby mouse of deficient 
Eda signalling, the pseudostratified columnar epithelium of the trachea showed a 
disorganized appearance and columnar epithelial cells were higher than observed in 
WT animals (Rawlins et al., 2007). In our study, no epithelial abnormalities were 
observed in the Fgf10 +/- animals compared to their WT littermates (Figure 5.5, D 
and E). 
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Figure 5.5 Anterior and posterior tracheal SMG phenotype of WT and Fgf10 +/- 
adults. 
(A-B) WT adults show extensively branched anterior SMGs adjacent to the cricoid 
cartilage (CC) while Fgf10 +/- littermates show a significant reduction in glands in a 
similar plane. (C) Posterior extension of the SMGs is noticeably reduced in Fgf10 +/- 
animals compared to their WT littermates. N numbers represent each specimen 
analysed while pink bars represent mesenchymal space where SMGs are found 
between each cartilage ring (C1-C8). (D-E) No differences were observed in the 
tracheal epithelium of adult WT and Fgf10 +/- littermates. A and B; scale 
bar=100µm, D and E; scale bar=50µm. 
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5.3.4 Fgf10 +/- Embryos Show no Tracheal Cartilaginous Defect 
Fgf10 has been shown to be expressed in the ventral tracheal mesenchyme from 
E12.5-E16.5 when tracheal patterning is underway (Sala et al., 2011). The significant 
role of Fgf10 in tracheal design was also emphasised by Fgf10 null embryos having 
truncated tracheas with disorganized rings replicating the phenotype seen in patients 
with tracheomalacia (Sala et al., 2011). As SMGs form between the tracheal cartilage 
rings, we wanted to test whether reduced gland numbers in the Fgf10 +/- is a 
secondary defect to abnormal cartilage patterning. Using whole mount Alcian Blue 
staining, it was observed that while ring arrangements differed in all WT and Fgf10 
+/- specimens irrespective of genotype, no apparent difference of cartilage phenotype 
was seen between WT and Fgf10 +/- littermates (Figure 5.6). 
 
 
                    
Figure 5.6 Cartilage ring staining with Alcian Blue of WT and Fgf10 +/- 
embryonic tracheas. 
E18.5 cartilage ring organization varied in both WT and Fgf10 +/- however all rings 





5.3.5 SMG Buds are Found in Fgf10 -/- Tracheas 
Having observed that tracheal SMGs bud as early as E18.5 (see section 5.3.1), we 
were able to look at bud initiation in Fgf10 -/- mice, which die at birth due to lung 
agenesis (Min et al., 1998; Sekine et al., 1999). A litter of Fgf10 mutant pups were 
collected on P0 yielding Fgf10 -/- (n=4), Fgf10 +/- (n=2) and Fgf10 WT (n=3). 
Analysis of the anterior tracheal SMGs in these specimens demonstrated that glands 
had already budded, elongated, cavitated and commenced branching in WT animals 
(Figure 5.7 A, A’). The development observed in these specimens was more advanced 
than those previously described in CD1 animals at P0 (see section 5.3.1), showing 
how rapid gland morphogenesis can be, even by a few hours. Similar stages of 
development were seen in Fgf10 +/- littermates however gland development appeared 
delayed and branching of the formed glands clearly reduced (Figure 5.7 B, B’). 
Interestingly, gland buds were found in all Fgf10 -/- specimens investigated (Figure 
5.7, C,C’). This result indicates that Fgf10 expression is not required for initial 
epithelial gland bud specification however it is required for subsequent bud 
elongation and branching. 
 
 
Figure 5.7 P0 tracheal SMG phenotype in Fgf10 mutant mice. 
(A, A’) WT animals collected showed SMGs reach lumen formation and branching 
stages in the ventral trachea. (B, B’) Fgf10 +/- littermates showed SMGs form 
lumens, however branching of the formed glands was reduced. (C, C’) Gland buds 
were found in Fgf10 -/- littermates however they had not elongated from the 




5.3.6 Fgf10 +/- Adult Mice Have a Reduction in Tracheal SMG Openings 
Previous experiments have used the application of mineral oil to the mucosal tracheal 
surface to investigate SMG fluid secretion (Joo et al., 2001; Ianowski et al., 2007). As 
a reduction in anterior SMGs was observed in Fgf10 +/- adults, we wanted to 
investigate if this defect in branching reduced the amount of mucus secreted into the 
airway lumen in heterozygous animals compared to their WT littermates. Consecutive 
images taken of tracheal tissue during mucus production analysis were examined and 
the amount of mucus bubbles present between CC and C2 were counted.  Each bubble 
represented the presence of a gland opening. Results elucidated that the amount of 
bubbles was significantly reduced in Fgf10 +/- animals (p=0.0000379) indicating a 
severe decrease in the amount of functional glands within the mesenchyme of the 
trachea between the anterior cartilage rings in Fgf10 +/- adults (Figure 5.8 A-C). 
 
5.3.7 Overall Mucus Secretion is Reduced in the Fgf10 +/- Anterior Trachea 
Following analysis of the number of mucus bubbles present in the anterior tracheal 
samples, area, circumference and feret diameter of each mucus bubble was measured. 
No significant difference in measurements between WT and Fgf10 +/- animals were 
observed (area p=0.6268; circumference p=0.6954; ferret diameter p=0.7487) (Figure 
5.9 A-C). This indicates that each functional gland present in heterozygous animals 
produces the same amount of mucus as WT glands.  
 
To elucidate the overall amount of mucus being secreted within the entire anterior 
trachea, the areas of each bubble were collected and added. This was significantly 
reduced in the Fgf10 +/- adults (p=0.0007) (Figure 5.9 D) indicating that there is a 
decrease in the amount of mucus within the tracheal lumen of heterozygotes 





Figure 5.8 Mucus secretion analysis from WT and Fgf10 +/- tracheal SMGs. 
(A) Visualisation of functional gland openings in WT anterior tracheal tissue by mucus 
bubble production. (B) A significant decrease in the amount of mucus bubbles was 
observed in Fgf10 +/- littermates. (C) Graphical representation of the number of mucus 
bubbles counted, showing a significant reduction in Fgf10+/- (n=6) animals compared to 









Figure 5.9 Single mucus bubble analysis and overall tracheal mucus secretion. 
Individual mucus bubble area (A), circumference (B) and feret diameter (C) analysis 
showed no significant difference in bubble sizes between WT and Fgf10 +/- adults 
indicating similar volumes of mucus secreted per functional gland. Summing up the 
areas of all bubbles was carried out to give a representation in the total amount of 
mucus secreted per anterior trachea with a significant reduction seen in Fgf10 +/- 






5.3.8 Ova-Alexa488 Transepithelial Transport 
Following the results of the oil experiment analysis, showing that Fgf10 +/- mice 
produce less mucus into their airway lumens, we hypothesised that this reduction in 
mucus secretion would hinder the mucin-rich barrier function of these animals. To 
test this, WT and Fgf10 +/- animals were intranasally administered with OVA-
Alexa488 and lung tissue was collected six hours later. We hypothesised that if 
Fgf10+/- animals had a significant decrease in mucus within their airways, this would 
render the epithelial barrier more permeable to OVA and a greater amount of 
AlexaFluor488 labelled OVA would reach the lung tissue, compared to WT 
littermates. A general trend was seen with an increase in positive cells found in the 




Figure 5.10 OVA-Alexa488 positive cells (%) found in the lung tissue of mice 6 
hours after inoculation with OVA-Alexa488 and TNF-a 
The treatment of 6-9 week old adult WT and Fgf10 +/- mice showed a slight increase 
in the number of OVA-TNFα positive cells found in Fgf10+/- lung tissue, however 




5.3.9 Inoculation of 625µg of HDM Causes an Airway Inflammatory Response 
Following the results of the OVA-Alexa488 inoculation results, it was considered that 
this exposure method should be used to target the inflammatory response in the 
animals, as opposed to directly testing the mucociliary barrier function. In light of 
this, we then turned to the inoculation of a more environmentally relevant allergen, 
house dust mite (HDM). Previous studies have specifically administered HDM extract 
to induce an IgE mediated allergic response (Johnson et al., 2004; Saglani et al., 
2009). We employed the use of whole house dust mites however, as this would test 
both the particle clearance potential of the mucociliary barrier as well as 
immunological sensitization to the allergen. As whole HDM inoculation has not been 
done before in an animal model, we administered CD1 mice for three weeks with 
different concentrations of HDM (25µg, 125µg and 625µg) to delineate the most 
suitable level of whole mites required to induce inflammatory responses. Analysis of 
lung tissue, trachea epithelium and BAL fluid showed that the highest concentration 
used, 625µg of HDM, gave the most significant results (Figure 5.11 and Figure 5.12). 
No significant differences were seen in lung weight or any inflammatory cell levels in 
animals treated with 25µg (Figure 5.11). An increasing trend of T-cell and eosinophil 
count, as well as lung weight was observed in animals given 125µg of HDM 
compared to adult PBS control however these results were not statistically significant 
(Figure 5.11). Analysis of BAL fluid from mice exposed to 625µg of HDM delineated 
that eosinophil count showed an increase compared to controls however was not 
statistically significant (p=0.1017). T-cell count was significantly higher (p=0.0449) 
and also lung weights indicated inflammation with a significant increase in weight 
(p=0.0171) compared to PBS controls (Figure 5.11). Neutrophil and 
macrophage/dendritic cell count was not significantly different in 625µg-exposed 
animals. Considering the results collected from the lung weight and BAL analysis, 
tracheal epithelium and lung tissue from those inoculated with 625µg of HDM were 
stained with H&E and Alcian Blue, and analysed histologically. Investigation of 
alveolar lung samples showed accumulation of inflammatory infiltrate in lungs of 
those inoculated with HDM compared to PBS controls (Figure 5.12 A and C, white 
arrows). While phenotype of tracheal SMGs did not show any noticeable differences, 
some areas of the respiratory epithelium of the trachea appeared hyperplastic in those 




Figure 5.11 Lung inflammation and BAL inflammatory cell analysis following 
three weeks of whole HDM inoculations. 
(A) Lung weight after 25µg and 125µg inoculations was not significantly different to 
PBS controls. Lung weight did increase significantly in animals exposed to 625µg of 
HDM. (B) T-Cell count was significantly higher in BAL fluid collected from mice 
inoculated with 625µg of HDM compared to PBS control, however was not 
significantly different in those inoculated with 25µg or 125µg of HDM. Eosinophil 
(C), neutrophil (D) or macrophage/dendritic cell (E) counts were not significantly 








Figure 5.12 Histological analysis of lung and tracheal tissue following three 
weeks of different HDM inoculations. 
(A) Lung tissue of PBS treated animals showing an odd inflammatory cell within 
alveoli. (B) Normal respiratory epithelium found in the trachea of PBS controls. (C) 
Tissue of HDM treated mice shows apparent inflammatory infiltrate throughout the 
lungs. (D) Respiratory epithelium of HDM treated mice appears swollen and possibly 
hyperplastic in some areas. Scale bar = 50µm. 
 
 
5.3.10 Inoculation of HDM may Cause Airway Hyperplasia in Fgf10 +/- 
When whole HDMs were used at the high concentration of 625µg, CD1 mice 
occasionally had problems inhaling the inoculant, as particles would block their nasal 
channels. To overcome this, when the experiment was repeated on Fgf10 mutant mice 
and their WT littermates, HDM were sonicated in short 2 second bursts for 
approximately 10 seconds using a Vibra-Cell™ ultrasonic processor. This short 
sonication allowed HDM to be broken up into smaller particles to aid in inhalation of 
the high concentration. HDM particles were then aliquoted into suitable volumes for 
each inoculation procedure and stored at -20°C. Sonication was carried out by Dr. 
Alistair Noble. Respiratory challenge of adult male and female Fgf10 WT (n=7) and 
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Fgf10 +/- (n=7) mice with 625µg of sonicated HDM was then carried out under the 
same conditions as CD1 mice, along with control mice inoculated with PBS (n=2 
CD1 + n=2 Fgf10 WT). 
 
Interestingly, analysis of lung weight and BAL fluid showed no significant difference 
between WT and Fgf10 +/- HDM treated animals (Figure 5.13 A-E). Furthermore, no 
significant difference was observed between the WT HDM treated and WT and CD1 
PBS controls (Figure 5.13 A-E). A similar result was observed between controls and 
Fgf10 +/- treated animals, however T-cell (p=0.038) and macrophage/dendritic cell 
counts (p=0.0066) were significantly higher in the treated heterozygous groups 
compared to PBS controls (Figure 5.13 A-E). In comparison to this, histological 
analysis of lung tissue did show an obvious increase in inflammatory infiltrate in 
those inoculated with HDM compared to PBS controls (Figure 5.13 F-H, white 
arrows). Histologically it was difficult to determine if inflammation was more severe 
in lungs of HDM treated Fgf10 +/- animals compared to their HDM-treated WT 
littermates (Figure 5.13 G and H, white arrows). 
 
The anterior epithelium of the WT PBS inoculated animals (n=2) did show slight tufts 
of epithelium however not substantial enough to consider irregular (Figure 5.14 A and 
D). The posterior epithelium of the WT control group was identified as regular 
(Figure 5.14 G). Analysis of tracheal respiratory epithelium showed noticeable 
differences between WT HDM-treated (n=3) and Fgf10 +/- HDM treated (n=3) 
animals. The epithelium appeared regular in the anterior of WT inoculated tracheas 
close to the cricoid cartilage (Figure 5.14 B and E) while in the same location in 
Fgf10 +/- treated animals the epithelium appeared irregular and assumed to be 
hyperplastic (Figure 5.14 C and F). Moving further posterior within the trachea areas 
of possible epithelial hyperplasia were seen in WT treated animals (Figure 5.14 H) as 
well as in the Fgf10 +/- mice (Figure 5.14 I). 
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Figure 5.13 Lung inflammation and BAL inflammatory cell analysis of WT and 
Fgf10+/- adult mice following three weeks of 625µg HDM inoculations. 
(A) Lung weight showed no significant difference between animals treated with HDM 
and those treated with PBS only. (B) A general trend of increasing T-cell count was 
observed in WTs treated with HDM, and a further significant increase in HDM-
treated Fgf10 +/- mice, compared to PBS controls. Difference between both treated 
groups was not significant. (C-D) Eosinophil and neutrophil counts showed no 
significant differences between any of the groups. (E) No significant difference in 
macrophage/dendritic cell count was observed between control and WT treated 
animals, or between both treated groups, however, a significant difference between 
controls and Fgf10 +/- treated mice was observed. (F-H) Analysis of lung tissue 
shows inflammatory infiltrate (white arrows) in alveoli of WT and Fgf10 +/- HDM 





Figure 5.14 Tracheal epithelium analysis of WT and Fgf10 +/- adults following 
HDM inoculations. 
(A-F) Anterior trachea of control and HDM treated animals showing SMG and 
respiratory epithelium. WT PBS inoculated animals show slightly tufted yet regular 
epithelium (A and D). WT HDM-treated mice show regular neat epithelium anteriorly 
(B and E) while Fgf10 +/- HDM-treated animals appear to have irregular hyperplastic 
epithelium (C and F). (G-I) The posterior epithelium was regular in all control 
animals (G), but showed possible hyperplasia in areas in WT HDM-treated (H) and in 





5.4.1  Normal Tracheal SMG Development Begins at E18.5 
Previous reports have indicated that SMG development in the mouse begins at P2 
(Rawlins and Hogan, 2005). Using the CD1 strain of mouse, anterior SMG gland 
analysis in our study elucidated that tracheal SMGs initiate as early as E18.5 in the 
ventral mesenchyme adjacent to the cricoid cartilage. At P0 it was recognised that 
glands had progressed from their early bud initiation stage to elongation through the 
underlying mesenchyme and the primary stages of lumen formation and branching. 
Images in the previous report suggest gland bud initiation was uncovered at P2 in the 
more dorsolateral walls of the trachea, which would agree with our investigation 
(Rawlins and Hogan, 2005). It must be emphasised, however, that gland development 
does begin first in the ventral mesenchymal wall and then as postnatal development 
continues, gland bud initiation progresses more dorsolaterally, and then posteriorly 
between the cartilage rings. Other studies have also delineated that the development 
and distribution of the SMGs can depend on genetic background (Borthwick et al., 
1999; Innes and Dorin, 2001). Different inbred strains of mice show different 
posterior extensions of the SMGs between cartilage rings, while the Cystic Fibrosis 
mouse model has an increase in posterior extension with mutants showing glands as 
far as the eighth cartilage ring compared to the fourth ring in WT littermates 
(Borthwick et al., 1999; Innes and Dorin, 2001). This dichotomous patterning 
however should not impede the mouse as a model of SMG development as the glands 
still show homologous cellular composition and structure compared to those within 
the upper and lower airways of humans (Borthwick et al., 1999; Finkbeiner, 1999). 
 
Developmental stages outlined in this study also emphasise homology between the 
tracheobronchial glands of mice and other animals. Unlike the nasal glands that 
develop for approximately two days as a long gland duct, followed by the branching 
of a distal gland (outlined in Chapter 3), the tracheal SMGs bud, elongate with a short 
stem, cavitate and begin branching. This developmental mechanism is similar to that 
seen in the branching of both the major and minor salivary glands, however in these 
structures gland it has been reported that branching occurs before lumen formation 
(Melnick and Jaskoll, 2000; Teshima et al., 2011).  
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5.4.2 Tracheal SMG Development and Distribution is Altered in Fgf10 +/- Mice 
Considering the variable SMG distribution patterns seen in different strains of mice, 
we analysed the anterior SMGs and their posterior extension in Fgf10 +/- adults. 
Rawlins & Hogan (2005) had already delineated that anterior SMGs were reduced 
and their posterior extension impeded in Fgf10 +/- adult mice compared to their WT 
littermates, and our analysis concluded the same phenotype. It must be mentioned that 
although the severity of branching reduction in the anterior SMGs did show variation, 
all Fgf10 +/- glands were smaller than WT counterparts. Variation in localisation of 
the glands was also observed between Fgf10 +/- littermates but all showed reduced 
posterior extension of the glands. While Fgf10 +/- mice have lost functional 
expression of one of two of their copies of Fgf10, this does not necessarily mean that 
precisely 50% of FGF10 protein is synthesized. From in vitro manipulation studies in 
culture, it is understood that branching organs are extremely sensitive to fluctuations 
in protein levels. Different concentrations of protein can induce branching organs to 
develop with slightly different phenotypes (Steinberg et al., 2005). Many post-
transcriptional aspects are tightly controlled before protein is synthesized (e.g RNA 
processing, RNA stability, translation and protein stability) meaning that proteome 
levels do not exactly reflect mRNA levels, and that protein concentrations can 
fluctuate (Vogel and Marcotte, 2012). In WTs, the effect of this does not influence 
phenotype however as protein expression may always be above a threshold required 
for normal gland development. In Fgf10 +/- animals however, some heterozygous 
mice may express proteins at a concentration above a threshold level that does not 
induce as severe a phenotype as other mutant littermates, whose overall protein 
production is severely reduced. This fluctuation in protein expression may induce 
variation in phenotype of the glands in Fgf10 +/- mice. It would then be expected that 
a defective phenotype could lead to a reduction in mucous secreted by these glands 
and negatively effect the mucin-rich protective barrier of the airways of Fgf10 +/- 
mice. Furthermore, variable expression of clinical symptoms are seen within patients 
who suffer from LADD syndrome, similar to the varying phenotypes observed in 
Fgf10 +/- mice (Thompson, Pembrey, and J. Graham, 1985; Rohmann et al., 2006). 
This again suggests that heterozygosity of Fgf10 may lead to differences in protein 
levels and thus phenotypic variation. 
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As a previous report has shown that the mesenchymal localisation of Fgf10, and its 
epithelial receptor Fgfr2b, play a critical role in tracheal cartilage patterning (Sala et 
al., 2011), we wanted to rule out a possible influence of abnormal cartilage ring 
structure as an influence on the branching of Fgf10 +/- glands. By cartilaginous 
preparation using whole mount Alcian Blue staining, it was clarified that Fgf10 +/- 
embryonic tracheas at E18.5 show no disorganization or patterning defects in the 
tracheal cartilage rings. This supports the hypothesis that Fgf10 plays a role in the 
mesenchymal-epithelial interactions involved in branching morphogenesis of the 
epithelial SMGs and that the observed gland phenotype is not a secondary effect of a 
cartilaginous defect. 
 
5.4.3  Fgf10 -/- Mouse Pups Develop SMG Buds 
Considering the initiation of ventral tracheal SMGs at E18.5 in our mouse line, this 
gave us an opportunity to collect Fgf10 -/- pups at P0, along with their WT and Fgf10 
+/- littermates, just after birth. Interestingly, gland buds were found in the ventral and 
slightly more dorsal anterior positions in the Fgf10 -/- specimens collected. Out of 
four mutants analysed, all had gland buds detected in ventral and some dorsolateral 
planes of the trachea. This result concluded that Fgf10 is not required for the initiation 
of the epithelial gland primordia or the outgrowth of the initial gland bud. 
Alternatively it is possible that Fgf10 plays a role in these early processes during 
normal gland development however in the Fgf10 -/- mouse other Fgfs may 
compensate. 
At P0, reduction in branching was also observed in Fgf10 +/- pups at this early stage 
of gland developmental. At P0 the ventral glands of WT animals had reached the 
lumen formation stage and are undergoing clefting and branching. Fgf10 +/- animals 
also showed glands had elongated into the underlying mesenchyme and formed 
lumens however the amount of gland branches was evidently reduced. This phenotype 
mirrors that reported for submandibular salivary gland (SMDG), where the gland does 
not progress passed the initial bud stage in Fgf10 -/- mice, and branching is reduced 
leading to aplastic glands in the Fgf10 +/- mouse (Jaskoll et al., 2005 and Chapter 5). 
This altered SMG development is similar to the aplastic lacrimal and salivary gland 
phenotypes observed in those that suffer from both ALSG and LADD syndrome 
(Milunsky et al., 2006; Shams et al., 2007; Entesarian et al., 2007). While no reports 
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have stated any pulmonary defects in patients with ALSG or LADD syndrome, it is 
quite likely that the airway SMGs would show aplasia and that this phenotype could 
possibly give rise to mucociliary deficiencies in those that suffer from these 
autosomal dominant diseases. 
5.4.4 Fgf10 +/- Adults Release Less Mucus Into Their Airways due to a Reduction 
in SMGs 
Previous studies have exploited the use of mineral oil to visualise gland mucus 
production in rodents and sheep (Joo et al., 2001; Ianowski et al., 2007).  We adapted 
these protocols to allow functional tests of mucus secretion in mice. The protocol 
used was effective and reproducible. 
 
The reduction in number of mucus bubbles produced was significant and could easily 
be observed with the naked eye. The number of bubbles counted in WT tracheal tissue 
averaged at 39 while in Fgf10 +/- the mean bubble number was 11, with one 
heterozygous specimen producing only 7 bubbles. Analysis revealed that there was 
over a 50% reduction seen in all Fgf10 +/- specimens investigated compared to their 
WT littermates and almost a 75% decrease in the most severe cases. As it was 
difficult to elucidate if there was a decrease in the amount of glands, as well as a 
decrease in branching, through histological means of adult tissue, this result 
demonstrates that there are fewer functional glands between the anterior cartilage 
rings in Fgf10 +/- adult tracheas.  
 
Previous studies have used volume and the equation V = 4/3 π r2 to represent mucus 
production, assuming spherical shape of each bubble (Joo et al., 2001; Ianowski et al., 
2007). As no bubbles followed an exact spherical shape the measurement of one 
single radius was found not to be an accurate representation of secretion therefore 
area of each bubble was chosen to study. Results of this analysis concluded that 
bubbles were not significantly larger in the WT specimens compared to their Fgf10 
+/- littermates. This was supported by additional investigation of bubble 
circumference and bubble feret diameter not showing any significant difference. 
These results indicate that the functional glands within Fgf10 +/- animals may 
undergo the same amount of branching as WT littermates, and therefore produce 
bubbles of the same size. The largest bubbles however were identified in the WT 
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specimens suggesting larger glands were present in WTs, however due to the greater 
number of glands within WTs of all different sizes, difference between those and their 
Fgf10 +/- littermates was not significant. Furthermore, our histological analysis of 
early gland development within WT and Fgf10+/-, showed early reduction of 
branching in heterozygous animals, indicating that measurement of mucus bubble 
production may not be an ideal representation of gland size. Considering this, total 
mucus bubble areas were accumulated per specimen to give an overall representation 
of the amount of mucus released into the anterior trachea. This result concluded a 
significant decrease in overall mucus released into the airway lumen in Fgf10 +/- 
animals. As only the anterior glands were included in the study, an even greater 
difference would be assumed if all mucus bubbles extending posteriorly in WT 
animals were calculated.  
 
Our analysis of Fgf10 +/- tracheal SMGs above, as well as our histological analysis in 
Chapter 4 indicating Fgf10 +/- also have hypoplastic nasal glands, suggest that these 
mutant mice secrete less mucus into their airway lumens. We hypothesised that trans-
epithelial transport of allergens from the airway lumen into lung tissue may be 
increased in mice that have reduced mucous levels. Our results indicate that there was 
a general trend of increasing fraction of lung cells that had taken up the OVA 
conjugate in Fgf10 +/- animals compared to their WT littermates, however this 
difference was not statistically significant. On reflection we concluded that use of a 
soluble protein allergen was not ideal to answer the question of reduced mucociliary 
clearance. 
 
Considering this, we decided to expose mice to whole HDM. Using whole mites, we 
hypothesised that while their allergens would induce an immune response in 
administered animals, their physical nature would also act as a damaging inhalant, 
and mucociliary function would be tested by the ability to remove these particles 
away from the lungs. Analysis of BAL collected from exposed CD1 adults using 
FACS showed that all HDM inoculations triggered a response represented by an 
increase in lung weight, indicating lung inflammation, and increased T-cell and 
eosinophil cell counts. These responses however were only statistically significant 
from administration of the highest concentration, 625µg, of HDM used. Analysis of 
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both lung and tracheal epithelium supported this conclusion, as inflammatory 
infiltrate was evident in the lung parenchyma of those induced with 625µg of HDM as 
well as possible hyperplasia of the respiratory epithelium in certain areas of the 
trachea. Considering this it was decided that 625µg of HDM in 30µl of PBS was the 
most suitable inoculation to analyse the inflammatory and tissue response in the WT 
and Fgf10 +/- animals. During administration of CD1 animals however in the test 
experiment, it was observed that inhalation rates of this high concentration was not 
consistent. HDM was seen to collect in the small nostrils of the mice and sneezing 
was periodically observed. Although this may not hinder the effectiveness of the 
experiment due to the overall experimental length of three weeks, and repetitive 
inoculations every three days, it was decided to sonicate the HDM to produce smaller 
mite particles for inhalation of WT and Fgf10 +/- animals. Sonication was successful 
and inoculant was inhaled more easily throughout the period of three weeks.   
 
Analysis of lung weight following three-week administration saw no significant 
difference between WT and Fgf10 +/- inoculated littermates. Comparison to PBS 
administered WTs also showed no significant difference. It must be mentioned 
however that this study was hindered by the general small litter size of the Fgf10 +/- 
mice. This therefore required the addition of age matched CD1 mice to act as WT 
PBS controls (n=2) to make up sufficient numbers for the study. Although these two 
mice were born on the exact same day as the other Fgf10 litters (taken from a Fgf10 
+/- and Fgf10 +/- mating) used for HDM analysis, by the end of the three-week 
experiment they were considerably larger and lung weights considerably heavier than 
PBS controls from the Fgf10 litter. While this characteristic should not affect other 
analysis, it may influence the fact that lung weight is not a reliable inflammatory 
indicator. Furthermore, although the lung weight analysis concluded no significant 
differences between all groups, histological examination of the lung parenchyma saw 
apparent inflammatory infiltrate within both WT and Fgf10 +/- HDM treated tissue. 
This suggests that the exposure to HDM did in fact cause inflammatory responses. 
 
T-cell count did show an increasing trend from WT PBS controls to WT HDM 
inoculated and then again in Fgf10 +/- HDM inoculated, with only heterozygous 
treated animals showing a significant increase compared to controls. Furthermore, 
 178 
there was no difference within eosinophil count between each group. Although no 
differences in inflammatory responses were observed between WT and Fgf10 +/- 
HDM inoculated animals, interestingly the PBS control WT animals showed no 
significant differences in T-cell count compared to WT treated, and no significant 
difference in eosinophil counts compared to both treated groups. Considering the 
satisfactory allergen response seen in CD1 animals exposed to HDM and the well 
established knowledge that HDM is a significant allergen causing inflammatory cell 
infiltrate, the results collected indicate that this experiment may not be an ideal 
representation of the effects of HDM administration. This result may be due to the 
potential loss of the soluble allergenic protein of the HDM by sonication. 
 
Interestingly, increased numbers of macrophage/dendritic cells were evident in the 
WT and Fgf10 +/- HDM inoculated groups, compared to controls, with the difference 
between heterozygous treated animals and controls being significant. Three types of 
macrophages are present within lung tissue; bronchial macrophages (BMs), interstitial 
macrophages (IMs) and alveolar macrophages (AMs) (Balhara and Gounni, 2012). 
Recent studies have emphasised the role of these cells in preventing allergic asthma 
symptoms and maintaining lung homeostasis through their two primary roles of 
allergen recognition and presentation, and phagocytosis (Careau et al., 2010; Bang et 
al., 2011; Lauzon-Joset et al., 2014). It is recognised that the BMs and IMs function in 
antigen presentation to induce an adaptive immune response (Gong et al., 1994; 
Moniuszko et al., 2007; Bedoret et al., 2009) while evidence shows that AMs, which 
are those collected in BAL fluid, are poor APCs (Lipscomb et al., 1986; Chelen et al., 
1995).  It has been established that there is tight self-regulation of the AM populations 
to remain quiescent in normal situations and release very little cytokines to prevent 
collateral damage of fragile lung tissue (Holt, 1978). Therefore it is considered that 
the increasing trend observed in macrophages in the HDM inoculated groups in this 
study primarily represents AM recruitment to carry out a phagocytic role of HDM 
particles, as opposed to an influx of macrophages recruited for antigen recognition. 
Histological analysis of lung parenchyma additionally shows aggregations of 
inflammatory cell infiltrate suggesting localised areas of phagocytosis, possibly more 
so in Fgf10 +/- animals compared to WT inoculated individuals.  
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Neutrophil count also showed a trend in increasing numbers in WT and Fgf10 +/- 
inoculated animals compared to PBS controls. The principal function of neutrophils is 
also phagocytosis (Nordenfelt and Tapper, 2011). Neutrophil count showed a marked 
increase in WTs, however, the increase was less marked in the Fgf10 +/- mice 
exposed to HDM. As macrophages function in ingestion and eradication of dead 
neutrophils (Savill et al., 1989), the high number of macrophages in Fgf10 +/- HDM 
exposed specimens could explain why neutrophils are slightly reduced in the 
heterozygous animals compared to WT HDM exposed animals.  
 
Papillary epithelial projections can be used to identify the development of epithelial 
hyperplasia (Sells et al., 2007). Considering this, it appears that these epithelial 
projections are present in the anterior trachea of Fgf10 +/- exposed to HDM compared 
to a smooth epithelium present in HDM inoculated WT littermates. Moving more 
posterior down the trachea it appeared that possible hyperplasia occurred in the 
epithelium of both inoculated groups. Using rodents as models to study the effect of 
toxic inhalants, it has been shown that exposure to HDM (Johnson et al., 2004; 
Saglani et al., 2009), industrial chemicals (Nyska et al., 2005), cigarette smoke 
(Mebratu et al., 2011) and other air pollutants (Harkema et al., 1999) gives rise to 
respiratory epithelium hyperplasia.  A potential metaplasia increasing the ratio of 
mucus cells to serous may also have occurred in both WT and Fgf10 +/- inoculated 
animals however this is difficult to delineate conclusively using histological methods 
alone. It is also problematic to compare rates of metaplasia between WT and Fgf10 
+/- animals due to the decreased size of Fgf10 mutant glands. Additionally, it has 
been shown that exposure to HDM can alter epithelial functionality and lead to the 
secretion of enzymes that target adhesion molecules and cause mucosal damage 
(Roche et al., 1997). Considering this, investigation into adhesion markers of the 
tracheal epithelium, such as E-cadherin, could be carried out to delineate it epithelial 
damage is more severe in Fgf10 +/- exposed to HDM compared to WT littermates. 
 
To conclude, exposure to sonicated HDM is not an ideal model for mucociliary 
clearance functionality of WT and Fgf10 +/- adult mice, and application of whole 
HDM inoculation is more effective. It is therefore suggested that if this experiment 
was repeated, 125µg doses of whole HDM should be used. While this concentration 
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did not give statistically significant results when used on CD1 animals, it did cause 
inflammatory response with rising levels of T-cell and eosinophil counts. Application 
of a weaker dose may also elucidate mucociliary differences between WT and Fgf10 
+/- animals, as a high dose of 625µg may have masked these effects. Furthermore, 
125µg of whole HDM was easily inhaled by young adult mice. Other experimental 
models could also be employed. For example, Hua et al. (2010) used planar gamma 
scintigraphy to optimally investigate nasal mucociliary clearance non-invasively in a 
mouse model. After isoflurane anaesthetization, mice were intranasally inoculated 
with radioactive particles. Using a planar gamma camera, timed retention and 
mucociliary clearance of radioactive particles within the nasal cavity was measured 
(Hua et al., 2010). This method could be applied to investigate clearance abilities in 
Fgf10 +/- mice, especially in the nasal region where, in Chapter 4, we showed that 




6.  Characterisation of Salivary Gland Dysplasia in Fgf10 Heterozygous Mice 
6.1 Introduction 
6.1.1 Mammalian Salivary Glands 
As mentioned in Chapter 1, humans and mice have three major paired salivary glands 
in the oral cavity that produce 90% of total saliva secretion (Tucker, 2007). The major 
salivary glands are derived from the oral ectoderm and neural crest derived 
mesenchyme (Rothova et al., 2012; Jaskoll et al., 2003). The parotid gland (PG), the 
largest of the salivary glands, is located at the back of the mouth in front and below 
the ear between the upper and lower jaws (Figure 6.1). This gland is made up of 
serous acini exclusively and secretes saliva via the Stenson’s duct, which opens into 
the oral cavity via the cheek. The submandibular gland (SMDG), consisting of a mix 
of serous and mucous acini, and the sublingual gland (SLG), predominantly made up 
of mucous acini, lie beneath the tongue and excrete their secretions via ducts which 
open into the floor of the mouth (Figure 6.1). In humans, the SMDG produces 70% of 
total saliva secretion and expels saliva via the Wharton’s duct (Miletich, 2010). The 
SLG excretes via the Bartholin’s duct, which is seen to open close to the SMG duct, 
but can also expel saliva through 8-20 smaller excretory ducts, called the ducts of 
Rivinus, that open out beneath the tongue (Miletich, 2010) (Figure 6.1). The 
remaining 10% of saliva is produced by the minor salivary glands which are located 
in the tongue, palate, cheeks and lips (Hand et al., 1999). 
6.1.2 Importance of Saliva 
The salivary glands have evolved to carry out an important function in maintaining 
oralpharyngeal health. The many functions of saliva include providing lubrication for 
digestion and speech, producing digestive enzymes and anti-microbials, buffering the 
pH of the mouth, as well as a protective function to the oral and oesophageal mucosa 
(Pedersen et al., 2002). A reduction in saliva leads to xerostomia, or dry mouth, an 
oral symptom that can seriously impinge the quality of life in human patients. This 
hyposalivation leads to problems such as mastication difficulties, halitosis, deficiency 
of taste and a high incidence of dental caries and candida infections. There are many 
reported biological driving factors that lead to xerostomia. The highest incidence of 
dry mouth is observed in people over the age of 65, reaching approximately 30% 
(Ship et al., 2002). It is not believed, however, that salivary gland dysfunction is 
concomitant of ageing, rather it is a side effect from prescription medications or an 
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outcome of a number of systemic diseases such as Sjögren’s Syndrome (OMIM 
270150) (Ship et al., 1995, 2002; Gupta et al., 2006; Zalewska et al., 2013). Sjögren’s 
Syndrome (SS) is a chronic autoimmune inflammatory disease targeting the exocrine 
glands changing both the quality and quantity of secretion produced. It has a 
prevalence of 3-4% in the United Kingdom and up to 3.1 million adult sufferers in the 
United States with 90% of patients being female (Thomas et al., 1998; Helmick et al., 
2008). Primary SS, where the disorder occurs alone, primarily affects the salivary and 
lacrimal glands while secondary SS arises along with other systemic connective tissue 
diseases such as rheumatoid arthritis (Peri et al., 2012). The prevalence of xerostomia 
is also common in patients with head and neck cancers, who are treated by radiation 
therapy and also administered chemotherapeutic drugs, which both lead to damage of 
the salivary glands and hyposalivation (Chambers et al., 2004). 
 
 
Figure 6.1 Location of the major salivary glands in humans. 
The parotid gland (PG), made up of serous acini, is located in front of the ear between 
the upper and lower jaws. Its duct opens out into the cheek. The sublingual (SLG) and 
submandibular glands (SMDG) lie beneath the tongue with their ducts opening into 
the floor of the mouth. The SLG, consisting of mucus acini, also has an array of 
smaller ducts that open into the bottom of the tongue. The SMDG is made up of both 




6.1.3 Fgf10 and Salivary Gland Development 
As described in Chapter 1, human autosomal dominant mutations in FGF10 or its 
receptor FGFR2b, lead to Lacrimo Auriculo Dento Digital (LADD) syndrome 
(OMIM 149730), or the milder Aplasia of Lacrimal and Salivary Glands (ALSG) 
(OMIM 180920). These syndromes are characterised by hypoplasia, aplasia or atresia 
of both the lacrimal and salivary systems (Milunsky et al., 2006; Shams et al., 2007). 
Due to these phenotypes, human LADD or ALSG patients suffer from severe 
xerostomia. The mouse SMDG has provided a valuable model for investigating gland 
development and research shows it requires the interaction between mesenchymal 
Fgf10 and its epithelial receptor Fgfr2b for successful branching morphogenesis 
(Ohuchi et al., 2000). As outlined in Chapter 1, knockout of Fgf10, or its receptor, 
leads to complete aplasia of the major salivary glands, which arrest at the epithelial 
thickening stage (Jaskoll et al. 2005). These mice however are perinatal lethal as they 
also lack lungs (Min et al., 1998; Sekine et al., 1999). In viable Fgf10 +/- mouse pups 
at P0, SMDGs are present but have fewer ducts and terminal buds (Jaskoll et al. 
2005). Another study investigated Fgf10 +/- adult salivary glands and concluded they 
were hypoplastic compared to WTs yet the histology of the SMDG and SLG were 
similar to WT counterparts (Entesarian et al. 2005). This study by Entesarian et al. 
(2005) however only investigated two Fgf10 +/- adults and a more thorough 
investigation using a larger number of samples should be carried out to delineate a 
true difference in salivary gland phenotype. 
6.1.4 The Need for a Model of Xerostomia 
Animal models are indispensable tools for delineating the underlying aetiology of 
diseases and their contribution to biomedical discoveries has been invaluable. Our 
advanced knowledge of the mouse genome and the physiological similarities shared 
with humans makes the mouse an important mammalian model in uncovering the 
pathogenesis of many diseases. Murine models of xerostomia, such as the non-obese 
diabetic mouse (NOD), have been generated and extensively researched, however the 
dry mouth phenotype in these mice is a result of autoimmune exocrinopathy and 
therefore the xerostomia is a secondary effect of the underlying autoimmune disease 
(Humphreys-Beher, 1996; Lavoie et al., 2011; Lee et al., 2012). While these 
autoimmune models are beneficial, an animal model of dry mouth without any 
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underlying disease is necessary to examine the effect of dry mouth in otherwise 
healthy individuals. 
6.1.5 Aims of Study 
• To delineate the exact phenotype of SMDG and SLGs in the adult Fgf10 +/- 
mouse. 





6.2 Materials and Methods 
6.2.1 P14 and Adult Salivary Gland Weight Analysis 
At postnatal day (P)14 WT and Fgf10 +/- littermates were culled by exposure to CO2 
gas. Animals of this age were chosen as sexual dimorphism in salivary glands does 
not arise until P15 (Gresik, 1975). Mice were weighed and the SMDG and SLG 
glands were dissected together. Excess fat surrounding the glands was removed. 
Glands were dried using an air stream and weighed immediately. Glands were then 
fixed in 4% paraformaldehyde in PBS (PFA) at 4°C overnight and processed for 
histological analysis. The same process was adopted for measuring the weight of adult 
(7-10 weeks) salivary glands from WT and Fgf10 +/- littermates. 
6.2.2 Adult Salivary Gland Function Tests 
Salivary gland function tests were primarily carried out by Prof. Gordon Proctor 
(Mucosal Biology and Salivary Division, Dental Institute, King’s College London) 
while I accompanied. WT and Fgf10 +/- adult littermates were put under mild 
anaesthetic (ketamine 80mg/kg; xylazine 16mg/kg) by peritoneal injection. Mice were 
weighed and positioned under a light microscope. An incision was made and a thin 
tube inserted into the trachea to facilitate breathing. Mice were then subcutaneously 
injected with a low dose of pilocarpine hydrochloride (0.54-0.64 µg/g body weight, 
Sigma Aldrich), individual SMDG and PG ducts were cut and after 10 minutes saliva 
was collected at the opening of ducts at room temperature and put into pre-weighed 
1.5ml eppendorf tubes kept on ice. Saliva secretion volume was calculated where 1mg 
= 1µl saliva. Following each procedure animals were humanely killed by one lethal 
dose of anaesthetic. Saliva secretion was calculated as volume of saliva per minute 
(µl/min). 
6.2.3 Statistical Analysis 
Differences in gland weight were analysed using a two-tail unpaired Student’s t-test 
on WT and Fgf10 +/- aged P14 and adults aged 7-10 weeks. Specimens used for 
saliva secretion tests were littermates from a range of adult ages (13-54 weeks). Data 
from these experiments were pooled and statistical significance was calculated using a 
Wilcoxon’s signed rank test. Due to the variation of ages used in secretion analysis, 
Fgf10 +/- saliva secretion was expressed as a ratio of secretion from a matched WT 
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littermate, where WT secretions equal 1. Graphs were generated using GraphPad 
Prism 6 software. 
6.2.4 Scanning Electron Microscopy (SEM) 
Female adult littermates (6 weeks old) were culled by exposure to CO2 gas. Tongues 
were dissected and fixed in 2.5% glutaraldehyde in 0.15M cacodylate buffer (pH 7.2) 
overnight at 4°C. The following tissue preparation procedure was carried out by Dr. 
Gema Vizcay-Barrena (centre for Ultrastructural Imaging, King’s College London). 
Tongues were washed in cacodylate buffer and postfixed in 1% osmium tetroxide. 
Tissue was then dehydrated through an ethanol series and dried using a Polaron 
E3000 critical point dryer. Tongues were mounted and coated with gold (Emitech 
K550X sputter coater). Using a Hitachi S-3500N scanning electron microscope 
(SEM) the surface mucosa of the tongue was analysed. Images were taken of specific 
temporal regions of different papillae of the tongue. All images were taken with the 





6.3.1 A Reduction in Fgf10 does not Affect the Gross Morphology of the Gland at 
the Histological Level 
To investigate a sex-independent affect of loss of Fgf10 on salivary gland 
morphology, we analysed glands at P14. At this age, sex hormones have not been 
released and sexual dimorphism is not evident (Gresik, 1975, 1994). In agreement 
with this, no obvious histological differences were seen between male and female WT 
animals at P14 (Figure 6.2 A-D). No obvious difference in histology was evident 
between Fgf10 WT and +/- littermates at P14 (Figure 6.3 A-D). In Fgf10 +/- glands, 
the numbers of ducts and acini appeared similar to WTs, however the overall size of 
gland lobes appeared smaller (Figure 6.3 A-B). 
6.3.2 Fgf10 +/- Animals Show Reduced Salivary Gland Weight at P14 
Given the lack of a change in histology, we moved to assess whether there was a 
weight difference between WT and Fgf10 +/- groups at P14. Comparison of WT and 
Fgf10 +/- gland weight showed a significant difference, with smaller glands observed 
in heterozygous animals (Figure 6.3, E). These results indicate that loss of function of 
one copy of Fgf10 leads to a reduction in size of salivary glands at an early postnatal 




Figure 6.2 No sexual dimorphism is observed in SMG and SLGs aged P14. 
No obvious morphological differences were noted in either SMDG (A, B) or SLGs 
(C, D) between both sexes. (E) No significant difference was seen between male and 
female salivary gland (SMG + SLG) weight in both WT and Fgf10 +/- animals at 






Figure 6.3 Comparison of WT and Fgf10 +/- salivary glands at P14.  
(A-D) General duct and acini arrangements of WT and Fgf10 +/- SMG and SLGs 
appeared normal at P14. A reduction in size was seen in glandular lobes in Fgf10 +/- 
animals compared to WT littermates (black dotted line) (A-B). (E) At P14 combined 
Fgf10 +/- SMGs and SLGs weighed significantly less compared to WT littermates. 
Scale bar = 200µM. A-D shows glands from female specimens. *** p<0.001. 
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6.3.3 Adult Fgf10 +/- Animals Have Reduced Salivary Gland Weight 
We further investigated SMDG and SLGs in littermates aged between 7-10 weeks to 
delineate if glands remained smaller throughout adult life. Smaller glandular lobes 
were observed in Fgf10 +/- glands compared to WT littermates (Figure 6.4, A-B). No 
morphological differences were seen between adult WT and Fgf10 +/- littermates at a 
histological level (Figure 6.4, C-F). Using salivary gland weight analysis, a significant 
difference in weight of WT and Fgf10 +/- glands was observed in both adult females 
and males, with smaller glands found in Fgf10 +/- animals (Figure 6.4, G). No 
significant difference was seen in body weight between WT and Fgf10 +/- littermates 
(males p=0.5, females p=0.2), therefore a reduction in overall body weight was 
excluded as a factor influencing the salivary gland phenotype.  
 
As expected a significant difference was seen between adult female and male glands 
in both genotypes, with males having considerably larger glands to females, due to 
having larger and more prevalent granular convoluted tubule (GCT) cells than those 
observed in females (Figure 6.4 and Figure 6.5). The larger and more numerous GCT 
cells is reflected functionally as GCTs are the location of amylase activity in postnatal 
and adult mice, which has been shown to be increased in males (Gresik, 1975).  
6.3.4 Adult Salivary Gland Secretion is Severely Reduced in Fgf10 +/- Mice 
Human patients with ALSG or LADD syndrome have severe dryness of mouth due to 
aplasia of the major salivary glands (Wiedemann and Drescher, 1986; Rohmann et al., 
2006). We therefore wanted to test whether the smaller size of the salivary glands in 
Fgf10 +/- mice lead to a reduction in salivary output. Saliva was collected from WT 
and Fgf10 +/- littermates after inoculation with pilocarpine. As predicted from gland 
weight, Fgf10 +/- animals showed a significant reduction in saliva flow compared to 
their WT littermates from both the SMDG and PG (Figure 6.6). Our results 
collectively suggest that the hyposalivation observed in Fgf10 +/- adults is due to the 






Figure 6.4 Comparison of adult salivary glands. 
(A-B) Smaller gland lobes are observed in Fgf10 +/- adult SMDGs (arrows)(scale 
bar=3mm). (C-F) Male glands; no histological differences are noted between WT and 
Fgf10 +/- SMGs (C, D) SLGs (E, F), and GCTs (inset images C, D). (G) Male and 
female Fgf10 +/- adult salivary glands show a significant decrease in weight 




Figure 6.5 Comparison of male and female adult salivary glands. 
(A-D) No morphological differences were seen in female WT and Fgf10 +/- SMGs 
(A-B) and SLGs (C-D). GCTs are smaller in female adult glands (inset images A-B) 
than those seen in male glands (Figure 6.4). A-D scale bar=200µm, inset scale 
bar=50µm. (E) A significant difference is seen between male and female salivary 




Figure 6.6 Saliva secretion from the (A) SMDG and (B) PGs. 
Flow rate was significantly reduced in heterozygous adults compared to WT 
littermates. Saliva secretion is collected from the gland duct openings and is measured 
as microliter of saliva produced in 10 minutes after pilocarpine stimulation (µl/min). 
Graph shows secretion rates of Fgf10 +/- animals normalized against WT secretion 
rate where WT secretion = 1. Data is expressed as mean ± SEM. * p<0.05, ** p<0.01. 
 
6.3.5 Reduction in Salivary Pellicle on the Tongue in Fgf10 +/- Mice 
To further investigate the reduction of saliva flow in Fgf10 +/- adults, we analysed 
the mucosa of adult tongue papillae (10 weeks) using scanning electron microscopy. 
In order to assess the thickness of the salivary pellicle, we used HCl to remove mucus 
from the oral surface. In WT animals, sheets of mucus were observed coating the 
tongue, particularly in the posterior region covering the Circumvallate Papillae (CVP) 
and fillifom papillae. In contrast, the Fgf10 +/- tongues showed no mucus on the oral 
surface. This suggests that HCl treatment is sufficient to remove the saliva on Fgf10 
+/- tongues however the thicker saliva pellicle in WT animals is only partially 
removed and sheets of saliva remain. The Fgf10 +/- tongues, did, however, display a 
healthy lawn of filliform papillae similar to their WT littermates, at this age.  
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Figure 6.7 Scanning electron microscopy of 10 week old adult female tongues. 
WT animals retained what appeared to be sheets of mucus covering the posterior CVP 
(A) and filliform papillae (C) while no mucus remained on Fgf10 +/- tongues 






6.4.1 Loss of Fgf10 Leads to Defective Salivary Gland Function 
In our study we show that adult Fgf10 +/- mice have a significant reduction in saliva 
flow compared to control animals. Previous work has emphasised the important role 
of Fgf10 in salivary gland development, with the Fgf10 knockout mouse showing 
absence of the major salivary glands at birth (De Moerlooze et al. 2000; Jaskoll et al. 
2005; Ohuchi et al. 2000). Additionally Fgf10 +/- mice have reduced terminal buds 
and ducts at P0 (Jaskoll et al. 2005) while another study, albeit using only two 
samples, reported that adult Fgf10 +/- SMDG and SLGs show normal histology 
(Entesarian et al. 2005). Our histological analysis concludes that there is no obvious 
structural differences between Fgf10 +/- and WT adult major salivary glands. A 
significant difference in gland weight was observed however; with heterozygous 
animals showing approximately a 23% decrease in gland weight in females and a 15% 
decrease in males. 
 
As first described in Chapter 1, Fgf10 expression is not required for budding of the 
SMDG from the oral epithelium however it is imperative for the successional 
branching. Addition of exogenous FGF10 peptide to developing SMDGs increases 
epithelial cell proliferation and the number of branches compared to control glands 
(Jaskoll et al. 2005). In our analysis of adult gland histology, no signs of altered 
differentiation were seen in Fgf10 +/- glands however smaller salivary gland lobes 
were observed. This indicates that a reduction in epithelial branching may occur in 
Fgf10 +/- glands leading to shorter branches and thus smaller lobes. Therefore we 
suggest that the hyposalivation observed in Fgf10 +/- adult mice is due to the 
reduction in weight and size of the salivary glands caused by a defect in early salivary 
gland patterning.  
6.4.2 Fgf10 Function is Independent of Sex 
It is well established that there is a significant sexual dimorphism in mature rodent 
salivary glands. Structural differences are most prominently seen in the granular GCT 
cells, which appear larger and more numerous in adult male mice, and the intercalated 
duct cells which appear more granulated in adult female mice (Lacassagne, 1940; 
Gresik, 1966). These cellular differences are androgen-dependant and begin to take 
shape at P15, with the development of GCT cells, and complete sexual dimorphism is 
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evident at P20 (Lacassagne, 1940; Gresik, 1975). To rule out any influence of sex on 
the Fgf10 phenotype, we analysed weight and cytology of glands at P14 in male and 
female mice. Our results support previous reports as no weight or structural 
differences were seen between the sexes at this stage in WT mice. While histology of 
Fgf10 +/- salivary glands at P14 appeared normal, whole weights of mutant glands 
were significantly reduced.  
 
Adult female glands are significantly smaller than male glands by age 7 weeks and 
GCT cells are less prominent. In both sexes, Fgf10 +/- glands are significantly 
smaller than WT littermates, with decrease in size being more significant in females. 
As both WT and Fgf10 +/- male glands develop to be much larger, and a secondary 
influence of androgens on salivary gland size is occurring, this may explain why the 
decrease in weight may be less notable compared to female heterozygotes. 
 
This data supports the hypothesis that Fgf10 heterozygosity is causing defective 
embryological salivary gland development, giving rise to a phenotype that is not 
rescued during postnatal development and adulthood. 
 
6.4.3 Adult Fgf10 +/- Mice as a Model for Xerostomia 
Xerostomia can be caused by a severe reduction in saliva production or a change in 
saliva composition produced by the salivary glands. Human studies investigating the 
affect of radiation therapy on head and neck cancers have shown that treatment gives 
rise to severe xerostomia and dysphagia (Epstein et al., 1999; Logemann et al., 2001). 
Our studies investigated the salivary gland cytology and function in postnatal and 
adult Fgf10 +/- mice with mutant glands showing an overall reduction in weight as 
well as evident hyposalivation. When 10 week old adult tongues were treated with 
hydrochloric acid to remove saliva from the surface mucosa, WT tongues maintained 
sheets of mucus covering their tongue papillae while no mucus remained on Fgf10 +/- 
tongues, indicating a thicker saliva pellicle is produced in WT animals. No evident 
defect in the tongue papillae was observed in Fgf10 +/- animals as might be expected 
as a consequence of dry mouth. This may be due, however, to the age restriction of 
animals investigated and the consequence of increased oral dryness may only be 
observed in older specimens. Considering the salivary gland phenotype observed in 
Fgf10 +/- adult mice, we propose it as a new mouse model of xerostomia. Further 
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research is encouraged to investigate the effects this hyposalivation has on the oral 
mucosa of Fgf10 +/- adult mice. Ogawa et al. (2013) visualised saliva secretion 
within the oral cavity by applying fluorescent sodium test paper to the tongues of 
mice, and observed diffusion rates of fluorescent dye within the mouth over 80 
minutes. Healthy mice, as well as those implanted with functional bioengineered 
salivary glands, showed diffusion of fluorescence throughout the oral cavity while 
little fluorescence spread in the mouth of mice with deficient salivary glands (Ogawa 
et al., 2013). A similar protocol could be carried out on WT and Fgf10 +/- adult mice 
to compare salivary diffusion and cleansing ability. Furthermore, it is established that 
xerostomia causes imbalances in oral bioflora and increased bacterial infections, such 
as Candida albicans and dental caries associated organisms (Navazesh et al. 1995; 
Turner & Ship 2007). Buccal swabs could be taken from both WT and Fgf10 +/- and 
bacterial propagation compared. Due to the hyposalivation phenotype reported in this 
chapter, we hypothesise that higher plated bacterial colonies would grow from Fgf10 
+/- animals compared to WT littermates. 
In conclusion, further investigation using the Fgf10 +/- adult mouse as a model of 
xerostomia will contribute to our understanding of this life-debilitating symptom and 




Many organs, such as the mammalian lung, kidney, pancreas, salivary gland, lacrimal 
gland, prostrate and mammary glands, adopt similar methods of bud induction, stalk 
elongation and branching morphogenesis. While the formation of these organs 
involves tightly regulated epithelial-mesenchymal interactions, tissue-specific 
mechanisms are recruited to shape each structure. The main aim of this thesis was to 
establish a detailed description of the developmental journey of both the anterior nasal 
and the tracheal submucosal respiratory glands (SMGs). Interest and investigation has 
been lacking in recent times as to how these imperative glands form and function, 
regardless of their crucial role in respiratory disease. It was our goal to uncover the 
role played by FGF signalling in shaping these organs and attempt to entice further 
research into understanding respiratory gland development.  
 
7.1 The Respiratory SMGs as a Model of Development  
The SMGs of the upper and lower airways function in producing a mucin rich 
secretion that filters air and protects delicate pulmonary organs from airborne 
pathogens. Although, it is believed, that all these SMGs share the same role, this 
thesis has emphasised that differential methods of development are recruited by 
subsets of these glands. Among the anterior nasal glands, the Steno’s gland first 
develops at E12.5 by invaginating and extending as a long duct with a preformed 
lumen, similar to the development seen in the lacrimal gland of the eye (Makarenkova 
et al., 2000). In contrast, the lateral nasal glands (LNGs) and the medial nasal glands 
(MNGs) bud and extend as long solid cords of epithelial cells which undergo lumen 
formation succeeding stalk elongation. This similar mechanism is seen in the 
submandibular salivary gland (SMDG), as outlined in Chapters 1, 3 and 6, as well as 
the prostrate. Interestingly in these organs, canalization of the epithelial stalks occurs 
following the induction of branching (Thomson and Marker, 2006; Miletich, 2010), 
however it was observed in our study that lumen formation within the LNGs and 
MNGs initiated before the branching of their distal glands. This early canalization 
was also observed before branching commenced in the tracheal SMGs, however these 
glands do not have a long stalk elongation stage, and rather adopt a structure with a 
short main duct, similar to that of the SMDGs and the prostate. Finally, the maxillary 
sinus gland (MSG) has no stalk elongation stage and its tubules with preformed 
lumens simply branch immediately from the sinus epithelium, allowing it to directly 
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secrete its mucus into the cavity. This method of development with a preformed 
lumen, similar to that seen in the Steno’s gland, is also observed in the lung, as 
endodermal lung buds branch and extend with preformed lumens (Bellusci, Grindley, 
et al., 1997). Considering these contrasting developmental mechanisms, we propose 
the respiratory SMGs as ideal models to study bud induction, stalk elongation and 
branching morphogenesis. 
 
7.1.1 The Anterior Nasal SMGs as a Model of Gland Budding and Stalk 
Elongation 
Chapter 3 describes in detail the stages of anterior nasal gland development and 
demonstrates that the Steno’s gland, LNGs and MNGs form long ducts that branch 
with distal glands. The reasoning for this could be to maximise the use of available 
space within the nasal region. The nose is a complicated structure with weaving 
concha and meatuses, increasing mucosal surface area to humidify and filter air. 
Large glands have evolved to develop in available mesenchymal spaces distal to the 
nostrils. The development of a long duct allows the secretion of the gland fluid close 
to the nares so air can be moistened and humidified from the earliest areas of the 
respiratory tree. Considering this developmental method, the nasal SMGs provide a 
model for investigating the cellular and molecular processes that are involved with 
gland budding and stalk elongation. In this study, we investigated the role of Fgf10 in 
controlling nasal gland development and observed noticeable differences in the 
function of this growth factor for early budding and stalk elongation. Results showed 
that Fgf10 is essential for the invagination and elongation of the Steno’s gland, while 
the extension of MNG and LNGs, is independent of FGF10 signalling (Figure 7.1). 
This suggests that FGF10 signalling may be required to act as both a mitogen and a 
chemo-attractant for the indentation of the respiratory epithelial lip to form a duct 
with a preformed lumen, however other paracrine factors are needed for the 
invagination of a solid bud of cells. In the case of the MNGs, it appears that FGF7 is 
needed for their duct elongation (Figure 7.1, B), based on their absence in the Fgfr2b 
null mouse and the localisation of Fgf7 mRNA in the nasal septum where these 
glands develop. The LNGs however appear to develop independent of FGFR2b 
signalling as their ducts are present in Fgfr2b -/-. Based on the findings of Grüneberg 
(1971), it may be that these glands require Eda signalling for their bud outgrowth and 
duct elongation (Figure 7.1, C). 
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Further investigation is required to elucidate other signalling molecules and pathways 
involved in SMG bud induction and development. Using the culture method 
established in Chapter 3, nasal SMG development can be manipulated in future 
studies and molecular signals involved in forming these organs can be elucidated. It 
must be emphasised however that signalling factors involved in development may be 




Figure 7.1 Possible mesenchymal paracrine factors required for anterior nasal 
gland outgrowth. 
(A) Steno’s gland bud induction requires FGF10 to act possibly as a mitogen or 
chemo-attractant for duct outgrowth. (B) Expression patterns of Fgf7 and the absence 
of the MNGs in the Fgfr2b knockout mouse indicate FGF7 may act as a 
chemoattractant for MNG duct outgrowth and elongation. (C) The LNG ducts 
develop in the Fgfr2b knockout mouse ruling out the dependence of FGF7 or FGF10 
for their outgrowth. Other paracrine factors involved in other signalling pathways are 




7.1.2 The Role of Fgf10 in SMG Branching Morphogenesis 
As mentioned continuously in this thesis, Fgf10 is known to be a critical player in 
branching morphogenesis of a number of structures with supporting evidence seen in 
the lung and salivary glands. In accordance with every other aspect of branching 
morphogenesis, there are important differences in the role of Fgf10 depending on the 
branching structure. In terms of the respiratory SMGs however, although their bud 
and duct elongation stages recruit different mechanisms for successful development, 
the branching of all respiratory SMGs seems to be Fgf10 dependent. From in situ 
hybridisation analysis, Fgf10 is expressed throughout the mesenchyme surrounding 
all branching nasal glands. During branch formation in the lung, Fgf10 expressing 
cells are located in two spaced groups, leading to the bifurcation of elongating 
epithelial stalks, attracting each branch to each FGF10 source. No localised 
expression of Fgf10 was seen in the mesenchyme of the nasal glands, however 
clefting epithelial branches may be attracted to areas of high Fgf10 expression that 
may not be seen using in situ hybridisation on tissue sections (Figure 7.2). Fgfr2 
expression, as well as Spry1 and Pea3 expression within the distal epithelial buds, 
further supports the requirement of FGF10 signalling in nasal gland branching 
morphogenesis. Using in situ hybridisation methods, the expression of both Fgfr2 and 
Spry1 appears more widespread in the gland bud epithelial cells than that of Pea3, 
suggesting that nuclear transcription factor activation is only occurring in the 
peripheral bud cells (Figure 7.2). A similar role for Fgf10 is assumed in the tracheal 
SMGs, as tracheal epithelial buds are present in the Fgf10 -/- mouse at birth, yet they 
do not continue to elongation and branching stages similar to their WT littermates. 
Furthermore, branching of extended glands in the Fgf10 +/- P0 mouse is reduced and 
this phenotype is not rescued in adults. Using the tracheal SMG oil experiment, we 
demonstrated that this developmental defect has an effect on function of the gland in 
adult life, with mucus secretion being significantly reduced in Fgf10 +/- animals. 
Additionally, our analysis of salivary gland dysplasia further highlights the 
requirement of Fgf10 in the branching of the SMDG and the influence loss of Fgf10 
expression has on saliva output. 
 
While our work primarily focused on the influence of mesenchymal Fgf10 on the 
outgrowth and branching of the respiratory glands, epithelial factors are also assumed 
to be critical in regulating gland development. For example epithelial Sonic hedgehog 
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(Shh) has been reported to tightly control branching of both lungs and SMDGs 
(Bellusci, Furuta, et al., 1997; Pepicelli et al., 1998; Jaskoll et al., 2004). During 
branching stages of lung development, Shh is upregulated in distal lung epithelium 
and increases cell proliferation in the extending branches (Bellusci, Furuta, et al., 
1997). Upregulation of Shh in the lung, was followed by down regulation of 
mesenchymal Fgf10, indicating a possible inhibitory role for Shh (Bellusci, Furuta, et 
al., 1997). Furthermore, in the Shh -/-, mouse, lungs fail to develop due to lack of 
outgrowth and branching, however differentiation of bronchiole epithelium and 
alveolar sacs is observed, indicating that Shh is not required for cellular differentiation 
(Pepicelli et al., 1998). In the developing SMDG, Shh is again similarly localised to 
ducts of the SMDGS as well as terminal end buds (Jaskoll et al., 2004). Interestingly, 
in the Shh -/- mouse at E18.5, an undifferentiated dysplastic gland forms, indicating 
that during SMDG development Shh is required for gland growth and cellular 
differentiation (Jaskoll et al., 2004). Spatial expression of Shh within these epithelial 
structures leads to inhibition of Fgf10 in inter-branching zones, and thus gives rise to 
focal expression of Fgf10 in the adjacent mesenchyme (Chuang and McMahon, 
2003). Investigation into the expression, role, and possible interaction of Shh with 
Fgf10 during development of the different subsets of respiratory glands should help 
uncover the role played by this signalling molecule during branching morphogenesis 
(Figure 7.2).  
Another possible FGF10 antagonist during respiratory gland development could be 
Bone morphogenetic protein 4 (BMP4). In lung development, Bmp4 is expressed in 
the ventral mesenchyme during early stages of lung induction however it is highly 
expressed in the distal gland buds at later branching stages (Weaver et al., 1999). It 
has been suggested that Bmp4 and Fgf10 play complimentary roles during lung 
branching morphogenesis, with initial mesenchymal Fgf10 expression indirectly 
inducing Bmp4 expression in the lung endoderm, which is followed by high levels of 
Bmp4 within the lung bud epithelium antagonizing Fgf10 (Weaver et al., 2000). This 
inhibition of Fgf10 allows the extension of one single bud as opposed to the 
development of numerous end buds. A new bud is formed when Fgf10 expression 
shifts to an area adjacent to lung epithelium low in Bmp4 expression (Weaver et al., 
2000). An antagonizing role of Bmp4 is also supported by the inability of lung buds to 
grow towards an FGF10 source in vitro when exogenous BMP4 protein is applied 
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(Weaver et al., 2000). During SMDG development, Bmp4 is mesenchymally 
expressed (Hoffman et al., 2002). Similarly to the lung, BMP4 inhibits gland budding 
during in vitro SMDG investigation, with glands cultured with BMP4 showing similar 
phenotypes to those incubated with FGF inhibitor SU5402 (Hoffman et al., 2002). 
Furthermore, when SMDGs are cultured with BMP antagonist sFRP1, branching of 
SMDGs is induced with a 26% increase observed in the amount of gland buds in 
treated glands compared to controls (Patel et al., 2011). Bmp4 has also been shown to 
be expressed in the mesenchyme surrounding budding and branching tracheal 
respiratory SMGs (Rawlins and Hogan, 2005). This data collectively poses interesting 
questions for the role and regulatory functions of Bmp4 in branching morphogenesis. 
Whether these functions are conserved during respiratory SMG development, or even 




Figure 7.2 Schematic representation of the main findings of this thesis on 
anterior nasal gland branching morphogenesis and proposed signalling network 
interactions based on the findings of others. 
    During branching morphogenesis of all the respiratory glands, Fgf10 is expressed 
all throughout the mesenchyme surrounding the forming end buds. Based on previous 
work on lung morphogenesis (Bellusci, Grindley, et al., 1997), it is hypothesised that 
high concentrations of Fgf10 are localised to the mesenchyme adjacent to extending 
buds (dotted sections), allowing Fgf10 expression to stimulate cell proliferation and 
cell migration towards a localised source. This FGF10 activity on the end buds is 
supported by Fgfr2b expression identified within the gland bud epithelial cells, along 
with downstream targets of FGF signalling Spry1 and Pea3. While Spry1 expression 
is seen in peripheral bud cells, Pea3 expression is more restricted to the outermost 
distal cells. This indicates that the FGF10 signal is stimulating intracellular responses 
in the Spry1 positive cells, however is only leading to a nuclear translocation of this 
signal and transcription factor activation in the Pea3 positive cells. Thus, changes in 
cellular behaviour only occur in these outermost distal epithelial cells. 
    Collecting data reported during lung (Bellusci, Furuta, et al., 1997; Pepicelli et al., 
1998) and SMDG (Jaskoll et al., 2004) branching morphogenesis, it is hypothesised 
that Shh may be expressed within the SMG gland epithelium, and may also play a 
Fgf10 inhibitory role to prevent new bud outgrowth in all epithelial areas exposed to 
mesenchymal FGF10, and thus control the patterning of the outgrowth of existing 
branches. 
     Furthermore, Bmp4 may also play a role in patterning the branching gland 
epithelium. Bmp4 expression may be induced in the gland epithelial buds, similar to 
the developing lung (Weaver et al., 1999), or may be expressed in the surrounding 
mesenchyme, as seen during SMDG development (Hoffman et al., 2002). 
Mesenchymal Bmp4 expression has already been elucidated during tracheal SMG 
development (Rawlins and Hogan, 2005) however must be investigated during 
anterior nasal gland development. The interaction between Bmp4 and Fgf10 needs to 
also be addressed, and delineated this is similar to that seen during lung and SMDG 
development (Weaver et al., 2000; Hoffman et al., 2002; Patel et al., 2011). 
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7.2 Lumen Formation in the SMGs 
In order for a branched organ to successfully carry out its function of transporting 
either a liquid or a gas, tightly controlled tubule formation must occur (Iruela-Arispe 
and Beitel, 2013). An array of tubulogenesis methods are adopted in different 
branched organs, but more interestingly these diverse mechanisms are seen within the 
anterior nasal glands alone. The Steno’s gland, as well as the MSG, has preformed 
lumens during ductal elongation and branching, respectively. This means that these 
glands provide a model system for investigation into cellular behaviours and 
interactions as it is assumed changes to cell-to-cell adhesion and apical-basal polarity 
of cells is required in order for the respiratory epithelium to invaginate and develop 
this way. In contrast, the LNGs and the MNGs form as epithelial buds and elongate as 
solid cords of cells that at a later stage cavitate and form hollow tubes. These glands 
provide a model system to investigate the cell behaviours involved in delayed lumen 
formation.  
 
Research is on-going into the mechanisms underlying cavitation of solid epithelial 
tubes. Some studies have suggested that programmed cell death along with 
polarization of luminal cells shape out hollows in mammary and salivary gland ducts 
(Humphreys-Beher, 1996; Jaskoll et al., 1998; Wells and Patel, 2010). From our 
analysis of the nasal SMGs, apoptosis, by the detection of activated Caspase-3, does 
not seem to be required for normal tubulogenesis within the LNGs and MNGs. More 
recent studies demonstrated that ductal cavitation is independent of cell death and 
relies on vasoactive intestinal peptide (VIP)-dependent neuronal signals that are 
required for lumen formation and lumen expansion (Nedvetsky et al., 2014). In this 
study it was proposed that there were four main stages of tubule formation in the 
developing SMDG (Nedvetsky et al., 2014). The first step involves the proliferation 
of already differentiated luminal cells, which can be identified with the marker 
cytokeratin 19 (K19) at E13. Between E13-E13.5 these K19+ cells aggregate along 
the midline of the epithelial stalk and subcellular mechanisms lead to the polarization 
of these cells, allowing them to reorganise and form small spaces within the stalk 
(Nedvetsky et al., 2014). These microlumena then fuse to form one single lumen. The 
final stage is then characterized by expansion of this lumen to form a hollow tube 
(Nedvetsky et al., 2014). 
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Our work suggests that lumen formation within the LNGs and MNGs may also 
employ this method of lumen formation and rely on neuronal factors due to the close 
proximity of nerves during all stages of their development. These recent revelations 
strike up interesting questions about how contiguous lumens form within solid 
epithelial ducts and we believe the LNGs and MNGS will provide another model 
system to investigate the cellular and molecular mechanisms required for tube 
formation.  Application of the tight junction marker Zona occluding-1 (ZO1) could be 
applied to developing LNGs and MNGs to elucidate if these glands follow a similar 
mechanism to that observed in the SMDG, where first microlumena form within solid 
epithelial cords and fusion of these spaces create a continuous lumen. Additionally, 
using the culture method established in Chapter 3, exogenous addition and inhibition 
of neurotrophic factors such as neurturin and neurotransmitters, specifically VIP, to 
developing anterior nasal glands will help delineate the necessity of the nerve supply, 
observed in our study, for their development and tubule formation. Furthermore, 
although the timing of the stalk elongation stage is shorter, tracheal SMGS also 
originate as solid epithelial buds that undergo lumen formation. Therefore, 
investigation could also be carried out with these glands of the lower airway to 
uncover if similar mechanisms are involved or if differential processes occur. 
7.3 The Future of SMG Research 
Although research is improving our understanding of numerous respiratory diseases, 
we must not ignore that one of the primary causes of pulmonary obstruction and 
infection is mucus blockage of the airway tubes. Due to the pivotal involvement of the 
SMGs in producing mucus, their form and function should be at the forefront of 
investigation. Before we uncover the developmental errors that occur in those that 
suffer from respiratory disease however, it is imperative we understand the 
coordinated activities of signalling pathways and complex tissue interactions that are 
required to pattern functional respiratory glands and delineate if SMG development 
influences gland secretion and contributes to airway disease. We hope, that the work 
of this thesis will provide an aid for future research in identifying patterns of 
respiratory gland development and help stimulate future investigation into the 
mechanisms involved in shaping these structures, in the hopes of understanding and 
tackling the causes of respiratory disease. 
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